



















A thesis submitted in partial fulfilment of the requirements of the University of Lincoln 






















STATEMENT OF ORIGINALITY 
 
“I, Anish Parmar, hereby declare that this submission is my own work and to the best of my 
knowledge it contains no materials previously published or written by another person, or 
substantial proportions of material which have been published or accepted for the award of 
any other degree or diploma at University of Lincoln or any other educational institution, 
except where references have been made in the thesis. Any contribution made to the research 
by others, with whom I have worked at the University of Lincoln or elsewhere, is explicitly 
acknowledged in the thesis. I also declare that the intellectual content of this thesis is the 
product of my own work, except to the extent that assistance from others in the project's 
design and conception or in style, presentation and linguistic expression is acknowledged.” 
 
All the work from Chapter 2 to 6 has been published (5 publications). In general, the work 
includes a highly efficient synthetic route to provide potent analogues and its SAR studies. 
My overall contributions to the publications have been provided below, however detailed 
contributions by all other authors will also be provided at the beginning of each chapter. 
1. Parmar, A. et al. Efficient total syntheses and biological activities of two teixobactin 
analogues. Chem. Commun. 52, 6060–6063 (2016). 
 
2. Parmar, A. et al. Defining the molecular structure of teixobactin analogues and 
understanding their role in antibacterial activities. Chemical communications 53, 2016–2019 
(2017) 
 
3. Parmar, A. et al. Syntheses of potent teixobactin analogues against methicillin-resistant 
Staphylococcus aureus (MRSA) through the replacement of L-allo-enduracididine with its 
isosteres. Chemical Communications 53, 7788–7791 (2017) 
 
4. Parmar, A. et al. Teixobactin analogues reveal enduracididine to be non-essential for highly 
potent antibacterial activity and lipid II binding. Chemical Science 8, 8183–8192 (2017) 
 
5. Parmar, A. et al. Design and Syntheses of Highly Potent Teixobactin Analogues against 
Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and 
Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo. Journal of Medicinal 
Chemistry 61, 2009–2017 (2018). 
All the building block synthesis, peptide synthesis for the analogues, optimisations, 
purifications and sample preparation for either mass analysis/NMR has been done by me. 





For work in Chapter 6: All the  animals  used  in  this  study  were  treated  in  accordance  
to the  tenets  of  the  Association  for Research  in  Vision  and  Ophthalmology  (ARVO) 
statement,  and  the  protocol  was  approved  by SingHealth Institutional Animal Care and 







Signed ……… ………  
 
 




APPRECIATION AND ACKNOWLEDGEMENTS 
It would be extremely selfish to believe that my entire PhD was solely earned by my effort and 
diligence. It will be nearly impossible to mention every single person here, but I would like to 
acknowledge those who have significantly supported me throughout my PhD, not only in terms of 
my scientific research, but morally and emotionally as well.   
Firstly, I would like to thank my supervisor, Dr. Ishwar Singh, for his overwhelming support, 
motivation, tremendous patience and immense knowledge throughout my entire program. You 
granted the opportunity with your door always open for any questions and discussions. Because of 
that, you ensured that I was without any doubts during my research. I cannot thank you enough for 
believing in me even when I may have not shown the confidence in myself. The knowledge I have 
gained from you is invaluable and will be treasured forever.  
 
I would like to now thank my immediate family. Pa, you left us early in life and, at times, I look up 
to the sky and say to myself, “I know you did that”. Thank you for looking out for me and showering 
your blessings over me. This one is for you and I really miss you! Mum, you have been my pillar of 
strength and tenacity throughout this journey.  You have sacrificed your life and dreams just to 
witness me achieve everything I set out to pursue. There are no words to describe how much I thank 
you for all the love, care and courage you have provided me. I owe you a lifetime! Reema, even 
though you are in Kenya, you have always been there and boosted my morale when I needed it the 
most. I am truly blessed to have you as my sister. Thank you for making Raunaav (my nephew) 
become certain that I am some sort of “super uncle” and trusting that I can be a good role model for 
him. This always makes me strive to be a better human being as I am aware that he is learning from 
my actions. I show high gratitude towards Hemil, who has always been my well wisher over the 
years and lifted my spirit when I was down.   
 
Among my colleagues and friends in Lincoln, I show extreme appreciation to my friend Dr. Abhishek 
Iyer. Abhishek, I have always said “If you were not around I would really struggle with my PhD.” 
Thank you for all the support you have given me. You’ve played a vital role in educating me with 
the relevant knowledge to kickstart my journey in the life of a PhD student. I am walking away with 
great memories like our late-night hours, jokes and adventures on campus. I would like to thank 
Aqssa and Ruba for always being compassionate, being by my side when I was down and sharing 
crazy little inside jokes over the years. I wish you both all the success in your respective PhD’s. I 
would like to thank Maria, Keverne, Alex and Laura for the “heart to heart” discussions and our time 
spent in the labs. Paolo, Odera, Ranga and Ahmed, I thank you for creating the amazing atmosphere 
at Lincoln University and the sports we have played throughout our time together. I would like to 
thank Shreesha, Christian, Luke, Vincent and Louis for all the organic chemistry discussions we have 
had. I would like to express my special thanks for the whimsical NMR work of Dr. Stephen Prior 
and the excellent broad sample testing for biological activity of Prof. Rajamani Lakshminarayanan 
IV 
 
at Singapore. I also thank Charlie, Dan and Edward for the initial biological tests carried out here at 
Lincoln. Without everyone’s contributions, this PhD would be incomplete. A sincere thanks to all 
those whose names I may have missed herein and have played a significant part in my research.  
 
There are notable people who played a significant part in educating me with the vital knowledge 
prior to starting my PhD. I would like to thank Kamal & Pinky Badiani for giving me beneficial 
advice and the opportunity to work at their company. I thank Hemal, Pawel, Rob and Andrew for 
their amazing support and always encouraging me that I could make it for a PhD position.  
 
All work and no play can make a PhD life very dull. Throughout this journey, I was surrounded by 
those who stood by me through the wins and woes of my research. I thank all my cousins and friends 
outside university: Meenaben, Jayuben, Balraj, Peri, Jilan, Alpa, Kalpu, Deep, Rajin, Jasni, Nikita 
Supriya, Prayna, Sunny, Shyam, Brijesh, Nikky, Anika, Jheel, Tirth and Mica. You all know which 
category you belong to, but whether it was for late movie nights, advice, FIFA, music, singing or our 
quirky experiences, you all have happily given me the company to get through this program with the 
positive of attitudes. Thank you for always being by my side and supportive towards almost anything 
challenging I have attempted over the years. Please know that your positive vibes have played a 
significant role in any success I attain. 
 
I would like to thank the members of the jury, Dr. Steven Cobb and Dr. Louis Adriaenssens, for 
taking out their valuable time to read, correct and be a part of my jury. 
 
My PhD journey has been very enjoyable, and I’ve learned beyond my expectations. Most 
importantly, I have grown as a person. This process has broadened my perspective of life and has 
given me a terrific platform to contribute to science and help others less fortunate than myself. Not 








LIST OF ABBREVIATIONS 
13C NMR Carbon NMR 
1H NMR Proton NMR 
2-CTC 2-Chlorotrityl 
Ac2O Acetic acid 
Alloc Allyloxycarbonyl (protecting group) 
AMP Antimicrobial peptide 
B. subtilis Bacillus subtilis  
B.cereus Bacillus Cereus 
Boc tert-Butyloxycarbonyl 
C55-P  Undecaprenyl phosphate  
Cbz Carboxylbenzyl 
CDI 1,1'-Carbonyldiimidazole 
CFU Colony-forming unit 
DCC N, N'-Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DIC N, N′-Diisopropylcarbodiimide 
DIPEA N,N’-diisopropylethyl amine 
DMAP 4-Dimethylaminopyridine 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
E.coli Escherichia coli 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
End Enduracididine  
ESI Electrospray Ionisation 
Et2O Diethyl ether 
Fmoc 9-fluorenylmethyloxycarbonyl  
GlcNAc N-acetyl glucosamine  
HATU N-[(dimethylamino-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide 
HCl Hydrochloric Acid 
hDFs Human primary dermal fibroblasts 
VI 
 
HGT Horizontal gene transfer 
HMBC Heteronuclear Multiple Bond Correlation 
HPLC High-Performance Liquid Chromatography 
HRMS High resolution mass spectrometry 
HSQC Heteronuclear single quantum correlation 
HTS High-throughput screening 
Ichip Isolation chip 
Kd Dissociation constant 
LCMS Liquid Chromatography-Mass Spectrometry 
L-FDLA 1-fluoro-2,4-dinitrophenol-5-L-Leucinamide 
MBC Minimum bactericidal concentration 
MD Molecular dynamics 
MDR Multi-drug-resistant  
MeCN Acetonitrile 
MeOH Methanol 
MIC Minimum Inhibitory Concentration  
MNBA 2-Methyl-6-nitrobenzoic anhydride 
MoeA Moenomycin A  
Mpp PLP-Dependent enzyme 
mRNA Messenger ribonucleic acid 
MRSA Meticillin-resistant Staphylococcus aureus 
MS Mass spectrometry 
MSSA Methicillin-susceptible Staphylococcus aureus 
Na2SO4 Sodium Sulphate 
NAG N-Acetylglucosamine 
NaHCO3 Sodium bicarbonate 
NAM N-Acetylmuramic acid 
NMR Nuclear Magnetic Resonance 
NOESY Nuclear Overhauser Effect Spectroscopy 
Oxyma Ethyl (hydroxyimino)cyanoacetate 




PBPs Penicillin-binding proteins 
PBS Phosphate-buffered saline 
Pd(PPh3)  Tetrakis(triphenylphosphine)palladium(0)  
PG Peptidoglycan 
PhSiH3 Phenylsilane 
PLP Pyridoxal Phosphate 
ppm Parts per million 
r.t Retention Time 
RMSD Root-Mean-Square Deviation 
RNA Ribonucleic acid 
RP-HPLC Reverse-phase high performance liquid chromatography 
rt Room Temperature 
S.Aureus Staphylococcus aureus 
S.epidermidis Staphylococcus epidermidis 
SAR Structure-activity relationship  
TB Tuberculosis 
tBu Tert-butyl 
TES Triethylsilyl ether 
Tf2O Trifluoromethanesulfonic anhydride 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TLC Thin Layer Chromatography 
TOCSY Total Correlation Spectroscopy 
Trt Trityl 
UDP Uridine 5'-(trihydrogen diphosphate) 
UTP Uridine-5’-triphosphate  
VRE Vancomycin-resistant enterococci 
WHO World Health Organization 




MESSAGE TO THE READER 
The work herein is part of my PhD for four years (April 2015- October 2018) at Lincoln University, 
UK. I have had the opportunity to travel to Temple University, Philadelphia, the USA, to advance 
my techniques and work on other collaborated projects. Other projects have not been included in this 
thesis due to the relevancy of work and I had gained enough data on teixobactin to cover this entire 
thesis.  
 
For convenience, I have split the descriptive and experimental sections and numbered tables, figures 
and references chapter-wise. Since all the work herein has been published by our group, me being 
the first author/co-joint first author, relevant texts have been directly taken from the articles and 
permissions have been granted from co-authors for the use of data. 
 
The first chapter of the thesis covers - the introduction of bacteria, antibiotics, antimicrobial 
resistance and teixobactin. The later chapters focus on the efficient synthesis of the teixobactin 
analogue and the invention of more potent analogues, followed by the final overview of work from 
myself and others on teixobactin.  
 
Please bear in mind, this thesis is a pinnacle of hard work, dedication and support not just by me and 
my supervisor but a range of collaborators from different research groups who have significantly 









TABLE OF CONTENTS 
 
STATEMENT OF ORIGINALITY ................................................................................................ I 
APPRECIATION AND ACKNOWLEDGEMENTS ................................................................. III 
LIST OF ABBREVIATIONS ......................................................................................................... V 
MESSAGE TO THE READER .................................................................................................... IX 
TABLE OF CONTENTS .............................................................................................................. XI 
 
I DESCRIPTIVE SECTION 
 
1 AN INTRODUCTION TO ANTIBIOTICS, ANTIBIOTIC RESISTANCE AND 
TEIXOBACTIN ................................................................................................................................ 3 
1.1 Antibiotic discovery – a brief history ................................................................................. 3 
1.2 Antibiotics modes of action ................................................................................................ 6 
1.2.1 Inhibition of cell wall synthesis .................................................................................. 7 
1.2.2 Breakdown of cytoplasmic membrane ........................................................................ 7 
1.2.3 Inhibition of nucleic acid structure and function ........................................................ 7 
1.2.4 Inhibition of protein synthesis ..................................................................................... 8 
1.2.5 Inhibition of metabolic pathways ................................................................................ 8 
1.3 Antibiotic resistance ............................................................................................................ 8 
1.4 Mechanisms of antibiotic resistance ................................................................................. 10 
1.4.1 Intrinsic Resistance ................................................................................................... 10 
1.4.2 Mutation .................................................................................................................... 11 
1.4.3 Inactivation of antibiotics .......................................................................................... 11 
1.4.4 Horizontal gene transfer ............................................................................................ 11 
1.4.5 Efflux pumps, Biofilm formation and quorum sensing............................................. 12 
1.5 Applications and solutions against AMR .......................................................................... 12 
1.6 Antimicrobial peptides (AMP’s) ....................................................................................... 13 
1.6.1 Mode of action of AMPs ........................................................................................... 13 
1.6.2 Challenges of AMPs and strategies to improve their therapeutic potential .............. 16 
1.7 Teixobactin:  a new hope in antibiotic discovery .............................................................. 16 
1.7.1 Ichip for the ‘uncultivable’ ....................................................................................... 16 
1.8 Teixobactin (1.23) identification ....................................................................................... 18 
1.8.1 NMR analysis ............................................................................................................ 18 
1.8.2 Marfey’s analysis of amino acids .............................................................................. 18 
1.8.3 Synthesis of enduracididine (1.21) ............................................................................ 19 
1.9 Structure of Teixobactin 1.23............................................................................................ 19 
XII 
 
1.10 Resistance and mechanism of action of multidrug-resistant (MDR) pathogens ............... 20 
1.10.1 Peptidoglycan bio-synthesis ..................................................................................... 21 
1.10.2 Mode of action of teixobactin (1.23) ........................................................................ 22 
1.11 Total Synthesis of Teixobactin ......................................................................................... 23 
1.11.1 Synthesis of Protected L-allo-Enduracididne (1.21) ................................................. 24 
1.11.2 Total synthesis of Teixobactin Schemes ................................................................... 26 
1.12 Project aims ...................................................................................................................... 29 
1.13 References ........................................................................................................................ 30 
 
2 EFFICIENT TOTAL SYNTHESES AND BIOLOGICAL ACTIVITIES OF TWO 
TEIXOBACTIN ANALOGUES ................................................................................................... 41 
2.1 Abstract ............................................................................................................................. 41 
2.2 Brief Inroduction .............................................................................................................. 42 
2.3 Aim of study ..................................................................................................................... 42 
2.4 Results and discussion ...................................................................................................... 43 
2.4.1 Cyclisation via ester bond ......................................................................................... 44 
2.4.2 Cyclisation via amide bond ...................................................................................... 45 
2.4.3 Analysis and Activity ............................................................................................... 47 
2.5 Conclusion ........................................................................................................................ 48 
2.6 References ........................................................................................................................ 48 
 
3 DEFINING THE MOLECULAR STRUCTURE OF TEIXOBACTIN ANALOGUES 
AND UNDERSTANDING THEIR ROLE IN ANTIBACTERIAL ACTIVITIES................... 51 
3.1 Abstract ............................................................................................................................. 51 
3.2 Introduction ...................................................................................................................... 52 
3.3 Aim of study ..................................................................................................................... 53 
3.4 Results and discussion ...................................................................................................... 53 
3.4.1 Structure-activity relationships (SAR) of LLLL and DDDD ................................... 53 
3.4.2 Root-Mean square deviation (RMSD) of teixobactin analogues to determine SAR 54 
3.5 Conclusion ........................................................................................................................ 57 
3.6 References ........................................................................................................................ 58 
 
4 SYNTHESES OF POTENT TEIXOBACTIN ANALOGUE AGAINST METHICILLIN-
RESITANT STAPHYOCOCUS (MRSA) THROUGH THE REPLACEMENT OF L-allo-
ENDURACIDIDNE WITH ITS ISOSTERES ............................................................................. 59 
4.1 Abstract ............................................................................................................................. 59 
4.2 Brief Introduction ............................................................................................................. 60 
4.3 Aim of study ..................................................................................................................... 60 
4.4 Results and Discussion ..................................................................................................... 61 
4.4.1 Synthesis of analogues and their guanidines ............................................................ 61 
XIII 
 
4.4.2 MIC evaluation on teixobactin analogues ................................................................. 62 
4.5 Conclusion ........................................................................................................................ 64 
4.6 References ......................................................................................................................... 64 
 
5 TEIXOBACTIN ANALOGUES REVEAL ENDURACIDIDNE TO BE NON-
ESSENTIAL FOR HIGHLY POTENT ACTIVITY AND LIPID II BINDING ....................... 67 
5.1 Abstract ............................................................................................................................. 67 
5.2 Brief Introduction .............................................................................................................. 68 
5.3 Aim of study ..................................................................................................................... 69 
5.4 Results and discussion ...................................................................................................... 71 
5.4.1 Design and synthesis ................................................................................................. 71 
5.4.2 Antibacterial studies .................................................................................................. 72 
5.4.3 Time -kill kinetics of analogues 5.12 and 5.13 ......................................................... 75 
5.4.4 Toxicity studies and haemolysis assay ...................................................................... 76 
5.4.5 Lipid II binding assay ............................................................................................... 76 
5.4.6 Geranyl Pyrophosphate (lipid II mimic) binding studies .......................................... 77 
5.4.7 Antagonization Assay ............................................................................................... 79 
5.4.8 NMR Structural Studies ............................................................................................ 79 
5.5 Conclusion ........................................................................................................................ 81 
5.6 References ......................................................................................................................... 82 
 
6 DESIGN AND SYNTHESES OF HIGHLY POTENT TEIXOBACTIN ANALOGUES 
AGAINST STAPHYLOCOCCUS AUREUS, METHICILLIN-RESISTANT 
STAPHYLOCOCCUS AUREUS (MRSA), AND VANCOMYCIN-RESISTANT 
ENTEROCOCCI (VRE) IN VITRO AND IN VIVO .................................................................... 85 
6.1 Abstract ............................................................................................................................. 85 
6.2 Breif Introducion ............................................................................................................... 86 
6.3 Aim of study ..................................................................................................................... 87 
6.4 Results and discussion ...................................................................................................... 88 
6.4.1 Design and synthesis ................................................................................................. 88 
6.4.2 In vitro Antibacterial studies ..................................................................................... 89 
6.4.3 Resistance and time depenadat killing of bacteria using teixobactin analogue 6.2 .. 92 
6.4.4 In vitro cytotoxicity studies ....................................................................................... 92 
6.4.5 In vivo Toxicity Studies ............................................................................................ 93 
6.4.6 In vivo antibacterial efficacy of  6.2 in bacterial keratitis model .............................. 94 
6.5 Conclusion ........................................................................................................................ 97 





7 OVERVIEW OF TEIXOBACTINS, SUMMARY, CONCLUSIONS AND 
PERSPECTIVES .......................................................................................................................... 101 
7.1 Overview of teixobactin analogues ................................................................................ 101 
7.1.1 Synthesis of teixobactin analogues ......................................................................... 101 
7.1.2 Structure-activity relationship (SAR) ..................................................................... 103 
7.2 Summary of work ........................................................................................................... 106 
7.3 Conclusions .................................................................................................................... 107 
7.4 Perspectives .................................................................................................................... 109 
7.5 References ...................................................................................................................... 110 
 
II  CHAPTER-WISE EXPERIMENAL SECTIONS 
 
EXPERIMENTAL SECTION FOR CHAPTER 2 .................................................................... 115 
I. Materials ............................................................................................................................. 115 
II. Equipment used for the analysis and purification of compounds: ...................................... 115 
III. Attempted synthesis of the teixobactin analogue (2.1) via route A: ............................... 116 
IV. Synthesis of teixobactin core ring structure (2.2): .......................................................... 117 
V. Synthesis and characterisation of AllocHN-D-Thr-OH (2.4) .............................................. 118 
VI. Synthesis of the Teixobactin analogue (2.1) via route B: ............................................... 122 
VII. Synthesis of the Teixobactin analogue (2.3) via route B: ............................................... 123 
VIII. Antimicrobial Activity. ................................................................................................... 124 
IX. HPLC/LC-MS analysis ................................................................................................... 124 
X. Detailed NMR Analysis of Compounds 2.1 and 2.3 .......................................................... 130 
XI. References: ..................................................................................................................... 141 
 
EXPERIMENTAL SECTION FOR CHAPTER 3 .................................................................... 143 
I. Materials ............................................................................................................................. 143 
II. Equipment used for the analysis and purification of compounds ....................................... 143 
III. Syntheses and HPLC/LC-MS analysis ........................................................................... 144 
IV. NMR Analysis ................................................................................................................ 152 
V. Structural Statistics for teixobactin analogues .................................................................... 156 
VI. Molecular Dynamic simulations ..................................................................................... 157 
VII. MIC testing ..................................................................................................................... 158 
VIII. Complex formation of teixobactin with lipid II and geranyl pyrophosphate .................. 158 






EXPERIMENTAL SECTION FOR CHAPTER 4 .................................................................... 161 
I. Materials ............................................................................................................................. 161 
II. Equipment used for the analysis and purification of compounds ....................................... 161 
III. Syntheses of teixobactin analogues ................................................................................. 161 
IV. HPLC/LC-MS analysis ................................................................................................... 162 
V. MIC testing ......................................................................................................................... 174 
VI. References ....................................................................................................................... 174 
 
EXPERIMENTAL SECTION FOR CHAPTER 5 .................................................................... 175 
I. Materials ............................................................................................................................. 175 
II. Equipment used for the analysis and purification of compounds ....................................... 175 
III. Syntheses of teixobactin analogues ................................................................................. 176 
IV. HPLC/LC-MS analysis ................................................................................................... 179 
V. NMR Analysis .................................................................................................................... 208 
VI. MIC testing (screening) .................................................................................................. 227 
VII. Antagonization assay ...................................................................................................... 227 
VIII. MIC testing (extended panel) .......................................................................................... 228 
IX. Time-dependent killing of bacteria by teixobactin analogues 5.12 and 5.13 .................. 230 
X. Complex formation of teixobactin with lipid II and geranyl pyrophosphate ...................... 230 
XI. Cytotoxicity assay ........................................................................................................... 232 
a) Cytotoxicity assay by Formazan bioreduction ........................................................................ 232 
b) Haemolytic Assay Protocol ..................................................................................................... 232 
XII. References: ...................................................................................................................... 233 
 
EXPERIMENTAL SECTION FOR CHAPTER 6 .................................................................... 235 
II. Materials ................................................................................................................................. 235 
III. Equipment used for the analysis and purification of compounds ....................................... 235 
IV. Syntheses of teixobactin analogues ..................................................................................... 236 
V. HPLC/MS analysis .................................................................................................................. 238 
VI. NMR analysis ...................................................................................................................... 248 
VII. MIC & MBC testing ........................................................................................................... 251 
VIII. Time-dependent killing of bacteria by teixobactin analogue 6.1 ........................................ 253 
IX. Cytocompatibility of 29 for mammalian cells .................................................................... 253 
X. The in vivo toxicity in a rabbit model of corneal epithelium-injured ...................................... 254 















1 AN INTRODUCTION TO ANTIBIOTICS, ANTIBIOTIC 
RESISTANCE AND TEIXOBACTIN 
1.1 Antibiotic discovery – a brief history 
Paul Ehrlich in 1909 discovered 
Salvarsan1, an antimicrobial to 
treat syphilis on his quest to find 
the ‘magic bullet’. However, it was 
strictly not regarded as an 
antibiotic. The first true antibiotic 
to have come to light was 
penicillin in 1928, discovered by 
Sir Alexander Fleming for which 
he was awarded the Nobel prize in 
19452. Whilst examining 
Staphylococcus aureus, he noticed contaminations of mould (Penicillium notatum) on his petri 
dishes. His findings were phenomenal. He found that the mould was inhibiting the growth of a wide 
range of bacteria.  Fleming struggled to isolate pure penicillin from the mould due to limited 
knowledge and resources at the time. However, other researchers such as Howard Florey and Ernst 
Chain from Oxford University with their ground-breaking research, turned several penicillins (Figure 
1.1) into lifesaving drugs which cured previous untreatable infections3.  
Penicillin is within the sub-class of β-lactams, which also includes cephalosporins, monobactams 
and carbapenems. They all contain a β-lactam ring (a four membered ring with an amide bond, Figure 
1.1) as part of their active core structure. B-lactams ability to bind to penicillin binding proteins 
(PBPs) results in bacterial cell lysis, due to the inhibition of the peptidoglycan synthesis4. Synthetic 
modifications (bulky side chains) of the ‘R’ group on the penicillins’ provided higher stability against 
β-lactamase degradation and broadened the spectrum of activity, especially in gram-negative bacteria 
(Figure 1.1, compounds 1.5-1.9) 5, 6. 





Figure 1.1: Class of antibiotics β-lactams (top) and variants of Penicillin (bottom).  
Flemings work inspired many more scientists such as Selman Waksman and Albert Schatz to further 
explore new antibiotics. This led to the origin of Streptomycin: the first drug that was active in animal 
models against the pathogen Mycobacterium tuberculosis which caused tuberculosis (TB)7.  
Although the claim for the work was ambiguous8, Waksman, in the end, was known to pioneer 
Actinomycetes to produce antibiotics and was awarded the name “Father of antibiotics”. 
Streptomycin later faded the scene due to severe side effects, which led to patients becoming deaf 
during the treatment of tuberculosis9.  
 





Figure 1.2: Structures of some of the most successful antibiotics the B-lactams (ampicillin 1.7), 
fluoroquinolones (ciprofloxacin 1.10)  and aminoglycosides (streptomycin 1.11).  
Most of the commonly used antibiotics were discovered between 1950 through 1960 which became 
known as the ‘golden age of antibiotics. The most successful classes were the β-lactams (1.7), 
aminoglycosides (1.11) and fluoroquinolones (1.10) (Figure 1.2). However, apart from the latest 
classes fluoroquinolones and the oxazolidinones, there has been a huge ‘discovery void’ in finding 
new classes for over 50 years (Figure 1.3)10.   
 
*Figure 1.3: Timeline of most successful antibiotic discovery and evolution of antibiotic resistance11.  
 
                                                     
* Image is original, concept derived from: Antibiotic Resistance Threats in the US. Centres for Disease Control and 











































Even in the early days, resistance was observed after a few years for all new antibiotics discovered. 
Some of the drugs being discovered had resistance appearing simultaneously10. To understand how 
bacteria evolve to form resistance, we need to understand the modes of action antibiotics in the first 
place.  
1.2 Antibiotics modes of action 
The potency of antibiotics pinpoints certain features of the bacteria or their metabolic processes. The 
successful antibiotics only target just a few pathways out of approximately 200 conserved proteins10. 
There are important functions that are necessary for bacterial growth (Figure 1.4) and inhibition of 
these make good targets for antibiotics12–14. The most successful antibiotics are listed in (Figure 1.3).  
 
†‡Figure 1.4: Functions of bacterial growth and targets for its inhibition. 
 
                                                     
† Image is original, concept derived from: Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371–
87 (2013) 
‡ Original article: Coates, A., Hu, Y., Bax, R. & Page, C. The future challenges facing the development of new antimicrobial 
drugs. Nat. Rev. Drug Discov. 1, 895–910 (2002). 




1.2.1 Inhibition of cell wall synthesis 
Bacteria have a peptidoglycan (PG) layer which protects and supports the bacterial cell in harsh 
conditions in case of osmotic pressure. For bacteria to thrive, the clockwork must be very efficient 
to produce these penicillin binding proteins (PBPs)15. PBPs belong to the enzyme family of 
transpeptidases which are essential for incorporating disaccharide pentapeptides to elongate the 
already formed PG layer. The β-lactams (Penicillins 1.4) work by inhibiting the peptide bond 
formation while glycopeptides (vancomycin 1.12, Figure 1.5) bind directly to the pentapeptide part 
of the lipid II ( D-Ala-D-Ala terminus) which in turn produces a damaged cell wall and leads to cell 
lysis16.  
1.2.2 Breakdown of cytoplasmic membrane 
There are different specific classes of antibiotics that will cause damage to the cell membranes of the 
bacteria, which also depends on the specific type of lipids in their membranes. One such example is 
daptomycin 1.13. Daptomycin 1.13 aggregates to the cell membrane which creates a distorted shape 
causing ions to leak through. The rapid depolarisation leads to the inhibition of cellular functions of 
the bacteria (Figure 1.5)17.  
 
Figure 1.5: Structures of vancomycin 1.12 and daptomycin 1.13 that work well against Gram-positive 
pathogens. 
1.2.3 Inhibition of nucleic acid structure and function 
Nucleic acid synthesis is extremely essential for the survival of bacterial cells. Inhibition of the DNA 
synthesis comes conjointly with the inhibition of topoisomerase II and IV18. Quinolines inhibit the 
function of the helicase enzyme known for unwinding the DNA, thereby stopping replication.  This 
also impacts the RNA synthesis of the bacteria19.  




1.2.4 Inhibition of protein synthesis 
Ribosomes translate the mRNA into proteins. There is no doubt that protein is essential for the 
survival of bacteria, this makes it a great target for antibiotics. 30S or 50S subunit of the ribosome 
can be targeted, disrupting the mechanism to produce proteins19.  
1.2.5 Inhibition of metabolic pathways 
For bacteria, tetrahydrofolic acid (derivative of folate/folic acid) is essential in the synthesis of 
nucleic acids. Bacteria metabolise para-amino benzoic acid (PABA) to folate. Sulphonamides are 
structurally very similar to folate and compete with the PABA precursor. This makes sulphonamides 
very selective to bacteria as humans do not produce folate12.  
1.3 Antibiotic resistance 
Within the last few decades, antibiotic resistance has steadily risen and now become a critical issue 
in medical research, healthcare and society. A report from the World Health Organisation (WHO) 
has revealed that by 2050, antimicrobial resistance will cause more deaths per year than cancer. 
Inaction on the current issue fears a massive economic loss estimated at costing $100 trillion, 
globally20. 
Other treatments such as chemotherapy, surgery and transplants will be threatened and hampered 
due to the risk of patients being infected with serious resistant infections21. Most of the antibiotics 
prescribed today are either not needed or not as effective. Overuse of antibiotics in healthcare and 
agriculture has been the main source of bacteria developing resistance to some of the previous 
antibiotics. The alarming rate at which these resistance bacteria are appearing compared to the 
production of drugs, it is evident that there is still a significant amount of research to be pursued in 
antibacterial drug development10.   
Even with High-throughput Screening (HTS), there has been a decline in finding new reasonable, 
broad spectrum antibiotics in the clinic. The major issues for this being; penetration of antibiotics 
through the bacterial membranes and production being hampered by Lipinski’s ‘rule of five’ 
guidelines22, 23. On the other hand, increasing the dosage for less potent drugs to give maximum 
efficacy compromises on the risk of toxicity. Antibiotics are short term treatments that hold the 
possibility of resistance occurring in the future, thus investment in chronic disease medications over 
antibiotics appeals more to pharmaceutical companies due to the longer shelf-life of the drugs10.  
Currently, the most serious multidrug resistant pathogens have been abbreviated ‘ESKAPE,’ 
globally. ESKAPE stands for Enterococcus spp., Staphylococcus aureus, Klebsiella spp., 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp24. In some cases for 
example, A.baumanni, there are specific strains that are resistant to all available antibiotics25. WHO 




released a priority list for the bacteria that we urgently need antibiotics, all ESKAPE pathogens are 
in a “critical” or “high” list of urgently required antibiotics.  
Bacteria will inevitably acquire resistance to the antibiotics we discover; there is urgent action that 
is obligatory to avoid this scenario. Prevention of diseases and tracking of resistant bacteria should 
be high on the list. Development and improvement of antibiotics is a necessity, and to allow us to do 
that, we must first gain an understanding of the structure and the response of bacteria upon antibiotics. 
 
Structurally, there are two main types of bacteria; the Gram-positive (G+) and the Gram-negative 
(G-) bacteria (Figure 1.6). A Danish microbiologist Hans Christian Gram in 1884 developed the 
Gram stain which consists of crystal violet and safranin26. Based on the thickness of the 
peptidoglycan layer, bacteria would stain differently allowing for rapid differentiation between G+ 
and G- bacteria. G+ bacteria with thick PG layer retained crystal violet dye and stained dark purple 
whereas G- bacteria with thin PG layer retained Safranin and stained red or pink27.  
 
§Figure 1.6: Structure of PG layer in Gram-positive (a) and comparison of the cell wall structures in Gram-
positive (b) and Gram-negative (c) showing significant difference in the thickness of peptidoglycan layer and 
the presence of outer membrane in Gram-negative bacteria. 
                                                     
§ Image is original, concept derived from:  Microbiology- an introduction Tortora et al. - Pearson – 2019, Figure 4.13 




1.4 Mechanisms of antibiotic resistance 
An antibiotic’s main function is to neutralise or kill the bacteria by attacking its basic cellular 
functions. Bacteria use numerous mechanisms to counteract the function of antibiotics such as, 
decreased drug permeability, biofilm formation and active efflux pumps. Figure 1.7 shows some of 
the common ways that bacteria develop resistance and will be discussed further. 
 
**††Figure 1.7: Some of the common ways by which bacteria overcome the antibiotic effect.  
1.4.1 Intrinsic Resistance 
It is known that bacteria adapt to many environmental changes28, 29. However, they also naturally 
inherit internal intrinsic resistance through which enzymes can detect and degrade the antibiotic 
preventing the drug binding to its target. Conserved proteins such as lipocalins are found in bacteria 
and are known to bind to hydrophobic compounds, causing claims of a role in resistance, although 
                                                     
** Image is original, concept derived from: Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371–
87 (2013) 
†† Original article: Coates, A., Hu, Y., Bax, R. & Page, C. The future challenges facing the development of new 
antimicrobial drugs. Nat. Rev. Drug Discov. 1, 895–910 (2002). 




certain mechanisms of resistance are unclear. Recently, a study found  Pseudomonas aeruginosa 
secreted a lipocalin (BCN) when exposed to antibiotic stress, provoking the naturally protective 
bacterial stress responses30. 
1.4.2 Mutation 
Bacteria multiply rapidly and random point mutations are obvious to occur. Wild-type bacteria can 
mutate and alter the shape of its binding site, where the antibiotic targets. The antibiotic is unable to 
destroy the bacteria and proliferation causes new resistant strains to form. An example is the cell wall 
modification of vancomycin-resistant bacteria, which causes a decreased binding affinity of 
Vancomycin31. 
1.4.3 Inactivation of antibiotics 
Bacteria possess enzymes that could basically modify or inactivate the antibiotic entirely. Structural 
properties within the antibiotics such as hydroxyl and amides are quite prone to hydrolysis and the 
addition of nucleotide, acetyl and phosphate groups32. The enzyme β-lactamases destroys a broad 
spectrum of β-lactam rings through hydrolysis of most β-lactam containing antibiotics, making it 
unusable33.  
1.4.4 Horizontal gene transfer 
Bacteria not only transfer genes to their offspring but have the ability to also transfer genes between 
different species. This is known as horizontal gene transfer (HGT) (Figure 1.8). Resistant genes can 
be transferred by three main processes: I) Conjugation is the transfer of genetic material via a direct 
interaction between two bacterial species, II) Transformation is the uptake of floating genetic 
material from another deceased bacterium, and III) Transduction is the transfer of genes by a virus 
which previously infected another bacterium and hosted it’s DNA34.  
It should be noted that there are several factors that contribute to the different mechanisms of HGT. 
Some of the common factors are competence levels of the recipient bacteria, environmental factors, 
and/or stabilised extracellular DNA. Out of the three mechanisms described above, conjugation is 
the most expected and frequently studied. Conjugation certainly provides a sufficient protective 
barrier, higher choice of species and an efficient route to transport genetic material, in comparison to 
utilising another medium to transport or capture genes34. 





‡‡Figure 1.8: Diagram showing different mechanisms of horizontal gene transfer: - Conjugation, 
transformation and transduction. 
1.4.5 Efflux pumps, Biofilm formation and quorum sensing 
Quorum sensing is the ability of bacteria to communicate with each other through autoinducers 
releasing information of cell population (cell density), which enables bacteria to respond to 
expression of genes for survival. Biofilm formations are interconnected with quorum sensing 
considering the  higher the cell density of bacteria, the easier for them to resist antibiotics. Bacteria 
require pumps to transport nutrients in and out of the cell. Bacteria can mutate and produce more of 
the specific pumps that flush the antibiotic out of the cell, lowering its concertation and increases its 
resistance.  How efflux pumps promote biofilm formations is still insufficiently researched, however 
studies have shown that inhibiting the efflux pumps decreased biofilm production35, 36.  
1.5 Applications and solutions against AMR 
It is obvious from the information gathered about AMR, optimum platforms and applications to 
tackle AMR are required. Investigating previous libraries may not be an adequate way in finding 
broad spectrum antibiotics. The main problem with most of the focused projects, is the Multi-drug 
resistant (MDR) pumps in the bacteria (especially Gram-negative), that limits the ligand-target 
binding. Therefore, drugs that focus on single targets may not be viable in the long run. Combination 
                                                     
‡‡ Image is original, concept derived from: von Wintersdorff, C. J. H. et al. Dissemination of Antimicrobial Resistance in 
Microbial Ecosystems through Horizontal Gene Transfer. Frontiers in Microbiology 7, 173 (2016). 
 




therapies will be more advantageous in finding lead candidates through the revival of outdated, yet 
successful platforms. These new developed platforms should reliably find lead compounds10.  
There are many other additional platforms for the discovery of novel antibiotics, such as targeting 
virulence factors37, phage therapy38 and antimicrobial peptides (AMP)39. Although teixobactin 1.23 
may not be regarded as a true AMP,  AMPs will be discussed extensively below as my entire PhD 
was based on the design, synthesis and the biological evaluation of analogues of the peptide 
teixobactin 1.23 40. 
1.6 Antimicrobial peptides (AMP’s) 
AMPs are the first line of protection in multicellular organisms39. Peptides are short proteins 
consisting of circa 12-50 amino acids sequences. AMPs are abundant in marine life, mammals, 
insects, plants and soil bacteria41. Each AMP has its unique profile, ranging from structure (e.g. α-
helical, β-sheet, coil (Figure 1.9))42–44, net charge (+2 to +9), solubility (cationic) and other physical 
properties (amphipathic)45. Most of these properties correlate to its activity. The positive charge 
allows electrostatic interaction between negatively charged membranes of the bacteria and the 
hydrophobicity enables penetration through membranes causing leaks, eventually cell lysis. Due to 
the unique properties that AMPs possess, which are related to its activity, modification and design 
synthetically can play a huge role in developing new AMPs. 
 
§§Figure 1.9: Structural varieties of major AMPs. Random/extended coils (indolicidin), B-sheets (human 
defensin 1) and α helix (magainin)43, 44. Regenerated using PDB id codes 1g89, 1kj5 and 2k6o respectively, 
utilising discovery studio.  
1.6.1 Mode of action of AMPs 
The mode of action of AMPs can be either direct killing or immune modulation. The direct killing 
mechanism is further divided into two categories, membrane targeting and non-membrane 
targeting46.  The membrane targeting peptides can also be receptor-mediated or non-receptor 
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mediated. Nisin for example has a receptor-mediated interaction binding to Lipid II, a cell wall 
precursor47.  
1.6.1.1 Direct killing: membrane targeting 
Electrostatic interactions are critical in determining how strong the binding is between the cationic 
peptide and the negatively charged bacterial membrane. Both Gram-positive and Gram-negative 
bacteria possess negatively charged head groups (phospholipids) that can strongly interact with the 
positively charged peptides48,49. Moreover, hydrophobic peptides avoid the risk of selectivity and 
toxicity to mammalian membranes. Mammalian membranes contain cholesterol and are more 
zwitterionic which influences stabilisation of lipid layer and protects it from damage50.  
Once there is a certain accumulation of AMPs on the surface of the membrane, there are different 
models as to which of these peptides perform their action on the membranes. The transmembrane 
pore forming models: barrel stave and toroidal pore model and the non-transmembrane pore models: 
the carpet model and detergent-like model (Figure 1.10)46. 
 
***Figure 1.10: Different mechanism of action (models) of Antimicrobial peptides (AMPs) 
In the barrel-stave model, first the AMPs are aligned parallel with the membrane surface and later 
forces its way vertically and into the membrane due to its amphipathic nature, creating pores51 (Figure 
                                                     
*** Image is original, concept derived from: Kumar, P., Kizhakkedathu, J. & Straus, S. Antimicrobial Peptides: Diversity, 
Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo. Biomolecules 8, 4 (2018). 




1.10a). Some examples of AMPs that form barrel stave are alamethicin,52 pardaxin53, 54 and 
protegrins55.  
In the toroidal model (Figure 1.10b), the AMPs again are aligned in parallel to the membrane surface; 
however, the aggregation of peptides forces the lipid bilayers to form a curve, causing the term 
“toroidal pores” mixed of peptide and lipid52. The difference between the barrel stave and toroidal 
model is that for the latter, the net arrangement of the hydrophobic and hydrophilic bilayer is 
disrupted, potentially allowing translocation of the AMP to further target intracellularly. Examples 
of some toroidal pore forming models include magainin 2 and melittin56.  
In the non-pore forming models like the carpet-like model (Figure 1.10c),48, 56, 57 AMPs align at the 
membrane surface and causes a “carpet” effect that induces the membrane destabilisation. Before the 
membrane undergoes complete disintegration as shown in the detergent-like model (micelle 
formation) (Figure 1.10d), it briefly forms a transient pore like the toroidal model56. LL-3757, 
indolicidin58 and cecropin59 are some of the AMPs which perform their action as carpet model.  
1.6.1.2 Direct killing: non-membrane targeting 
Initially, it was thought that AMPs were not targeting intracellular components. DNA and RNA are 
stereospecific targets. A study revealed that an alteration of L-Amino acids to the D stereochemistry 
had similar potency, which confirmed no intracellular targets were involved60. However, it is now 
evident that AMPs at first engage at cytoplasmic membranes at low concentrations without initiating 
pore formation, to which it then accumulates intracellularly inhibiting several processes, triggering 
cell lysis55. A typical example is the action of burofin II, which passes the membrane and binds DNA 
and RNA of E.coli61.  
Other non-membrane targets of peptides are the bacterial cell wall precursors; Lipid II 1.25 
(peptidoglycan precursor) and Lipid III 1.26 (wall teichoic acid (WTA) precursor) which are highly 
conserved in bacteria. Nisin, a lantibiotic binds to the Lipid II and creates a phosphate cage enabling 
pore formation62.  
Teixobactin 1.2340 on the other hand, specifically binds to the lipid II, lipid III and undecaprenyl 
pyrophosphate (C55-PP), which are essential for bacterial cell wall synthesis. Teixobactin and Lipid 
II will be extensively discussed later within the chapter.  
1.6.1.3 Immune modulation 
The production of AMPs is facilitated by certain immune cells such as neutrophils and macrophages. 
When an infection arises the first response is our immune system is to try and fight the foreign 
material. AMPs (LL-37, β defensins) attract and activate immune cells such as leukocytes, mast cells 
and dendritic cells, enhancing microbial death and inflammation control63–65. 




1.6.2 Challenges of AMPs and strategies to improve their therapeutic potential 
Not many AMPs that have been discovered have passed through  the United States Food and Drug 
administration (FDA) for clinical trials66. The ones that have been approved have been limited to 
topical treatment, of which cytotoxicity and protease degradation contributing to the main factors. 
Enzymes such as pepsin and trypsin in the digestive system break down peptides causing short half-
lives for treatments. In many cases, rapid renal clearance is also an issue67, 68.  
The issue of proteolytic digestion of AMPs have been overcome by the chemical modification of 
AMPs to the D-Amino acids. In many cases, modifications of the L-amino acids to the D-counterparts 
has prevented enzyme degradation without compromising the activity profile, due to enzymes being 
very stereospecific46, 69–71. Addition of non-proteogenic amino acids have also shown promise to 
proteolytic stability72. In some cases, the addition of an acetyl group also prevents degradation of 
AMPs by aminopeptidases, but the loss of charge compromises on activity73, 74. Different modes of 
cyclisation of peptides, such as disulphide bridges and head to tail cyclisation have also shown to 
improve serum stability75, 76 and leads to better membrane permeation77.  
Delivery systems ranging from organic/inorganic molecules, polymers, surfactants and peptides have 
been used to improve AMPs78, 79. A former PhD student from our group, Abhishek Iyer, under the 
guidance of Dr. Ishwar Singh used peptides to improve the delivery of the Moenomycin A (MoeA) 
– a natural product with potent antibacterial activity against Gram positive bacteria but inactive 
against Gram negative bacteria. Specific ‘delivery’ peptides were designed, which contained residues 
Arg, Lys and/or Trp, known for their cell permeability80–82. The strategy involved the simple mixing 
of the cationic peptides with MoeA which resulted in the formation of non-covalent complexes, 
enabling the delivery of MoeA across the outer membrane of Gram-negative bacteria. This has 
resulted in a 30 times improvement in antimicrobial activity (PhD thesis, Abhishek Iyer, unpublished 
results). 
1.7 Teixobactin:  a new hope in antibiotic discovery 
1.7.1 Ichip for the ‘uncultivable’ 
As discussed previously, most of the antibiotics that have been produced during the golden age came 
from mining soils. Selman Waksman was the first to use such a platform. However, 99% of the soil 
bacteria cannot be grown under laboratory conditions. This has been a long problem in cultivating 
micro-organisms from the soil. “The great plate anomaly83” was first observed by Winterberg84 an 
Austrian microbiologist where uncultured bacteria seen under a microscope cannot be grown on a 
petri dish. There have been efforts on trying to play with the media including different growth factors, 
but this limitation has stalled to find novel class of antibiotics and there is need to find new platforms 
to revive what Waksman had started.  




Kim Lewis and his colleague Kaeberlein from Northeastern University had an idea which was very 
simple and efficient85. If we can’t grow it in the lab lets send it back to its natural environment. They 
took a diluted sample from marine sediment and placed it onto a semipermeable membrane between 
an ‘O’ (Figure 1.11A). The polycarbonate membrane (0.03-µM pore-size) allows chemicals or 
nutrients exchange but restricts cell movement. This is then taken back to its natural environment. 
 
†††Figure 1.11: Diffusion growth chamber. (A) A semipermeable membrane between 2 ‘O’ rings. (B) Growth 
chamber placed back to its original environment.  
The authors found that a new species MSC1 could be grown as a pure culture in the chambers, but 
not on a petri dish. Their findings also revealed that bacteria do not like to grow in unfamiliar 
environment due to the signalling of growth factors with their neighbours. The authors further went 
on to study what these growth factors were and they happened to be siderophores86. Siderophores 
have a high binding affinity for Fe(III) which bacteria use to scavenge Fe(III) and then transport iron 
back to the cell when its low87–89.  
Having already established the design and knowledge of how to grow the ‘uncultivables’ a more 
sophisticated design was employed. The Isolation chip (Ichip)90 which is very similar to the diffusion 
chamber is immersed in liquid-agar based medium containing mixed cells for cultivation(Figure 
1.12A). Depending on the dilution, on average only a single cell is trapped in the tiny wells once the 
agar solidifies (Figure 1.12B). The membranes are then placed and screwed up (Figure 1.12C). The 
chip is then placed in its original environment for the colonies to form.   
 
                                                     
††† Reproduced from: Microorganisms in Pure Culture in a Simulated Natural Environment. Science 296, (2002), 




‡‡‡Figure 1.12: Ichip design and procedure for microbial cultivation in situ40, 90. 
1.8 Teixobactin (1.23) identification 
Using the Ichip technique, microbial growths were screened and tested for antibacterial activity 
against S. aureus. A new species from the β-proteobacteria named Eleftheria terrae, was producing 
a compound that had high activity against Gram-positive bacteria. A partly purified analysis of the 
compound revealed a molecular weight of 1,242 Da, which was not reported in literature before. 
Further analysis was carried out by Selcia and Novobiotic pharmaceuticals to deduce the full 
structure of 1.2340. 
1.8.1 NMR analysis 
NMR 2D analysis data performed by NovoBiotic pharmaceuticals of Teixobactin revealed a 11 
amino acid peptide, a 13 membered macrolactone ring and a rare unusual enduracididine amino acid 
1.1940. 
1.8.2 Marfey’s analysis of amino acids 
To determine the chirality of amino acids in the structure of teixobactin, advanced Marfey’s 
analysis91 was used in conjunction with liquid chromatography. A UV- active reagent L-FDLA (1-
fluoro-2,4-dinitrophenol-5-L-Leucinamide) reacts with a racemic mixture of amino acids and forms 
separable diastereomers which can be detected by reverse-phase HPLC (RP-HPLC) (Figure 1.13). A 
combined advantage of UV detection and separation can reveal the stereochemistry of the amino 
acids92, 93. 
                                                     
‡‡‡ Reproduced from: Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Applied 
and environmental microbiology 76, 2445–50 (2010). 





Figure 1.13: Figure showing Marfey’s reagent 1.14 (blue) reacting with mixed stereoisomers (red) to give 
diastereoisomers 1.15a and 1.15b which can be analysed by RP-HPLC. 
1.8.3 Synthesis of enduracididine (1.21) 
 
Figure 1.14: Biosynthetic pathway of L-enduracididne 1.19 (left) and stereoisomers of enduracididine 1.20-
1.22. 
 Biologically, 1.19 creation begins with the catalysation of L-arginine 1.16 by a PLP -dependent 
hydroxylase (mppP) to a guanidinovaleric acid 1.17. The guaninidine acid undergoes cyclisation by 
the pyruvate aldose enzyme (mppR) to form 1.18. The final transamination step by mppQ yields L-
enduracididine 1.1994.  
To determine the stereochemistry for the enduracididine amino acid all 4 diastereomers were 
synthesised by Selcia chemists. A few synthetic routes have been published for the rare amino acid, 
however most of them are inefficient and have tedious procedures94. Selcia chemists managed to 
synthesise all 4 diasteroemers of enduracididne and using the previously mentioned Marfey’s 
analysis, teixobactin 1.23 adopts a L-allo-enduracididne 1.21 (L-allo-End). More on the chemical 
synthesis of enduracididine will be discussed in later sections of this chapter.   
1.9 Structure of Teixobactin 1.23  
Combining the NMR data and Marfey’s analysis of amino acids and enduracididine, a full structure 
determination was possible (Figure 1.15). Teixobactin 1.23 is a cyclic depsipeptide and contains 11 
amino acids, out of which 4 are D-aminoacids, namely N-Me-D-Phe1, D-Gln4, D-allo-Ile5 and D-Thr8. 
An ester bond in the 13 membered macrolactone ring is formed with D-Thr8 and L-Ile11. Other two L-
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Ile come at position 2 and 7 and an Ala at position 9. Thus, structural complexity of 1.23 can been 
described as moderate to difficult. 
 
Figure 1.15: Structure and sequence numbering of teixobactin 1.23 with D-amino acids highlighted in red and 
the rare amino acid enduracididine marked in blue.  
The gene cluster consists of Txo1 and Txo2, which are both large (~697kDa) nonribosomal peptide 
synthetases (NRPSs). Txo1 has a MT (methyltransferase) domain which is responsible for the 
methylation of phenylalanine and Txo2 has a unique two consecutive thioesterase domain which 
involves in the ligation of Thr8 and Ile11.  
1.10 Resistance and mechanism of action of multidrug-resistant (MDR) pathogens 
1.23 was tested against an extended panel for Minimum Inhibitory Concentration (MIC)40 and it 
exhibited very high potency (low MIC) against very stubborn Gram-positive pathogens such as 
methicillin-resistant Staphylococcus aureus (MRSA), Penicillin-Resistant streptococcus pneumonia 
(PRSP) and vancomycin-resistant Enterococcus (VRE). It also has extremely high potency against 
Mycobacterium tuberculosis (Mtb) and Clostridium difficile (Table 1.1).  
Organism Teixobactin (1.23) MIC (µg ml-1) 
S. aureus (MSSA) 0.25 
S. aureus (MRSA) 0.25 
Enterococcus faecalis (VRE) 0.5 
Enterococcus faecium (VRE) 0.5 
Streptococcus Pneumoniae (penicillinR) ≤0.03 
B.anthracis ≤0.06 
Clostridium difficile 0.005 
Escherichia coli 25 
Pseudomonas aeruginosa >32 
Klebsiella pneumoniae >32 
























































Teixobactin 1.23 is effective against Gram-positive bacteria, however it not very effective against 
Gram-negative strains. This is most likely due to the outer membrane that Gram-negative possesses. 
To prove this concept a defected outer membrane strain of E.coli asmB1 was tested and showed 
improved activity. 1.23 was not only nontoxic to mammalian cells, but no mutations in S.aureus or 
M.tuberculosis was observed under subminimum inhibitory concentrations (MIC). To check for 
resistant mutants a technique known as serial passage is employed95.  A slightly lower dose is given 
initially that does not entirely kill the pathogen and can recover from the dose.  Later a slightly higher 
dose than the previous is given, and this cycle is repeated until resistant mutants are observed. 
The absence of detectable resistant mutants suggested that teixobactins’ mode of action was clearly 
tracking towards something specific. Authors later discovered that it was a peptidoglycan synthesis 
inhibitor40. Proteins are more susceptible towards mutation and if no mutations were observed it 
couldn’t be an enzyme or protein. Another molecule with similar characteristics was vancomycin 
1.1296, a lipid II inhibitor, a peptidoglycan precursor.  
1.10.1 Peptidoglycan bio-synthesis 
Peptidoglycan layer (Murein) is the most important component of the bacterial cell wall allowing its 
structural rigidity and protects it against osmotic pressure97. As the name suggests, it’s a combination 
of glycans (sugars) and peptide crosslinks. The two major alternating sugars to form the 
peptidoglycan layer involved are N-acetyl Muramic acid (MurNAc) and N-acetyl glucosamine 
(GlcNAc). There are three main stages involved in the synthesis if peptidoglycan synthesis. 
Cytoplasmic stage where GlcNAc and MurNAc are synthesised, membrane stage where the GlcNAc 
and MurNAc are attached and transferred to the cell membrane and the final extracellular stage where 
cross linking of the precursors occur98 (Figure 1.16).  
1. In the cytoplasmic stage GlcNAc, initially made from glucose gets converted to UDP- 
GlcNAc with the help Uridine-5’-triphosphate (UTP). UDP-GlcNAc then undergoes 
another conversion to the second sugar UDP-MurNAc catalysed by enol pyruvate 
transferase. UDP- MurNAc is then conjugated to a tripeptide (L-ala, D-Glu, L-Lys or 
meso-diaminopimelic acid (A2pm)) and further converted to a pentapeptide (UDP- 
MurNAcpp) by addition of another two D-Ala residues99–101. 
2. C55-P (undecaprenyl phosphate or bacterprenol) is a key lipid known for the synthesis 
and transportation of the GlcNAc-MurNac from the cytoplasms to the external sites of 
the growing peptidoglycan layer. The UDP- MurNAcpp attaches to C55-P which in turn 
triggers the conjugation of the UDP- GlcNAc to MurNAc. This forms a complex (Lipid 
II) and an enzyme peptidoglycan synthase (flippase102) transports lipid II to the growing 
cell wall. An enzyme phosphatase dephosphorylates C55-P to be reused again, however 
this recycling step is not understood well103–105. 
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3. The alternating MurNAc and GlcNAc which are polymerised by glycotransferase 
(GTase) are crosslinked with Transpeptidase (Penicillin binding protein or PBPs) with 
neighbouring pentapeptides hanging on the lipid II106. 
 
§§§Figure 1.16: Peptidoglycan synthesis stages and steps107. 
1.10.2 Mode of action of teixobactin (1.23) 
Both 1.12 and 1.23 inhibit the peptidoglycan synthesis, by binding to the lipid II precursor. 1.12 
binds to the D-Ala-D-Ala terminus of the lipid II 1.25, while 1.23 binds to the highly conserved 
phosphate moiety of both lipid II 1.25 and III 1.26 (Figure 1.17).  
                                                     
§§§Image is original, concept derived from:  R. T. Gale, E. D. Brown, New chemical tools to probe cell wall biosynthesis 
in bacteria. Current Opinion in Microbiology. 27, 69–77 (2015). 





Figure 1.17: Figure showing Interactions of Teixobactin (1.23) and Vancomycin (1.12) with lipid II (1.25) and 
lipid III (1.26). 
Vancomycin-Resistant bacteria mutate and change their lipid II D-Ala-D-Ala terminus to D-Ala-D-
Lac. Since 1.12 binds via hydrogen bonding, the substitution of the NH to ester decreases the potency 
to 1000-fold96, 108. Efforts to redesign vancomycin 1.12 derivatives and the ability to bind to both the 
mutated and wild type lipid II 1.25 have been mentioned to enhance its activity109.  
Teixobactin 1.23 not only binds to lipid II but also lipid III, a precursor of wall teichoic acid (WTA), 
not surprising as the structures of both lipids are very similar (Figure 1.17, 1.25 & 1.26). The binding 
of these highly conserved lipids in the bacteria inhibits the reprocessing of undecaprenyl 
pyrophosphate (C55-PP), which is crucial in the biosynthesis of both lipid II and lipid III. 
Accumulation of UDP- MurNAcpp in the treatment of S.aureus determines the inhibition of the 
peptidoglycan synthesis, similar to those tested with Vancomycin 1.12. Teixobactin 1.23 binds in a 
2:1 (teixobactin/lipid) molar ratio with Lipid I, Lipid II, Lipid II (D-lac), lipid III and C55-PP40. Due 
to the multiple binding non-protein sites, it is less likely for resistance developing in the near future.  
In vivo studies of 1.23 on mouse models, showed high efficacy in antibacterial activity at a protective 
dose (PD50) of 0.2mg/kg which contrasted positively to the 2.75mg/kg PD50 of 1.12.  
1.11 Total Synthesis of Teixobactin 
Teixobactin 1.23 attracted a lot of media attention due to its high potency against MDR strains and 
the synergistic mode of action on non-protein targets (lipid II 1.25 and III 1.26). This excited different 
groups including ours to pursue teixobactin research. The total synthesis of 1.23 would open 
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determining the structure-activity relationship (SAR) of teixobactin 1.23. Our group initially also 
focused and attempted the total synthesis of 1.23. Due to the laborious synthesis of L-allo-End 1.21, 
our group decided to divert the focus more on designing simple and economical potent analogues, 
which will be discussed in later chapters. 
1.11.1 Synthesis of Protected L-allo-Enduracididne (1.21) 
To achieve the total synthesis of 1.23, an appropriately protected, not commercially available L-allo-
End 1.21 was compulsory to synthesise. A few procedures were already reported in literature110–113, 
however these methods needed to be improvised to give access to a suitably protected enduracididne. 
One of the challenges was to establish the C4 chirality position of the L-allo-End 1.2140. As 
mentioned previously,  Selcia chemists had already prepared the building block for Marfey’s analysis 
from a four-step synthesis starting from the nitro alcohol (Scheme 1.1, 1.27). The nitro alcohol was 
synthesised from an optimised protocol by Rudolph et al114. The final synthesis yielded the 
production of both 1.19 and 1.21 in a 1:6 ratio respectively. 
 
Scheme 1.1: Synthesis of L-allo-End 1.21 by Lewis et al.40 
Using Rudolph’s method of converting the protected aspartic acid 1.30 to nitro ketone 1.27, Payne 
et al. then stereoselectively reduced the nitro ketone to the nitro alcohol using L-selectride achieving 
a diastereoisomeric product at a 5:1 ratio (Scheme 1.2, 1.31)115. The minor stereomer was removed 
by flash column chromatography. The guanidine moiety was introduced using an improvised 
Goodman’s reagent, and an intramolecular cyclisation resulted in the L-allo-End frame (Scheme 1.2, 
1.33). A simple Boc-removal step followed by a Fmoc coupling step on the α-amine produced the 















































Scheme 1.2: L-allo-End synthesis by Payne et al115. 
Yuan et al. in 2015 published a highly stereoselective and scalable synthesis of L-allo-End (Scheme 
1.3)113. The 10-step procedure started with the unique trans-hydroxy proline (1.35) obtaining a final 
product with high diastereoselectivity and an overall yield of 31%. A notable highlight was the use 
of bulky protection to cover the carboxylate (Scheme 1.3, 1.36) which prevented the forming of both 
a lactone and a lactam, efficiently resulting in the L-allo-End 1.21 synthesis. 
 
Scheme 1.3: L-allo-End synthesis by yuan et al113 
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1.11.2 Total synthesis of Teixobactin Schemes 
Once the enduracididne synthesis had been optimised, a few groups delivered the total synthesis of 
teixobactin. Most of them employed the Fmoc-SPPS but had varying strategies113, 115–117.  
Payne group initially started their synthesis using the 2-chlorotrityl (2-CTC) resin, but they were not 
able to esterify the D-Thr8 to Ile11115. Payne group believed it was due to the bulky 2-CTC resin that 
was hindering the hydroxy group of the Thr8. As an alternative, a less, bulkier group (4-
(hydroxymethyl)-3-methoxyphenoxy) acetic acid (HMPB), polyethylene glycol-based NovaPEG 
resin was selected118. A protected Fmoc-D-Thr(TES)-OH was loaded to the resin followed by the 
esterification of Alloc-Ile-OH. The rest of the linear synthesis through Fmoc-SPPS was followed to 
achieve (Scheme 1.4, 1.45). 
 
Scheme 1.4: Total synthesis of 1.23 by Payne group115  
The protected Alloc from the Isoleucine group was then removed by palladium chemistry to free the 
amine and coupling of enduracididine (1.46). However, the conventional Fmoc deprotection was not 
successful due to the formation of diketopiperazine between the α-amine of the L-allo-End and α-
carboxylic acid of the L-isoleucine. To minimise the diketopiperazine formation, the authors used a 
quick 30s deprotection solution (10% vol piperidine in DMF) and added a preactivated alanine 
coupling after rapidly washing the piperidine. The removal of Fmoc from the alanine provided the 
free amine to which the resin underwent partial cleave, leaving a fully protected depsipeptide (1.48). 
Cyclisation followed by full deprotection of the side chains provided 1.23 in an overall 24 step 



















































































































In 2016 Li et al. also reported the total synthesis of 1.23 (Scheme 1.5)117. They adopted a Ser/Thr 
ligation strategy adopted from their lab previously119 by constructing the cyclic depsipeptide part of 
the teixobactin and conjugating it with the linear hexapeptide. The authors started off with a dimer 
synthesis in solution to obtain Alloc-D-Thr-O(Fmoc-Ile)-OH 1.49 moiety and immobilising that onto 
the resin. Boc-Ser(tBu)-OH coupling after removal of the alloc protecting group followed by Fmoc-
SPPS of L-allo-End and alanine yielded the pentapeptide (1.50). L-allo-End was very slow requiring 
three repetitive 10h couplings to achieve completion. The mild resin cleavage followed by cyclisation 
produced the cyclic-depsi-pentapeptide moiety (1.52). The other linear hexapeptide salicylaldehyde 
ester was synthesised by conventional Boc-SPPS followed by ozonolysis (1.51). Ligation between 
the linear and the cyclic peptide in the presence of pyridine/AcOH (6:1) produced 1.23 in a 37% 
yield in the final step.   
 
Scheme 1.5: Total synthesis of 1.23 by Li et al.117 
Very recently another paper by Chen et al. reported the total synthesis of 1.23 and its 
stereoisomers116. They combined solution and solid phase synthesis to overcome racemisation and 
achieve an efficient convergent synthesis. Although the authors also reported a complete solid 
support synthesis of teixobactin, a half solution phase strategy was a better choice due to the 
racemisation between Thr8 and Ile11. Due to the distinctive nature of the synthesis in comparison to 




























































































Scheme 1.6: Total synthesis of teixobactin by Chen et al116 
The synthesis began in solution with the reaction of the carboxyl protected H-Alanine-OtBu (Scheme 
1.6, 1.53) with Fmoc-D-Thr to form the dimer (1.54). Fmoc-Ser(Bn)-OH was then coupled prior to 
removal of Fmoc. Esterfication then proceeded to create the tetramer (1.56). Esterfication was also 
possible at the dimer stage to get the esterified trimer. However the further coupling of serine failed 
due to the facile O to N acyl transfer between the Ile and the Thr, during the removal of Fmoc on the 
Thr. Once the deprotected carboxyl tetramer was available, 2-CTC was reacted to attach the tetramer 
onto the resin followed by conventional Fmoc-SPPS. Alloc removal and coupling of enduracididine 
gave the complete on resin protected uncyclised teixobactin (1.60). Partial cleavage released the 
protected teixobactin and macrolactamisation by HATU produced the cyclised product to which full 
deprotection produced 1.23.  
Although it was not a fully synthesised teixobactin 1.23, it is noteworthy to mention that Dhara et 
al120. synthesised a solution phase macrocyclic core of 1.23 with gram scale synthesis of 1.21 but 
were not able to attain full deprotection of the enduracididne. The present strategy might not be as 
advantageous to previous methods, but it can be used as a complementary one.  




1.12 Project aims 
This chapter comprises a brief overview highlighting the major challenges involved in overcoming 
antimicrobial resistance, the difference between multidrug resistant Gram-positive and Gram-
negative bacteria, modes of action of antibiotics and resistant mechanisms with examples and 
additional details covering important aspects of antimicrobial peptides. 
The last 30 years have been a colossal failure in terms of discovering new classes of antibiotics. AMR 
is continuing to grow at an alarming rate and the demand for new antibiotics is much higher than the 
current supply. Nonetheless, it does look that we are moving in the right direction with the recent 
technological advances in antibiotic research although there is still a significant amount of work to 
be completed. The issue of unculturable soil bacteria can now be circumvented using the novel ichip 
technique, which in the future is most likely to harbour new antibiotics. 
AMPs have shown promise as future therapeutic agents. Developments of current AMPs aimed at 
therapeutic applications could reveal benefits in the next decade. The mode of action of several AMPs 
has not yet been fully understood.  In addition to the models and mechanism of actions described 
earlier, it is possible that AMPs operate with other different modes.  Understanding the modes of 
action of recently discovered antibiotics such as teixobactin (although may not be fully regarded as 
an AMP) and with the help of different imaging and assays, it is more likely that more modes of 
action will be revealed. Nonetheless, research and resistance must be kept on check and with novel 
studies, we should steadily be able to avoid the “post-antibiotic’’ era.   
Teixobactin falls under a new class of antibiotics and has emerged at a time when we urgently needed 
it. The 11-mer macrocyclic depsipeptide is produced by a soil bacterium named Elefteria terrae. It 
has shown better activity to vancomycin and oxacillin, which is our last defence against multi-drug 
resistant pathogens. The synergistic action of teixobactin on peptidoglycan and WTA biosynthesis 
inhibits cell wall synthesis. More importantly, due to this behaviour, resistance is less likely to be 
observed in the near future as the targets are non-protein based where mutations are not prone to 
form. 
There is excellent potential for teixobactin to progress further to combat the resistance issue. There 
is also ample opportunity for researchers to study its structure-activity relationships by synthetically 
obtaining teixobactin, its analogues and understanding their mechanisms of action through 
modifiable residues in the teixobactin sequence. This will give rise to several analogues that will 
benefit the clinical industry by rewarding future antibiotic drug therapy.  
Despite the encouraging results of teixobactin, which has shown very high promise against many 
multidrug Resistant bacteria, there are certain limitations that halts teixobactin being further 
developed as a potential candidate for drug development. Teixobactin is limited to a single molecule 
and there is a very rare chance that it reaches the regulatory approval due to the high dilapidation rate 
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in drug development. The production of teixobactin is also hampered by the synthetically 
challenging, expensive and low yielding L-allo-End building block.  It is therefore critical that we 
pursue in designing novel synthetic teixobactin analogues to generate libraries to address the 
challenges posed in drug development. 
Keeping the current challenges in mind the current project aims at the development of a synthetic 
protocol which will aid in the total synthesis of teixobactin and its analogues. The role and 
importance of the D-amino acids in teixobactin could uncover understanding of its mechanism of 
action along with providing insight into to its Structure-activity relationship (SAR). More potent 
analogues can then be synthesised with point modifications and an established synthetic route, which 
could in turn provide more potent analogues than native teixobactin. These analogues can be further 
tested in advanced biological models. 
Our group during the past four years has worked extensively in designing potent analogues of 
teixobactin in order to better understand the SAR of the teixobactins.. There have been more than 
700 citations of the original article since it was first published, therefore only relevant work has been 
discussed in the final chapter. The total synthesis described above has been mentioned earlier in this 
chapter, however several analogues of teixobactin were synthesised and evaluated for their activity 
prior to the total synthesis of native teixobactin. These molecules are relevant to our work and will 
be mentioned in the final chapter as an overview discussion. 
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2 Efficient total syntheses and biological activities of two 
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2.1 Abstract 
The discovery of the new antibiotic teixobactin has 
been timely in the race for unearthing novel 
antibiotics wherein the emergence of drug resistance 
bacteria poses a serious threat worldwide. Herein, we 
present the total syntheses and biological activities of 
two teixobactin analogues. This approach is simple, 
efficient and has several advantages: it uses 
commercially available building blocks, has a single 
purification step and a good recovery (22%). By using 
this approach we have synthesised two teixobactin 
analogues and established that the D-amino acids are 
critical for the antimicrobial activity of these 
analogues. With continuing high expectations from 
teixobactin, this work can be regarded as a stepping 
stone towards an in-depth study of teixobactin, its analogues and the quest for synthesising similar 
molecules.  




2.2 Brief Inroduction 
The decreased potency of antibiotics such as penicillin 1.4,1 vancomycin 1.122 and oxacillin3 due to 
their excessive use is a consequence of the emergence of drug resistant bacteria. It has been predicted 
that antimicrobial resistance (AMR) will have disastrous consequences and it is estimated that by 
2050 an additional 10 million people yearly could succumb to drug resistant infections.4 The recently 
published article5 describing the discovery of teixobactin 1.23 has provided a much needed 
breakthrough in the challenging field of antibiotic peptides. There has been no detectable resistance 
reported against 1.23. Moreover, given the multiple mechanisms of attack by teixobactin 1.23 
described by Süssmuth6 resistance is less likely in the near future. Unfortunately, although 
teixobactin 1.23 provides some much needed answers, the problem is far from over. Organic chemists 
have worked round the clock to synthesise novel antibiotics and although progress has been steady, 
bacteria have time and again confounded even the best in this field.7 This is where the multichannel 
device, iChip,8 has made a considerable contribution enabling the identification of molecules like 
1.23, some of which could be active against drug resistant bacteria. However, the iChip device has 
its limitations. The probability of finding an antibiotic is extremely low (10-7 percent) and even with 
high-throughput screening, which takes considerable time and resources, there is no guarantee when 
the discovery of the next drug like teixobactin 1.23 will be. Undeniably, breakthroughs via organic 
synthesis have to be made to keep the drug resistance problem under check. The time for this is 
indeed now and teixobactin is a good starting point. 
2.3 Aim of study 
Teixobactin is a single potent molecule that has been produced by a bacterium and it is very rare a 
single molecule from the drug discovery phase will reach regulatory approval due to the high attrition 
rate in the drug development process. To realise the therapeutic potential of teixobactin, there is need 
for developing synthesis of teixobactin analogues.  This study is aimed at a general approach through 
which, not only teixobactin but also other analogues can be synthesised. The synthetic approach will 
give access to analogues which nature cannot provide us with and therefore an organic synthesis 
approach to the bigger problem at hand should not be prematurely discarded. Moreover, the role of 
the D-amino acids have not been proven.9 Our work presents an efficient syntheses of both the D and 
L versions of the analogues of teixobactin (22% yield for 2.1) and their role in antibacterial activity. 
  





Figure 2.1: (a) (above) Structure of teixobactin 1.23. (b) (below) Structure of the teixobactin analogue 2.1 
showing the bonds to be cleaved for the synthesis routes A (in blue) and B (in red) and the structural differences 
(in green). 
2.4 Results and discussion 
Since teixobactin 1.23 has been fully characterised by NMR and LC-MS, the structural complexity 
of 1.23 can be described as moderate to difficult. It has also been described as an unusual 
depsipeptide due to the presence of the non-natural amino acids L-allo-End10 1.21 and N-Me-D-Phe1 
along with four D-amino acids (Figure 2.1). Despite not possessing a lipid tail, the commercial 
unavailability of the amino acid 1.21 makes the total synthesis of 1.23 more time consuming than 
expected.10  
The commercially available natural amino acid arginine (a linear guanidine) is the closest structural 
match suitable for the replacement of the 1.21 (a cyclic guanidine) as can be seen in Figure 2.1 
(green). In this work, arginine was selected as a replacement of L-allo-End10 1.21 for synthesis of 













































































































2.4.1 Cyclisation via ester bond 
A first approach towards tackling this molecule was to synthesise the complete peptide on solid phase 
and cyclise post-cleavage from the resin via an ester bond (Figure 2.2). This route has been previously 
used with success for the synthesis of the analogues of callipeltin B.11 
 
Figure 2.2: Scheme showing the attempted synthesis of the teixobactin analogue via route A 
 
Briefly, commercially available 2-chlorotrityl (2-CTC) resin was loaded Fmoc-Ile OH (a). After 
loading determination, the Fmoc protecting group was removed by standard 20% piperidien in DMF 
and subsequent amino acids were successfully coupled using standard SPPS (b). Partial cleave with 
TFA:TIS:DCM (2:5:93) respectively released a fully protected peptide from the resin (c) and after 
solvent evaporation, several conditions for esterification (d) was tested as described in Table 2.1. 
*Table 2.1: Esterfication conditions for cyclisation. 
Unfortunately, none of them yielded the esterified product.  This could be due to the steric bulk of 
protecting groups on the amino acids. This led to the conclusion that a direct and linear route is not 
the way to cyclisation. 
                                                     
*Diisoproplycarbodiimide (DIC), Dicyclohexylcarbodiimide (DCC) 2-methyl-6-nitrobenzoic anhydride (MNBA), 1-Ethyl-




Reagents Solvent Duration Temperature
1. 1.2 eq. DCC/5 eq. DMAP DMF 24h r.t.
2. 2 eq. DCC + 1 eq. after 4h /5 eq. DMAP DMF 24h r.t.
3. 3 eq. DCC/20 mol% DMAP DMF 2h r.t
4. 1.2 eq. MNBA/2.4 eq. DMAP DMF 12h r.t.
5. 2.5 eq. EDCI/0.5 eq. DMAP DMF 24h r.t.
6. 18 eq. DCC/28 eq. DMAP DMF 30 min, 6h 0-4 deg., r.t
7. 1.2 DCC/6 eq. DMAP DMF 24h 60, heating
8. 1.2 eq. DIC/6 eq. DMAP DMF 24h 60, heating




2.4.2 Cyclisation via amide bond 
2.4.2.1 Fragment (core ring) cyclisation 
A new second synthetic route had been devised which involves cyclisation via amide bond formation 
(Figure 2.1, route B). For the total synthesis of 2.1, an optimised pathway for the synthesis of the 
core ring structure (Figure 2.3, 2.2) of teixobactin was required. Therefore, the initial efforts were 




Figure 2.3: Synthesis scheme for the core teixobactin fragment 3 starting from Wang resin:   a. 10 eq. Fmoc-
Ala-OH, 10 eq. DIC, 1 eq. DMAP followed by 10% Ac2O/DIPEA in DMF.   b. 2.5 eq. Fmoc-D-Thr(Trt)-OH, 
2.5 HATU/5 eq. DIPEA, 3h DMF followed by 20% piperidine in DMF.   c. 4 eq. Allyl Chloroformate/8 eq. 
DIPEA in DCM, 1h.  d. 1:5:96 TFA:TIS:DCM. 3 x 15 min.   e. 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 10 mol% 
DMAP in DCM, 2h followed by 10% Ac2O/DIPEA in DMF, followed by 20% piperidine in DMF.   f. 4 eq. 
Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 20% piperidine in DMF.   g. 
TFA:TIS:H2O = 95:2.5.2.5, 1h.   h. 1 eq. HATU/10 eq. DIPEA in DMF, 1h, monitored on HPLC. 
For optimisation of the synthesis, we chose Wang resin. Fmoc-Ala-OH was loaded onto this resin 
via ester bond formation. The unreacted resin was capped using 10% acetic 
anhydride/diisopropylethylamine (Ac2O/DIPEA) followed by (a) the attachment of Fmoc-D-
Thr(Trt)-OH via amide bond formation and subsequent (b) Fmoc removal. The orthogonal Alloc 
protecting group was installed on the amine (c) followed by (d) trityl group removal by 1:5:96 
Trifluoroacetic acid/Triisopropylamine/Dichloromethane (TFA:TIS:DCM) and proceeded with (e) 
the challenging esterification reaction between Ile and Thr. It is to be noted that excess Ile and base 
were required to drive the reaction to completion.12 This was succeeded by (f) amide bond formation 
using Arg and subsequent (g) cleavage from the resin using 95:2.5:2.5 TFA:TIS:H2O to give 2.2a. 
The final step was (h) the amide bond formation between Arg and Ala which proceeds smoothly 
yielding the desired cyclised fragment 2.2. 
  




2.4.2.2 Total synthesis of analogue 2.1 
After the successful fragment cyclisation, the approach was then slightly modified and used for the 
total synthesis of 2.1 as described in Figure 2.4. 
 
Figure 2.4: Total synthesis of 2.1 starting from 2-CTC resin: a. 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3h.   
b. 20% piperidine in DMF followed by 3 eq. AllocHN-D-Thr-OH 2.4, 3 eq. HATU/6 eq. DIPEA.   c. 10 eq. 
Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2h followed by capping with Ac2O/DIPEA 10% in DMF, 
20% piperidine in DMF   d. 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 20% 
piperidine in DMF   e. 10 eq. Trt-Cl, 15% Et3N in DCM, 1h.  f. [Pd(PPh3)4]0 (0.2 eq.) + 24 eq. PhSiH3 in DCM, 
2 x 1 h.   g. Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting group), HATU/DIPEA followed by 
20% piperidine in DMF.   h. TFA:TIS:DCM = 2:5:93, 2h.  i. 1 eq. HATU/10 eq. DIPEA in DMF, 1h, monitored 

















































































































































(a) The first amino acid loaded on the resin in this case is Fmoc-Ala-OH followed by (b) an amide 
bond coupling with Alloc-D-Thr-OH 2.4. (c) Fmoc-Ile-OH is then coupled at this stage via an ester 
bond to the free –OH side chain of threonine. Next, (d) arginine was coupled via an amide bond, the 
Fmoc protecting group is removed and (e) the N-terminus is protected via a trityl protecting group13 
(combining cleavage and deprotection in a single step) to facilitate the cleavage and cyclisation as 
described in reactions h and i. (f) The alloc group protecting the N-terminus of the threonine is then 
removed14 and (g) the peptide chain is built via standard Solid Phase Peptide Synthesis (SPPS). 
Partial cleavage was performed using 2:5:93 TFA:TIS:DCM followed by cyclization using 1-
[Bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU) as a coupling reagent and DIPEA as a base in DMF for 1 hr. The protecting groups are then 
cleaved off using 95:2.5:2.5 TFA:TIS:H2O yielding the desired peptide 2.1 (22% recovery).  
2.4.2.3 Total synthesis of analogue 2.3 
After successful synthesis of 2.1, the general applicability of this approach was tested for the 
synthesis of analogue 2.3 (Figure 2.5). In 2.3, the three D-amino acids residues (Phe, Gln and Ile) 
were replaced by L-amino acid residues. The synthesis of analogue 2.3 also worked efficiently (17% 
recovery). 
 
Figure 2.5: Structure of the aceytelated and L-version of Arg10-Teoxobactin (2.3). 
2.4.3 Analysis and Activity 
The detailed characterisation of 2.1 and 2.3 were performed using LC-MS and NMR. The NMR 
spectra of product 2.1 (Experimental chapter 2, section X) was shown to be identical as reported 
previously5,9. The NOEs of 2.1 were characteristic of a random coil, however, the NOEs of 2.3 
suggested a considerable degree of structure.  
The analogues 2.1 and 2.3 were evaluated for their antibacterial activity. MIC results showed a 
similar trend to teixobactin for analogue 2.1 against both Gram-positive and Gram-negative bacteria. 
Analogue 2.3 was not active against Gram-negative bacteria. Moreover, analogue 2.1 was 64 times 
more effective than analogue 2.3 (Table 2.2) against Gram-positive bacteria. This difference in 




antibacterial activity has established that the three D-amino acids residues of 2.1 are critical for the 
antibacterial activity. 
Entry Organism 2.1  2.3  Teixobactin (1.23) 
1 S. aureus ATCC 25923 2 128 0.25* 
2 E. coli ATCC 25922 64 GAW‡ 25 
Table 2.2: MIC (µg/ml) for 2.1 and 2.3 and teixobactin 1.23 (MICs from ref. 5, 0.25* were from a different 
strain of S. aureus). ‡Growth in all wells 
2.5 Conclusion 
In conclusion, this work reports efficient total syntheses of two teixobactin analogues (22% yield of 
teixobactin analogue 2.1). Analogue 2.1 is identical to 1.23 in all aspects with the exception of the 
L-allo-End10 amino acid.  The methodology described here is not specific to only one molecule, but 
it can also be used as a general strategy for synthesis of other analogues of 1.23. The role of three D-
amino acids had also been established. The three D-amino acids present in the teixobactin analogue 
2.1 but absent in analogue 2.3 are critical for antibacterial activity.  This work also reports the 
synthesis of new AllocHN-D-Thr-OH 2.4 building block (Experimental Chapter 2) and has 
incorporated it as such in the syntheses of teixobactin analogues 2.1 and 2.3. We believe that this 
work to be pivotal for the synthesis of teixobactin and its analogues and therefore will be helpful to 
address the current challenges of antimicrobial resistance. 
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3 Defining the molecular structure of teixobactin analogues and 
understanding their role in antibacterial activities 
 
Author contributions: All the building block synthesis, peptide synthesis for the analogues, optimisations, 
purifications and sample preparation for either LC-MS analysis/NMR has been done by me. The initial drafting 
of the manuscript and supplementary information has been done by me with inputs from Abhishek Iyer. Stephen 
H. Prior carried out and analysed the NMR experiments.  The antibacterial study has been carried out by 
Charlotte S. Vincent and Edward J. Taylor. Dorien Van Lysebetten and Annemieke Madder were responsible 
for the LC-MS analysis. Eefjan Breukink provided the Lipid II. The project was designed by Ishwar Singh.  
3.1 Abstract 
The discovery of the highly potent 
antibiotic teixobactin, which kills the 
bacteria without any detectable 
resistance, has stimulated interest in 
its structure activity relationship. 
While working in this project, a 
molecular structure-activity 
relationship had not yet been 
established so far for teixobactin. Moreover, the importance of the individual amino acids in terms 
of their L/D configuration and their contribution to molecular structure and biological activity was 
still unknown. For the first time, we have defined the molecular structure of seven teixobactin 
analogues through the variation of the D/L configuration of its key residues, namely N-Me-D-Phe, D-
Gln, D-allo-Ile and D-Thr. Furthermore, we have established the role of the individual D-amino acids 
and correlated this to the molecular structure and biological activity. Through extensive NMR and 
structural calculations, including molecular dynamics simulations we have revealed the residues for 
maintaining a reasonably unstructured teixobactin which is imperative for biological activity. 





In Chapter 2, replacing the amino acid L-allo-End10 1.21 with its structurally closest natural amino 
acid arginine leads to an efficient Arg10-teixobactin 2.1 synthesis. 2.1 follows a similar antibacterial 
activity trend as teixobactin 1.23 (Figure 3.1).1,2,3,4 Therefore, conclusions drawn by synthesising 
analogues of 2.1 derivatives should hold true for teixobactin as well.  
Teixobactin 1.23 contains 11 amino acids, out of which 4 are D-amino acids, namely N-Me-D-Phe1, 
D-Gln4, D-allo-Ile5 and D-Thr8 (Figure 3.1, marked in red). Peptides containing more D-amino acids 
are generally less susceptible to enzymatic degradation5 which may well be applicable for 
teixobactin.6 In my previous chapter,3 we had already established the importance of the D-amino acids 
through the total synthesis of both D and L analogues of teixobactin (2.1 and 2.3 respectively). 
Replacing the D-amino acids with their corresponding L-configurations (except D-Thr8) results in a 
64-times decrease in antibacterial activity against S. aureus.  
 
Figure 3.1: Structure of (A) Teixobactin (1.23) and (B) Teixobactin-Arg10 (2.1) with the D-amino acids 
highlighted in red and the structural differences marked in blue. 
 




3.3 †Aim of study 
It is not yet known, however, if a molecular structure (three- dimensional structure)-activity 
relationship exists for teixobactin 1.23. To date, except for the structural deduction of 1.23 published 
by Ling et. al.,6 no molecular structural studies on teixobactin or its analogues have been reported. 
Moreover, the impact on the molecular structure and activity of teixobactin by varying individual 
amino acids in terms of their L/D configuration is still unknown.  This study aims to explain why L-
analogues of teixobactin are not active. We have selected the systematic replacement of D-amino acid 
residues with L configurations to understand the minimum number of D-amino acid residues required 
for biological activity. Furthermore, the low cost of L-amino acids was expected to lower the financial 
constraint on teixobactin development. For the first time, we have the determined molecular 
structures of seven teixobactin derivatives by changing D/L configurations from NMR, their 
antibacterial activity and lipid II binding. The results from our work will enable the better 
understanding of molecular structure-activity relationship of teixobactins and their further 
development as drug like molecules. 
3.4 Results and discussion 
Through this work, we investigate the role of each of the D-amino acids, their impact on the molecular 
structure and activity of teixobactin and whether there exists a structure-activity relationship for the 
molecule. Through the syntheses of seven analogues of 2.1 (Table 3.1), followed by extensive NMR 
and structural calculations we have shown the importance of the D-amino acids on the structure and 
activity of teixobactin analogues. 
3.4.1 Structure-activity relationships (SAR) of LLLL and DDDD 
Our initial efforts were focused towards understanding the pivotal role played by the stereochemistry 
of D-Thr8 upon the gross structure of 1.23. This was achieved through the synthesis of analogue 2.12 
(LLLL) and subsequent comparison with analogue 2.11 (DDDD, Figure 3.2). Outside the cyclic 
region encompassing residues 8 to 11 the peptide is largely unstructured (Figure 3.2A).  The altered 
topological environment available to the analogue 2.12 (LLLL) makes it energetically favourable to 







                                                     
† When this work was conducted, no previous structure-activity relationship had been performed. All analogues in this 
chapter are derived from Arg10-teixobactin (2.1 or 2.11). To avoid confusion to the reader, in most cases the code of the 
analogue (e.g. DDDD or LDDD) will also be heavily utilised in this chapter.   




Analogue No. Code Configuration of Amino Acids 
  N-Me-Phe1 Gln4 Ile5 Thr8 MIC† 
2.1 or 2.11 DDDD D D D D 2 
2.12 LLLL L L L L GAW‡ 
2.13 DDLD D D L D GAW 
2.14 DLDD D L D D GAW 
2.15 LDDD L D D D 32-64 
2.16 LLDD L L D D GAW 
2.17 LLLD* L L L D 128 
Table 3.1: List of analogues of Arg10-teixobactin 2.1 synthesised by varying the D/L configuration of the key 
residues N-Me-D-Phe1, D-Gln4, D-allo-Ile5 and D-Thr8.† MIC values were measured against S. aureus and are given in 
µg/mL. ‡ Growth in all wells. *This analogue contains an acetylated Phe1 instead of an N-Me-Phe1 residue. 
3.4.2 Root-Mean square deviation (RMSD) of teixobactin analogues to determine SAR 
 
Figure 3.2:  A. Structure of teixobactin analogue 2.11 (DDDD) exhibiting native stereochemistry. B. Structure 
of analogue 2.12 (LLLL) containing L-Thr8. Overlays of the 20 lowest energy structures aligned to the backbone 
atoms of the cyclic region are displayed. Atoms are colored according to their RMSD, fading to white at higher 




RMSD. Atom transparency also increases with RMSD, with more highly disordered regions fading to 
invisibility. For clarity, only backbone atoms and the non-hydrogen atoms of Arg10 are displayed.  
 
Figure 3.3: Effect of stereochemistry at different positions on the structure of teixobactin analogues. A. 
Majority of variation observed in structural ensembles accounted for by varying levels of disorder in the N-
terminal residues. Positions labelled in black type have had their stereochemistry altered. The name of the 
analogues is as described in Table 3.1. (B-F) Backbone traces of 20 lowest energy structures aligned to the 
backbone atoms of the cyclic region. Atom colour and transparency as in Figure 3.2. 
The teixobactin analogues routinely gave spectra of the highest quality (Figure S3.16), which made 
complete atomic assignment of each analogue possible (Table S3.2). Subsequent measurement of 
dipolar correlations allowed for full structural characterisation. The number of visible NOE cross-
peaks (Figure S3.16) varied with different analogues: those with D-Gln4 (for example Figure S3.16 
red contours) contained very few medium- and long-range correlations, which is typical for highly 
dynamic, unstructured peptides in which nuclei are seldom in close enough proximity for NOE build-
up to occur. This flexibility is reflected in their high RMSD (Figure 3.2A, Figure 3.3, Table S3.3). 
In contrast, analogues possessing L-Gln4 (2.12, 2.14, 2.16, 2.17) (for example Figure S3.16 blue 
contours) contained many more cross-peaks in their NOESY spectra, some of which are categorised 
as long-range (Table S3.3), a category entirely missing from the D-Gln4 containing analogues (2.11, 
2.13, 2.15). Having numerous medium- to long-range NOEs is characteristic of peptides adopting a 
higher degree of structure, and this situation is reflected in their sub- to low Angstrom convergence 
(Figure 3.2B, Table S3.3). 
Possessing an L-Ile5 imparts a slight tendency for the structure on the teixobactin analogues (Figure 
3.3 A, B and F) but does not result in a high deviation from the original structure unlike that observed 
for L-Gln4. For instance, the RMSD of analogue 2.11 (native stereochemistry) is ~3 Å (Figure 3.2A, 




Figure 3.3A) whereas that of 2.13 (DDLD), in which D-allo-Ile5 has been replaced by L-Ile5, is 
reduced to ~2 Å (Table S3.3, Figure 3.3 A, B). A similar slight reduction in RMSD is observed in 
2.17 (LLLD, 0.93 Å; Table S3.3, Figure 3.3 A, F) when compared to 2.16 (LLDD, 1.06 Å; Table 
S3.3, Figure 3.3 A, E) where again, the only difference between them is the stereochemistry at 
position 5. The stereochemistry of position 1 has little to no effect on overall structure, as can be seen 
when one compares the RMSDs of 2.11 (DDDD) to 2.15 (LDDD, both ~3 Å; Figure 3.2A, Figure 
3.3A, D, Table S3.3). Although highly disordered, the N-terminal domains of both these analogues 
occupy a similar overall spatial region. Since the stereochemistry of position 1 is not important to 
the structure, it is likely that D configuration is important for slowing down enzyme degradation or 
for biological activity. 
Taken together, these data allow us to conclude that the stereochemistry of position 4 is critical to 
structural stability. A ubiquitous structural characteristic of the L-Gln4 containing analogues absent 
from the D-Gln4 containing analogues is that Ile6 packs against Ile11. It is therefore possible that this 
long-range packing arrangement is made possible by the altered stereochemistry at position 4 and 
has the effect of stabilising the structures. We analysed the nature of this packing through extended 
molecular dynamics (MD) simulations on the microsecond time-scale. Trajectories were calculated 
for a total of 0.1 µs for analogue 2.11 and 2.17 in explicit solvent (Figure S3.17). It was immediately 
obvious from the simulations that the native analogue seldom visits this packing arrangement (Figure 
S3.17 B), and on the few occasions it does, it is very short-lived.  However, the sidechains of Ile6 
and Ile11 remain in constant hydrophobic contact throughout the entire simulation in the case of 2.17 
(LLLD, Figure S3.17 B). 
Functionally, it was important to discover how this increased stability through packing might explain 
the MICs observed in all analogues except 2.15 (LDDD, Table 3.1). A plausible mechanism was also 
revealed through MD, in that the sidechain of Arg10 is less solvent exposed in 2.17 (LLLD, Figure 
S3.17 A). This interaction is stabilised through the formation of numerous transient intramolecular 
hydrogen bonds between Arg10 and other residues (Figure S3.17, bottom panel), a situation almost 
entirely lacking in the native analogue. 
Therefore, it is possible to surmise that if the hydrogen bond donors of the guanidine group of Arg10 
are spending a considerable proportion of their time in forming intra-molecular hydrogen bonds then 
they are unavailable for the formation of inter-molecular bonds. Thus, if Arg10 is unavailable for 
involvement in intermolecular recognition events, this could help to explain the decrease in MIC in 
case of analogue 2.17 (LLLD) as compared to 2.11 (DDDD, Table 3.1). The frequency of unfavoured 
backbone torsion angles present in the teixobactin analogues (Table S3.3) correlates strongly with D 
amino acid content. This could be due to limitations with the analysis algorithms used. 
Figure S3.17 reveals that native teixobactin analogue (Arg10) is highly dynamic in solution, whereas 
an analogue containing L-Gln4 is both more tightly packed and structurally stable. This increased 




burial (Figure S3.17 A) is probably a result of the formation of a number of transient hydrogen bonds 
between the guanidine group of Arg10 and other polar sidechains in the analogue (teal bars). In 
contrast, Arg10 only forms two short-lived hydrogen bonds (red bars) throughout the whole 
simulation in the native form. 
Complex formation of teixobactin analogues 2.11 (DDDD) and 2.12 (LLLL) with lipid II and geranyl 
pyrophosphate were performed as described previously using TLC (Experimental VIII).6 Both 
analogues bind to lipid II and geranyl pyrophosphate which is indicated by the reduction of 
lipid/phosphate visible on TLC (Figure S3.18 & S3.19). The binding of lipid II to LLLL analogue is 
unexpected as the LLLL is not biologically active. Therefore, it can be concluded that the binding 
assay on isolated lipid II does not necessarily reflect whole cell activities. A plausible explanation 
for this can be that lipid II is more freely available in solution than in the case of bacteria. 
3.5 Conclusion 
We have for the first time determined the 3D molecular structure of seven teixobactin analogues and 
established the importance of the individual amino acids in terms of their D/L configurations in 
maintaining a relatively unstructured teixobactin. Furthermore, we can directly correlate this 
propensity for structure with antimicrobial activity and have identified a possible mechanism by 
which this disorder is maintained. We have shown that the D- N-Me-Phe11 is not important from a 
structural standpoint. On the other hand, we have identified D-Gln4 as being very essential and D-Ile5 
being important in maintaining the disordered structure of teixobactin imperative for its biological 
activity. We believe this work to be critical in understanding the structural-activity relationship and 
mechanism of teixobactin and its analogues and their further development as drug like molecules. 
The results presented in this work are of broad general interest and are expected to facilitate the future 
development of teixobactin derivatives and peptide-based antibiotics for addressing the serious 
challenges posed by AMR. 
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4 Syntheses of potent teixobactin analogue against methicillin-
resitant staphyococus (MRSA) through the replacement of L-
allo-enduracididne with its isosteres 
 
Author contributions: All the building block synthesis, peptide synthesis for the analogues, optimisations, 
purifications and sample preparation for either LC-MS analysis/NMR has been done by me. The initial drafting 
of the manuscript and supplementary information has been done by me with inputs from Abhishek Iyer. Stephen 
H. Prior carried out and analysed the NMR experiments.  The antibacterial study has been carried out by 
Daniel G. Lloyd, Charlotte S. Vincent and Edward J. Taylor. Annemieke Madder was responsible for the LC-
MS analysis. The project was designed by Ishwar Singh.  
4.1 Abstract 
In this work, we have synthesised 8 
analogues of teixobactin using 
commercially available building blocks 
by replacing the L-allo-enduracididine 
amino acid with its isosteres. 
Furthermore, we have tested all the 
compounds against a panel of Gram-
positive bacteria including MRSA and 
explained the observed trend in 
biological activity. Although all the 
analogues were active, three analogues 
from this work, showed very promising 
activity against MRSA (MIC 1 µg/mL). 
We can conclude that amino acids which are the closest isosteres of L-allo-enduracididine are the 
































































































Teixobactin, MIC against MRSA = 0.25 µg/ml
Teixobactin analogues, MIC against MRSA = 1 µg/ml
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m = 4, -X = -H









4.2 Brief Introduction 
In the previous chapters, we have managed to develop a synthetic route to which many more 
analogues of teixobactin 1.23 can be synthesised and have performed a study to identify that D-amino 
acids are essential to maintain an unstructured teixobactin which correlates with its activity. 
To further develop potent analogues of 1.23 against resistant bacteria such as MRSA, we are 
particularly interested in understanding the role of the polar amino acid residues at position 10 
namely L-allo-End 1.21, arginine and lysine. It has been suggested that 1.21 is important for the 
biological activity of 1.23,  however, as discussed previously, the synthesis of a properly protected 
1.21 and its subsequent incorporation in 1.23 synthesis is complex and low yielding (3.3% overall 
yield).1 Several research groups including us have already substituted this amino acid with 
commercially available building blocks such as Arginine,2 3 Lysine4 or Histidine.5 The obtained 
analogues were less active than the natural product and will be discussed broadly in an overview 
chapter. However, the biological activity of teixobactin analogues suggests they are still suitable for 
further development as potential antibacterials. Therefore, it is important to synthesise new, potent 
derivatives with comparable biological activity to 1.23 which do not contain the L-allo-End 1.21. 
4.3 Aim of study 
In this work, we have synthesised a total of eight analogues (seven new) of teixobactins using 
commercially available building blocks by replacing the L-allo- End 1.21 (Figure 4.1) with a series 
of amino acids that can be considered isosters thereof. We have tested all the analogues (2.1, 4.1-4.7) 
against a panel of Gram-positive bacteria including MRSA to compare the biological activity with 
teixobactin. This study is aimed at deciphering the most suited amino acids which can replace L-allo-
End. We believe that the amino acids which possess a similar structure and functional group (isostere) 
as the L-allo-enduracididine amino acid are best suited for its replacement. 
 
Figure 4.1: A. Teixobactin B. General structure of teixobactin analogues (2.1, 4.1-4.7) with the 
hydrophilic/charged residues shown in red, hydrophobic residues shown in black and structural differences 
shown in blue. 
 
 




4.4 Results and Discussion 
4.4.1 ‡Synthesis of analogues and their guanidines 
The amino acids Lysine (Lys), Ornithine (Orn), L-2,4- Diaminobutyric acid (DAB) and L-1,3-
Diaminopropionic acid (DAP) were chosen as these are the closest amine containing isosteres to 
1.21. Furthermore, through these amino acids we could sequentially shorten the side chain length by 
one methylene unit from 4 C atoms to 1 C atom. To further expand the number of teixobactin 
analogues and to reduce the overall cost and time taken by avoiding the re-syntheses of analogues 
containing non-natural guanidine side-chains, we have used a one-step route from our previous 
synthesis3 and inspired by the results of Tor et. al.6 to directly convert the deprotected amino-side 
chains into their corresponding guanidines (Figure 4.2).  
 
Figure 4.2: General scheme for the syntheses of teixobactin analogues 4.2, 4.5 and 4.7 from their amino 
precursors 4.1, 4.4 and 4.6 respectively. 
For this purpose, the commercially available 1H-Pyrazole-carboxamidine hydrochloride in MeOH 
with Et3N was used (Figure 4.2, Experimental Section III) followed by HPLC purification to remove 
any excess reagent present in the reaction mixture. By introducing Lys, Orn, DAB and DAP one at 
a time at position 10 we synthesised analogues Lys10-teixobactin 4.1, Orn10-teixobactin 4.3, DAB10-
teixobactin 4.4 and DAP10-teixobactin 4.6 (Figure 4.3). We then directly converted Lys10-teixobactin 
4.1 to (Homoarginine) HoArg10-teixobactin 4.2, DAB10-teixobactin 4.4 to NorArg10-teixobactin 4.5 
and DAP10-teixobactin 4.6 to (L-2-amino-3-guanidinoaminopropionic acid) GAPA10-teixobactin 4.7 
using the aforementioned protocols (Figure 4.3). We thus synthesised 8 teixobactin analogues 
namely Lys10-teixobactin 4.1, HoArg10-teixobactin 4.2, Orn10-teixobactin 4.3, Arg10-teixobactin 2.1, 







                                                     
‡ For simplicity, in most cases both the analogue name and number have been frequently used throughout the chapter. 





Figure 4.3: Complete structure of teixobactin analogues (2.1, 4.1-4.7) and structure of L-allo-End 1.21. The 
amino acids at position 10 and L-allo-End 1.21 have been numbered and highlighted in red for clarity. 
4.4.2 MIC evaluation on teixobactin analogues 
Table 4.1:Minimum Inhibitory Concentration (MIC) values of analogues against MRSA ATCC 33591, 





































































































































































































































































































































































































































epidermidis ATCC 12228 
(µg/mL) 
MIC against Bacillus 
subtilis 168 (µg/mL) 
1.23 Teixobactin 0.257 0.078-0.317 0.027 
2.1 Arg10-teixobactin 2 2 1 
4.1 Lys10-teixobactin 1 1 0.25 
4.2 HoArg10-teixobactin 1 0.25 0.125 
4.3 Orn10-teixobactin 2 1 0.25 
4.4 DAB10-teixobactin 2 2 1 
4.5 NorArg10-teixobactin 1 1 0.5 
4.6 DAP10-teixobactin 4 2 0.5 
4.7 GAPA10-teixobactin 4 4 1 
1.12 Vancomycin 2 2 0.25-0.5 




The syntheses and biological activity against Staphylococcus aureus of Lys10-teixobactin 4.14,5, 
Orn10-teixobactin 4.38,  Arg10-teixobactin 2.12,3 and NorArg10-teixobactin 4.59 have already been 
reported. There has been very limited evaluation of teixobactin analogues against MRSA. Among 
the synthesised analogues, Orn10-teixobactin (4.3) (MIC 2 µg/mL)8 and NorArg10-teixobactin 4.5 
(MIC 16 µg/mL)9 are the only ones tested against MRSA. However, a different strain of MRSA was 
used. To address this, we have evaluated the antibacterial activity of our eight teixobactin analogues 
(2.1, 4.1-4.7) against MRSA ATCC 33591 (identical to the strain reported in earlier7) to compare the 
biological activities with that of teixobactin 1.23 (Table 4.1). All the analogues were also screened 
against Staphylococcus epidermidis and Bacillus subtilis to provide a more comprehensive overview 
of the biological activities of these molecules. Vancomycin 1.12 was used as a control. 
Herein we report for the first time the MIC of Lys10-teixobactin 4.1 against MRSA which was found 
to be two times better than that of Arg10-teixobactin 2.1 (Table 4.1) against the same species. 
HoArg10-teixobactin 4.2 was found to have identical activity as Lys10- teixobactin 4.1. The MIC of 
Orn10-teixobactin8 4.3 was found to be consistent with that reported in literature and identical to that 
of Arg10-teixobactin 2.1. The MIC of Dab10-teixobactin 4.4 was found to be identical to Orn10- 
teixobactin 4.3 (Table 4.1) which is expected as both DAB and Orn can be considered isosters of L-
allo-Enduracididine (Figure 4.3). NorArg10 teixobactin 4.5 showed two times better MIC than 2.1 
(Table 4.1) although both Norarginine and Arginine are isosteric with L-allo-End. The difference can 
be potentially attributed to lower flexibility of 4.5 due to a reduced carbon chain length of NorArg 
and therefore being structurally more similar to L-allo-End. On further reducing the side-chain length 
of the amino acid at position 10 by one methylene group we obtained the analogues Dap10-teixobactin 
(4.6) and GAPA10-teixobactin 4.7 which were found to be less active than analogues (2.1, 4.1-4.5) 
in MRSA. Both Dap10-teixobactin 4.6 and GAPA10-teixobactin 4.7 have an MIC two times higher 
than Arg10-texiobactin 2.1. The higher MICs in MRSA are probably because although both DAP and 
GAPA have structural similarities to L-allo-enduracididine (Figure 4.3), they have a shorter carbon 
chain thereby affording less flexibility. The MIC trend observed in Staphylococcus epidermidis and 
Bacillus subtilis is similar to that of MRSA. However, all compounds (2.1, 4.1-4.7) have shown 2-4 
times better MICs in B. subtilis compared to MRSA and S. epidermidis. HoArg10-teixobactin 4.2 was 
found to be the most potent analogue possessing the lowest MIC in all three species, followed by 
Lys10-teixobactin 4.1 and Orn10-teixobactin 4.3. Overall, the MICs observed are consistent with the 
hypothesis that the closest isosteres of L-allo-End 1.21 are most suited for its replacement. 
  





In conclusion, we have synthesised seven new teixobactin analogues and tested them against a panel 
of Gram-positive bacteria including MRSA to determine the most suited amino acids for replacing 
the synthetically challenging L-allo-End at position 10. Furthermore, for the rapid syntheses of 
guanidine containing teixobactin analogues from amines, we have used the direct conversion of 
amines to guanidines for completely deprotected teixobactin analogues. This method is compatible 
with secondary amines as well as other amino acid side chains and will therefore be suitable for 
diverse peptides. Based on the MICs against MRSA, we observe that all the synthesised compounds 
are active and therefore can be used as leads for further derivatisation. Lysine, homoarginine and 
norarginine are all equally suitable substitutions for L-allo-End. Furthermore, almost no difference 
in MIC was observed between the amino derivatives and their corresponding guanidine counterparts. 
This implies that there is a considerable tolerance for the substitution of L-allo-End with both 
proteogenic and non-proteogenic amino acids containing amine or guanidine side-chains. We have 
synthesised eight potent teixobactin analogues three of which show very promising activity against 
MRSA (MIC 1 µg/mL). The results from this work are expected to facilitate the development of 
teixobactin analogues against MRSA and have the potential to address the challenges posed by multi-
drug resistant bacteria.  
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5.1 Abstract 
Due to many challenges in obtaining L-
allo-End 1.21, the total synthesis of 
teixobactin 1.23 is laborious and low 
yielding (3.3%). In this work, we have 
identified a unique design and developed 
a rapid synthesis (10 min mwave assisted 
coupling per amino acid, 30 min 
cyclisation) of several highly potent 
analogues of teixobactin with yields of 
10–24% by replacing the L-allo-End with 
commercially available non-polar 
residues such as leucine and  isoleucine. 
Most importantly, the Leu10-teixobactin 5.13 and Ile10-teixobactin 5.12 analogues have 
shown highly potent antibacterial activity against a broader panel of MRSA and 
Enterococcus faecalis (VRE). Furthermore, these synthetic analogues  displayed  identical  
antibacterial  activity  to  natural  teixobactin  (MIC  0.25  mg  mL-1) against MRSA ATCC 




33591 despite their simpler design and ease of synthesis. We have confirmed lipid II binding 
and measured the binding affinities of individual amino acid residues  of  Ala10-teixobactin 
towards geranyl pyrophosphate by NMR to understand the nature and strength of binding 
interactions. Contrary to current understanding, we have shown that a cationic amino acid 
at position 10 is  not essential for target (lipid II) binding and potent antibacterial activity  
of  teixobactin.  We thus provide strong evidence contrary to the many assumptions made 
about the mechanism of action of this exciting new antibiotic. Introduction of a non-cationic 
residue at position  10  allows  for  tremendous  diversification in the design and synthesis 
of highly potent teixobactin analogues  and  lays  the  foundations for the development of 
teixobactin analogues as  new  drug-like molecules to  target MRSA  and Mycobacterium 
tuberculosis. 
5.2 Brief Introduction 
So far, all the analogues that have been described in previous chapters have all had lower potency in 
comparison to the natural product. Teixobactin scaffold contains 11 amino acids, with a mix of 
polar/non-polar residues with a cationic residue at position 10 known to be important for its activity. 
The insight of the role of each amino acid could provide better progress in the design and synthesis 
of simpler and more potent analogues against MDR bacterial pathogens, such as MRSA.  
Alanine scanning is a technique that has been used has widely to determine the functions of different 
amino acids in proteins and peptides for its antibacterial studies. Since the simplest amino acid 
glycine is achiral, alanine is the next simplest amino acid which is chiral and can be used to retain 
the absolute conformation of the peptide. Because of its non-bulky nature, it does not enforce high 
electrostatic or steric effects1. Alanine is very abundant and frequently found in secondary structures 
of proteins. Due to the methyl group, it gives a structural understanding of the side chains of different 
amino acids in the sequence. Alanine-scanning has been utilised in several other antimicrobial 
compounds such as nisin2 and feglimycin3 which attributed to successfully synthesising novel 
peptides with increased activity.  




5.3 Aim of study 
 
Figure 5.1: Structure of  Teixobactin 1.23 and Leu10-Teixobactin 5.13 with the D-amino acids highlighted in 
red and the L-allo-End 1.21 and replaced L-Leu residue highlighted in blue. MRSA ATCC 33591, 
Staphylococcus aureus ATCC 29213. 
In this work, we describe a unique design and rapid synthesis of several highly potent analogues of 
teixobactin against Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus 
(MRSA) and Enterococcus faecalis (Vancomycin-resistant Enterococcus, VRE) by replacing the 
synthetically challenging L-allo-End with commercially available non-polar residues such as alanine, 
leucine and isoleucine. This study aims to answer two important questions. Firstly, is it essential to 
incorporate a residue with a positively charged side chain at position 10 for maintaining target 
binding (lipid II) and biological activity of teixobactin and its analogues? Secondly, what are the key 
residues involved and what are the target binding contributions of the individual amino acid residues 
in the teixobactin analogues?  To evaluate both these questions and identify the key residues 
particularly with respect to position 10, an alanine scan was performed on Arg10-teixobactin 2.1 
(Figure 5.2, 5.1-5.8). The alanine scanning technique has been used earlier on other antimicrobial 
peptides with success4 but has not yet been performed on teixobactin or its analogues. In order to 
further improve the antibacterial activity of Arg10-teixobactin by modifying the amino acid at 
position 10, new analogues of teixobactin were prepared by systematic replacement of Arg10 with D-
Ala (D-Ala10-teixobactin, 5.9), Gly (Gly10-teixobactin, 5.10), Val (Val10-teixobactin 5.11), Ile (Ile10-
teixobactin, 5.12), Leu (Leu10-teixobactin, 5.13), Ser (Ser10-teixobactin, 5.14) and Phe (Phe10-
teixobactin, 5.15) (Figure 5.2, 5.9-5.15). We thus synthesised 15 analogues (Figure 5.2) of 
teixobactin using the conditions described in Figure 5.3, Figure S5.1. 













5.4 Results and discussion 
5.4.1 Design and synthesis 
The synthesis of all our analogues involved loading Fmoc-alanine-OH on the 2-CTC resin, followed 
by amide coupling with Alloc-NH-D-Thr-OH, resin esterification with 10 eq. Fmoc-Ile-OH, and 
adding 10 eq. DIC and 5 mol% DMAP for 2h. The next amino acid (AA) was then coupled using 4 
eq. AA with 4 eq. HATU/8 eq. DIPEA in DMF for 1h followed by Fmoc deprotection and trityl 
protection. Next, the N-terminal alloc protecting group was removed using Pd(PPh3)4 and 
phenylsilane (Figure 5.3). All other amino acids were coupled using 4 eq. AA with 4 eq. DIC/Oxyma 
using an automated microwave peptide synthesiser (coupling time of 10 min each). Fmoc 
deprotection was performed using 20% piperidine in DMF (Figure 5.3, Figure S5.1). Cyclisation was 
performed using 1 eq. HATU and 10 eq. DIPEA and was found to be complete within 30 min with 
complete conversion of the linear product into its cyclised counterpart (Experimental Figures S5.2 – 
S5.59). Yields after HPLC purification were found to be 10-24% (Table S5.1). We have identified a 
unique design in which the introduction of hydrophobic residues such as leucine at position 10 
(Figure 5.1) has several advantages over the lengthy low-yielding (3.3%) synthesis of teixobactin, 
including overall yields of up to 24%, faster automated syntheses, and use of commercially available 
building blocks. 
 
Figure 5.3: Synthesis of 5.13 starting from 2-CTC resin: a. 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3h.   b. 
20% piperidine in DMF followed by 3 eq. AllocHN-D-Thr-OH, 3 eq. HATU/6 eq. DIPEA, 1.5h   c. 10 eq. 
Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2h followed by capping with Ac2O/DIPEA 10% in DMF, 
20% piperidine in DMF   d. 4 eq. Fmoc-Leu-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 20% 




piperidine in DMF   e. 10 eq. Trt-Cl, 15% Et3N in DCM, 1h.  f. 0.2 eq. [Pd(PPh3)4]0 + 24 eq. PhSiH3 in dry 
DCM, 1x20 min, 1x45 min.   g. 4 eq. Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting group), 4 
eq. DIC/Oxyma (µwave, 10 min) followed by 20% piperidine in DMF (3 min, 10 min).   h. TFA:TIS:DCM = 
2:5:93, 1h.  i. 1 eq. HATU/10 eq. DIPEA in DMF, 30 min.   j.  TFA:TIS:H2O = 95:2.5:2.5, 1h.   
Teixobactin and its active analogues such as Arg10-teixobactin 2.1 and Lys10-teixobactin 4.1 contain 
two positive charges. However, the analogues 5.1, 5.8-5.15 contain only one positive charge and 
were therefore found to be more hydrophobic than the analogues 5.2-5.7. All the compounds were 
found to be completely soluble in DMSO. Therefore, stock solutions of these compounds were 
prepared in DMSO for MIC testing. Upon dilution in the Mueller Hinton broth (Oxoid) culture media 
in which bacteria were grown (concentration ~256 µg/mL), no turbidity or precipitation was 
observed indicating that the compounds were soluble in the culture media. 
5.4.2 Antibacterial studies 
Analogues of teixobactin derived through an alanine scanning of teixobactin reveal that residues N-
Me-Phe1, Ile2 D-allo-Ile5, L-Ile6 and Ser7 are important for antibacterial activity and their replacement 
by L-Ala or D-Ala results in decrease in biological activity (Table 5.1). Interestingly, replacement of 
L-Ser3 and D-Gln4 by L-Ala and D-Ala has no effect on antibacterial activity. Thus, the two residues 
L-Ser3 & D-Gln4 are ideal candidates for replacement in the case of teixobactin due to their more facile 
synthesis and minimal impact on biological activity. It has been suggested that replacement of any 
of the residues in the core ring structure of teixobactin negates all biological activity of the molecule.5 
In our case, however, the most interesting result was obtained through the replacement of L-Arg10 by 
L-Ala 5.8. 
The design and syntheses of potent teixobactin analogues published in the literature has thus far been 
limited to the substitution of L-allo-End with amino acids such as Arg,6 7 Lys5 and Orn8, all of which 
possess a cationic side chain. A positive charge is a common structural characteristic of depsipeptides 
which bind to lipid II9. L-allo-End is thus reported to be important for potent antibacterial activity of 
teixobactin.10 Therefore, it was expected that replacement of this residue with alanine, which is non-
polar and uncharged, would completely abolish the biological activity of the molecule. Contrary to 
this, we observed that Ala10-teixobactin was highly active against MRSA (Table 5.1) with an MIC 
of 1-2 µg/mL. 
A plausible explanation could be that Ala10-teixobactin binds to the pyrophosphate motif of lipid II 
using the amide backbone in a similar way to that proposed for the binding of nisin.11 Superior results 
were obtained with Ile10-teixobactin 5.12 and Leu10-teixobactin 5.13, which consistently gave 
identical MIC values of 0.25 µg/ml as compared to the reported MIC for teixobactin against MRSA 
(Table 5.1). Leu has a very similar hydrocarbon framework to L-allo-End (Figure 5.1), followed very 
closely by Ile, which could explain the identical MIC value of these analogues 5.12 & 5.13 to 
teixobactin 1.23 against MRSA. In order to determine the effect of serum on antibacterial activity, 




the MIC of compounds 5.12 and 5.13 were measured in presence of 10% human serum (Table S5.4). 
In both cases no change was observed in the MIC (Table 5.1) indicating that 10% human serum has 
no effect on the antibacterial activity. 
Compound Name MICa (µg/mL)         
1.23 Teixobactin 0.25 
2.1 Arg10-teixobactin 2 
5.1 Ac-D-Ala1-Arg10-texiobactin >128 
5.2 Ala2-Arg10-teixobactin >128 
5.3 Ala3-Arg10-teixobactin 1-2 
5.4 D-Ala4-Arg10-teixobactin 2-4 
5.5 D-Ala5-Arg10-teixobactin 64-128 
5.6 Ala6-Arg10-teixobactin >128 
5.7 Ala7-Arg10-teixobactin 16-32 
5.8 Ala10-teixobactin 1-2 
5.9 D-Ala10-teixobactin 32 
5.10 Gly10-teixobactin 2 
5.11 Val10-teixobactin 0.5 
5.12 Ile10-teixobactin 0.25 
5.12a Ile10-teixobactin + 10% human serumb 0.25 
5.13 Leu10-teixobactin 0.25 
5.13a Leu10-teixobactin + 10% human serumb 0.25 
5.14 Ser10-teixobactin 16 
5.16 Phe10-teixobactin 2 
1.12 Vancomycin 2 
Table 5.1: List of teixobactin analogues (1-15). aMIC: Minimum Inhibitory Concentration. MRSA ATCC 
33591 used. Culture Media: Mueller Hinton Broth (Oxoid). b 10% volume with human serum (SIGMA, H4522) 
The fact that a cationic residue at position 10 is not essential for antibacterial activity represents a 
significant breakthrough in teixobactin research given the earlier stated importance of the L-allo-End 
amino acid in the total synthesis of teixobactin.10 Our design has considerably improved not only the 
antibacterial activity of teixobactin analogues but also the ease of synthesis. Our findings are of 
particular importance as MRSA is responsible for many infections worldwide.12 
D-Ala10-teixobactin shows 16-times lower antibacterial activity than Arg10-teixobactin which would 
be expected, as inversion of configuration of even a single amino acid in the core ring structure can 
significantly lower the MIC value of a  teixobactin analogue.5 Surprisingly, Gly10-teixobactin 5.10 
shows identical activity to Arg10-teixobactin 2.1 showing that complete removal of the chiral center 
at position 10 is tolerated provided the configuration of the remaining residues is intact. Val10-
teixobactin 5.11 shows 4-times better antibacterial activity than Arg10-teixobactin but Ser10-
teixobactin 5.14 shows 8-times lower activity, indicating that Ser at position 10 probably interferes 
with hydrogen bonding between the core ring structure of teixobactin and lipid II. Phe10-teixobactin 
5.15 gave an MIC of 2 µg/mL against MRSA indicating that an aromatic amino acid such as 
Phenylalanine at position 10 is also tolerated. Overall, from our work it appears that the claimed 
importance of a charged residue at position 10 in the form of an amine or guanidine group in 
texiobactin 1.23 has been overstated in the literature given that the most potent analogues obtained 
thus far are the Leu10-teixobactin and Ile10-teixobactin both of which are non-polar and non-charged. 




This unexpected result facilitates the development of several highly potent teixobactin analogues 
against a broader panel of MRSA, MSSA and Enterococcus faecalis (VRE) including 
Mycobacterium smegmatis (Table 5.2) but with significantly higher yields compared to teixobactin. 
Although analogues of teixobactin with improved yields have been synthesised previously6-13, none 
possess comparable activity to teixobactin and therefore the yields obtained for Ile10-teixobactin and 
Leu10- teixobactin (Table S5.1, S5.4, 10-20%) cannot be compared to those of the other less potent 
analogues of teixobactin described in literature.6-13  
Based on the initial MIC results (Table 5.1), we identified Ala10-teixobactin 5.8, Val10-teixobactin 
5.11, Ile10-teixobactin 5.12 and Leu10-teixobactin 5.13 as our lead compounds. These compounds 
along with Arg10-teixobactin 2.1, and vancomycin 1.21/daptomycin 1.13 as controls, were tested 
against an extended panel of Gram positive bacteria (Table 5.2) to provide a more comprehensive 
overview of the biological activity of these molecules. A substancial difference in MIC was observed 
in the presence and absence of polysorbate 80 (Table S5.4).14 Leu10-teixobactin 5.13 showed potent 
activity against M.smegmatis (MIC ~ 1 µg/mL). Ala10-teixobactin 5.8 and Arg10-teixobactin 2.1 
showed comparable activity against M. smegmatis with MICs in the range of 1-2 µg/mL. In general, 
the minimum bactericidal concentration (MBCs) of all compounds were found to be 2-4 times the 
MIC value. Ile10-teixobactin 5.12 and Leu10-teixobactin 5.13 were found to be the most potent 
compounds showing MICs ≤ 0.25 µg/mL in all strains.  
The MICs and MBCs of both analogues against Staphylococcus aureus ATCC 29213 were found to 
be ≤ 0.0625 µg/mL and ≤ 0.125 µg/mL respectively, lower than the reported MIC of native 
teixobactin14 against the same strains. Ile10-teixobactin (5.12) in particular was found to be highly 
active against both VRE strains with MICs ≤ 0.0625 µg/mL and also an MIC 0.5 of µg/mL against 
M. smegmatis. We thus report, for the first time, two analogues of teixobactin showing highly potent 
antibacterial activity against a broader panel of resistant Gram-positive bacteria including clinical 
isolates. This is a very significant advancement in terms of teixobactin research and allows for the 
synthesis of a library of teixobactin derivatives based on Ile10-teixobactin and Leu10-teixobactin 
which can be simpler, highly potent and significantly more cost effective than the synthesis of 
teixobactin. 
  




Table 5.2: MIC and MBC (in µg/mL) of the teixobactin analogues 2.1, 5.8, 5.11-5.13 and daptomycin control 
against an extended panel of Gram positive bacteria. Strain information: MRSA 1: MRSA ATCC 700699, 
MRSA 2: MRSA DR 42412 (sputum), MRSA 3: MRSA DM21455 (eye). MRSA 2 and MRSA 3 are clinical 
isolates. Staphylococcus aureus ATCC 29213, Enterococcus faecalis (VRE 1:  VRE ATCC 700802, VRE 2: 
VRE ATCC 29212). M. smegmatis ATCC 607. Culture Media: Mueller Hinton Broth. 
5.4.3 Time -kill kinetics of analogues 5.12 and 5.13 
Early stage time-kill kinetics for Ile10-teixobactin 5.12 and Leu10-teixobacitn 5.13 against MRSA 
ATCC 21455 using vancomycin as a control were carried out as described (Experimental section 
IX).14 At 0.5 µg/ml, both 5.12 and 5.13 were found to elicit complete bactericidal activity within 8 h 
whereas substantial growth was observed in the presence of vancomycin (0.5 µg/ml, Figure 5.4A). 
The concentration of vancomycin needs to be increased to 8 µg/ml in order to have similar effects as 
the teixobactin analogues 5.12 & 5.13 (Figure 5.4B). 
 
Figure 5.4: A. Time-kill kinetics of teixobactin analogues 5.12 & 5.13 with a comparative antibiotic 
(vancomycin) against MRSA 21455. The concentration of teixobactin analogues and vancomycin 1.12 are 
maintained at 0.5 µg/ml.  B. Time-kill kinetics of teixobactin analogues with vancomycin against MRSA 21455 
strains at elevated concentrations of the antibiotics. At 8 µg/ml concentration the kill kinetics profiles are 
similar for vancomycin & teixobactin analogues 5.12 & 5.13. The horizontal dotted line represents the limit of 
detection. 
































































Strain        Compound  
   





MIC 4 1 0.25 0.25 1 2 0.5 
MBC 16 4 1 2 2 - - 
MRSA 2 
MIC 1 0.5 ≤ 0.0625 ≤ 0.0625 0.125 2 0.5 
MBC 4 4 ≤ 0.0625 ≤ 0.0625 0.5 - - 
MRSA 3  
MIC 1 0.25 ≤ 0.0625 ≤ 0.0625 0.5 2 0.5 
MBC 2 2 0.125 ≤ 0.0625 1 - - 
Staphylococcus 
aureus 
MIC 1 0.25 ≤ 0.0625 ≤ 0.0625 0.25 4 0.25 
MBC 2 1 0.125 0.125 1 -  
VRE 1 MIC 4 0.5 ≤ 0.0625 0.25 2 >4 0.5 
VRE 2 MIC 4 0.5 ≤ 0.0625 0.25 2 >4 0.5 
M. smegmatis MIC 1-2 - 0.5 1 1-2 >64 - 
         




5.4.4 Toxicity studies and haemolysis assay 
The analogues Ala10-teixobactin 5.8, Val10-texiobactin 5.11 and Leu10-teixobactin 5.13 were tested 
on HeLa cell cultures and no significant toxicity was observed (relative survival 90-100%) up to a 
concentration of 100 µM (Figure S5.79) which is well above the MIC values (0.2-0.8 µM, 125-500 
times). Additionally, a haemolytic assay using Leu10-teixobactin and Ile10-teixobactin against rabbit 
erythrocytes using Melittin as a control (Figure 5.5) indicated that peptides 5.13 and 5.12 did not 
show any discernible haemolytic activity, even at concentrations that exceed >500x the mean MIC 
values whereas substantial haemolytic activity was observed for melittin (Figure 5.5). These results 
establish the non-haemolytic properties of the designed teixobactin analogues. 
 
 
Figure 5.5: Hemolytic activity of teixobactin analogues for rabbit erythrocytes. The blood cells were exposed 
to various concentrations of peptides for 1 h and the release of haemoglobin was determined 
spectrophotometrically. Each value represents an average of triplicate experiments. 
5.4.5 Lipid II binding assay 
To better understand the potent antibacterial activity of Ala10-teixobactin we have performed the lipid 
II TLC binding assay as reported earlier for teixobactin.14 Teixobactin and Arg10-teixobactin bind to 
lipid II in a 2:1 ratio resulting in the complete disappearance of the lipid II spot on TLC (Figure 
S5.76). Although Ala10-teixobactin also shows binding with lipid II in a 2:1 ratio, a small amount of 
lipid II was still visible on TLC. The lipid II spot, however, completely disappears by increasing the 
concentration of Ala10-teixobactin (Figure S5.76). TLC binding studies with Leu10-teixobactin also 
showed complete disappearance of the lipid II spot when a ratio of 2:1 was used (Figure S5.78). It is 
very interesting that Ala10-teixobactin and Leu10-teixobactin were able to bind to lipid II without 









5.4.6 Geranyl Pyrophosphate (lipid II mimic) binding studies 
In order to evaluate target binding, we have performed the lipid II TLC binding assay14 with Ala10-
teixobactin. This assay provides qualitative binding data of Ala10-teixobactin 5.8 with lipid II. 
Although the technique is fast and effective, the results obtained via this method do not necessarily 
reflect whole cell activities. This has been reported previously by us where both D and L derivatives 
of teixobactin were found to bind to lipid II but only the former was biologically active.15 Therefore, 
in order better understand the target binding of teixobactin analogues in a quantitative manner, 
extensive NMR studies (Figure 5.6) on 5.8 and geranyl pyrophosphate were performed. Geranyl 
pyrophosphate possesses a pyrophosphate and isoprenyl chain similar to lipid II making it suitable 
for solution phase NMR studies.  
 
Figure 5.6: Selected binding isotherms obtained from titrations of geranyl pyrophosphate into Ala10-
teixobactin demonstrating residue-specific binding behavior with cooperative characteristics. Error bars show 
RMS of function fit. PC: Principal Component. 
Both TLC (Figure S5.77) and NMR (Figure 5.6, Table 5.3) suggest a 2:1 binding between Ala10-
teixobactin 5.8 and geranyl pyrophosphate. When titrating geranyl pyrophosphate into 5.8 certain 
residues such as Ser7 were found to bind with classic Michaelis-Menton binding kinetics (Figure 
5.6B). However, some isotherms exhibited a sigmoidal shape (Figure 5.6A). This can occur due to 
intermediate exchange on the NMR time-scale, and therefore cooperative binding is not an obvious 
choice. However, given our initial TLC data which shows a binding of 2:1 we have fitted the 
sigmoidal data using the Hill coefficient. It was found that all N-terminal residues weakly bound (KD 
~0.5mM) geranyl pyrophosphate in a highly cooperative (Hill coefficient ~2) manner, whereas ring-
proximal residues bound significantly tighter but less cooperatively. Tightest binding was observed 
for Ser7 (KD ~125μM), which in a recently published teixobactin X-ray structure12 points its hydroxyl 
directly towards a bound anion. Analysing the overall binding using PCA (Figure 5.6C), which 
removes any influence of intermediate exchange from the isotherms,16 gave a net KD of ~138 μM. 





Table 5.3: Dissociation constants between Ala10-teixobactin 5.8 and geranyl pyrophosphate at residue 
resolution, as determined by NMR titration. A blank Hill coefficient indicates Michaelis-Menton binding 
kinetics was sufficient to satisfactorily describe the titration data. 
In order to determine if teixobactins aggregate in the presence of geranyl pyrophosphate 1H DOSY 
(diffusion ordered spectroscopy) spectra were recorded at each titration point and the diffusion 
coefficients calculated for both geranyl pyrophosphate and 5.8 (Figure 5.7). Over the course of the 
titration the diffusion coefficient obtained from 5.8 remained constant, indicating no aggregation 
occurred. The diffusion coefficient observed for geranyl pyrophosphate increased slightly over the 
course of the titration, indicating that it may have adopted a more compact structure upon association 
with the teixobactin analogue. 
 
Figure 5.7: Graph of Diffusion co-efficient vs concentration of geranyl pyrophosphate indicating teixobactin 
does not aggregate when exposed to increasing geranyl pyrophosphate concentrations. Error bars indicate 
standard deviation of the fitting function. 
Entry KD (μM) Hill 
coefficient 
1  Me-D-Phe 
Hα 
n.d. n.d. 
2  Ile Hα 348 ± 18 2.1 
3  Ser Hα 503 ± 8 2.0 
4  D-Gln Hα 507 ± 2 2.2 
5  D-Ile Hα 483 ± 4 1.7 
6  Ile Hα n.d. n.d. 
7  Ser Hα 125 ± 3  
8  D-Thr Hα 204 ± 3  
9  Ala Hα 394 ± 4 2.1 
10 Ala Hα 314 ± 3  
11 Ile Hα 391 ± 4 1.5 
Net 138 ± 5  




5.4.7 Antagonization Assay 
In order to further prove a lipid II mediated mode of action, an antagonization assay was performed 
using Leu10-teixobactin 5.13 with lipid II as described in literature.14 The ratios of 5.13 to lipid II 
tested were 1:0.5, 1:1, 1:2 and 1:5 and growth was observed. These results are consistent with the 
2:1 binding ratio observed using the TLC assay (Table S5.3). However, in case of Leu10-teixobactin 
5.13 (control) no growth was observed. 
5.4.8 NMR Structural Studies 
NMR analysis of teixobactin analogues (Figure 5.8) reveals common structural characteristics 
between those analogues which retain some residual antibacterial activity. Analogue 5.8 was chosen 
for NMR studies as it provides the most direct comparison with other analogues. All analogues retain 
most of the NOEs observed in the Arg10-teixobactin 2.1, despite some differences in amide chemical 
shift (Figure 5.8A). From Figure 5.8B and Figure 5.8C it can be observed that α proton chemical 
shifts show little variation between analogues at both termini: N-terminal similarities are likely due 
to these residues existing in a random coil environment; C-terminal similarities are likely due to the 
restraints placed upon these residues by the ring structure. Amide chemical shifts are more variable, 
particularly for residues 7 and 8, in which the chemical shift of these protons is ~1 ppm downfield in 
Ala10-teixobactin 5.8. This is likely due to the loss of the guanidinium group and suggests proximity 
between these residues and Arg10. The N-terminus again shows little variation, characteristic of a 
random coil. The mutated residue chemical shifts were excluded from the statistics. Figure 5.8D 
shows that in all three mutants Ala3-Arg10-teixobactin 5.3, Ala4-Arg10-teixobactin 5.4 and Ala10-
teixobactin 5.8 the N-termini were unstructured but were showing evidence of structure starting 
approximately from residue 5, where in all cases the RMSD had dropped by ~50% from that observed 
at their termini. The RMSDs observed at the C termini are low, as this area is highly constrained in 
structure by the ring. 
 





Figure 5.8: (A) Overlay of the amide fingerprint regions of the 1H-1H NOESY spectra of wild type (Arg10-
teixobactin) and active teixobactin analogues. (B and C) Chemical shift data obtained from α (B) and amide 
(C) protons. (D) Statistics of structures calculated using the NOEs obtained from panel (A). For clarity, the 
DMSO (~3.3 ppm) and residual water (~2.5 ppm) signals have been obscured with grey boxes. Data show the 
average RMSD of each atom in the residue from all 20 members of the ensemble. Error bars are standard 
deviation in the RMSDs of each residue's atoms. Standard deviations were calculated including the chemical 
shifts for 16.7 Ensembles of 20 structures generated by Cyana 2.117 and refined in Gromacs18. Error bars 
indicate standard deviation amongst all the atoms of that residue. Spectra were recorded on 1 mM teixobactin 
samples dissolved in DMSO-d6 on a 500 MHz spectrometer at 300 K. Legends for Figure 5.8B and Figure 
5.8C are the same, and are shown in panel (C). 
  





In conclusion, we have described a unique design and rapid synthesis of several highly potent 
teixobactin analogues by replacing the synthetically challenging amino acid L-allo-End with the 
commercially available non-polar residues such as leucine 5.13 and isoleucine 5.12. The teixobactin 
analogues from this work have shown highly potent antibacterial activity against a broad panel of 
MRSA, MSSA and VRE, despite their simpler design. Early stage kill kinetics data suggests Leu10-
teixobactin and Ile10-teixobactin to be superior to vancomycin against MRSA. An antagonization 
assay suggests a lipid II mediated mode of action for Leu10-teixobactin. Most importantly, contrary 
to the current understanding we have demonstrated that cationic amino acids such as L-allo-End, 
arginine or lysine at position 10 are not essential for target (lipid II) binding and antibacterial activity. 
This surprising finding opens the door to the design and syntheses of several highly simplified potent 
teixobactin analogues and challenges many of the current assumptions about the mechanism of action 
of teixobactin. Our design of highly potent teixobactin analogues has several advantages such as 
improved yields ~10-20%, ease of synthesis (including 10 min µwave assisted coupling steps and a 
30 min cyclisation step) and uses commercially available building blocks.  
NMR studies reveal that the analogues Ala3-Arg10-teixobactin 5.3, Ala4-Arg10-teixobactin 5.4 and 
Ala10-teixobactin 5.8 are more unstructured towards the N-termini but highly structured towards the 
C termini due to the close-by ring. We have performed qualitative lipid II binding experiments and 
measured the binding affinities of individual amino acid residues of Ala10-teixobactin and geranyl 
pyrophosphate (lipid II mimic) by NMR to understand the role of amino acid residues in binding. 
Ser7 was found to have the tightest binding with an experimental KD of 125 µM. 
To the best of our knowledge, Ile10-teixobactin 5.12 and Leu10-teixobactin 5.13 are the only reported 
teixobactin analogues which have shown superior potency against resistant Gram-positive bacteria. 
The results from this work represent a significant advancement in our current understanding of the 
residues critical to the biological activity of teixobactin and associated analogues. We anticipate that 
our design and relatively rapid synthesis will help overcome current challenges in the field. As it 
stands, our work herein provides ready access to highly potent teixobactin analogues and will enable 
the development of teixobactin analogues with drug like properties against resistant bacterial strains. 
The findings presented in this work have broad implications and are expected to facilitate the 
development of peptide-based antibiotics for combatting the serious global challenges posed by 
AMR. 
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6.1 Abstract 
The cyclic depsipeptide, teixobactin 
kills a number of Gram-positive 
bacteria including Methicillin-
resistant Staphylococcus aureus 
(MRSA) and Mycobacterium 
tuberculosis without detectable 
resistance. To date, teixobactin 1.23 
is the only molecule in its class 
which has shown in vivo antibacterial efficacy.  In this work, we designed and synthesised 10 new in vivo ready 
teixobactin analogues. These analogues showed highly potent antibacterial activity against Staphylococcus 
aureus, MRSA, and vancomycin-resistant Enterococci (VRE) in vitro. One analogue, D-Arg4-Leu10-
teixobactin 6.2 was found to be non-cytotoxic in vitro and in vivo. Moreover, topical instillation of peptide 6.2 
in a mouse model of S. aureus keratitis decreased the bacterial bioburden (>99.0% reduction) and corneal 
edema significantly as compared to untreated mouse corneas. Collectively, our results have established the 
high therapeutic potential of teixobactin analogue in attenuating bacterial infections and the associated 
severities.  




6.2 Breif Introducion 
From the previous chapter, to expedite access to highly potent teixobactin analogues, a new design 
was reported by which we replaced the synthetically challenging enduracididine with commercially 
available hydrophobic residues such as as leucine and isoleucine.1 Leu10- teixobactin (5.13) and  Ile10-
teixobactin (5.12) showed identical activities against MRSA in vitro that were identical to 
teixobactin. However, increased hydrophobicity may have an adverse influence on the in vivo 
capacity to be further developed as therapeutic drugs. Teixobactin 1.23 and key teixobactin analogues 
and their antibacterial activities are summarised in Figure 6.1.  
Teixobactin 1.23 has shown antibacterial efficacy in vivo in three mouse models of infection. 
Although these results are encouraging, a significant amount of work remains  in developing 1.23 as 
a therapeutic antibiotic for human use.2 The translation of molecules from a discovery phase to that 
of useful therapeutic antibiotics is prone to high failure rates due to numerous challenges, such as 
balancing high efficacy in vivo against a broad spectrum of pathogens with minimal liabilities against 
human targets and the balancing of hydrophobicity with hydrophilicity to address water solubility 
issues.3 There is a pressing need for highly potent analogues of 1.23 to address common drug-
development challenges. To date, there have been no in vivo evaluation studies of teixobactin 
analogues. 
 
Figure 6.1: Teixobactin and its analogues containing cationic and hydrophobic amino acids. Cationic 
analogues 1.231, 4, 5, 2.16–8, 4.18, 9 and hydrophobic analogues 5.131, 5.111, 5.81, 10 with the (D-amino acids 
highlighted in red and the position 10 amino acids are highlighted in blue). 




6.3 Aim of study 
To address teixobactin development challenges, we report herein the design and synthesis of 10 
highly potent teixobactin analogues (Figure 6.2)  and their antibacterial evaluations aganist S. aureus 
(SA), MRSA, VRE; and the in vivo evaluation of one analogue in a mice model of S. aureus keratitis. 
This work lays the foundation for the development of in vivo ready teixobactin analogues.  
 




























































































































































































































































































































































































































































































6.4 Results and discussion 
6.4.1 Design and synthesis 
To date, teixobactin 1.23 is the only molecule in its class which has shown in vivo antibacterial 
efficacy. To realise the therapeutic potential of molecules based on the teixobactin scaffold, there is 
a pressing need for in vivo ready simplified teixobactin analogues with ease of access to address the 
current challenges associated due to the lengthy and daunting total synthesis of teixobactins. 
In this work, to address such teixobactin development challenges, we speculated that the replacement 
of Ser3, D -Gln4 and Ala9 of Leu10-teixobactin and Ile10-teixobactin with  cationic arginine would 
mimic the suitable balance of hyrophobicity and hydrophilicity of natural teixobactin. We thus 
replaced the Ser3, D -Gln4 and Ala9 of Leu10-teixobactin and  Ile10-teixobactin with arginine in a 
systematic fashion (6.1-6.10, Figure 6.2). In this way, we realised an optimal balance between 
hyrophobicity with hydrophilicity. Six of these analogues (6.1-6.3 and 6.8-6.10, Figure 6.2) have 
hyrophobic-hydrophilic profiles (two positive charges at physiological pH) similar to that of natural 
teixobactin. Three analogues (6.4-6.6, Figure 6.2) feature three positive charges and one analogue 
(6.7, Figure 6.2) bears four positive charges. In total, we synthesised 10 new and highly potent 
teixobactin analogues (6.1-6.10, Figure 6.2) in a smilar fashion to our recently reported highly 
efficient strategy (Scheme 6.1 and experimental section III, Scheme S6.1).1 
 
Scheme 6.1: Synthesis of 6.2 starting from 2-chlorotritylchloride resin: a. 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in 
DCM, 3h.   b. 20% piperidine in DMF followed by 3 eq. AllocHN- D -Thr-OH, 3 eq. HATU/6 eq. DIPEA, 1.5h   
c. 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2h followed by capping with Ac2O/DIPEA 10% 




in DMF, 20% piperidine in DMF   d. 4 eq. Fmoc-Leu-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1h followed by 
20% piperidine in DMF   e. 10 eq. Trt-Cl, 15% Et3N in DCM, 1h.  f. 0.2 eq. [Pd(PPh3)4]0 + 24 eq. PhSiH3 in 
dry DCM, 1 x 20 min, 1 x 45 min.   g. 4 eq. Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting group), 
4 eq. DIC/Oxyma (µwave, 10 min) followed by 20% piperidine in DMF (3 min, 10 min).   h. TFA:TIS:DCM 
= 2:5:93, 1h.  i. 1 eq. HATU/10 eq. DIPEA in DMF, 30 min.   j.  TFA:TIS:H2O = 95:2.5:2.5, 1h. 
6.4.2 In vitro Antibacterial studies 
The antimicrobial potencies of teixobactin analogues 6.1-6.10 were assessed against MRSA ATCC 
33591. Leu10-teixobactin 5.13 and natural teixobactin 1.23 were included as benchmark for activity. 
The six analogues 6.1-6.3 and 6.8-6.10 with two cationic charges have hydrophobic-hydrophilic 
balances like that of 1.23 (two cationic charges). These analogues showed comparable potencies 
(MIC 0.125 - 0.25µg/ ml) to 1.23 (MIC 0.25µg/ ml, Table 6.1). Analogues 6.4-6.6 each possess three 
cationic charges. Interestingly, analogue 6.4 showed comparable antimicrobial activity (MIC 0.25µg/ 
ml) to natural teixobactin. However, analogues 6.5 and 6.6 showed 4 times reduced antibacterial 
activities (MIC 1µg/ ml) than 1.23 or 5.13. The analogue 6.7 with four cationic charges, also showed 
reduced antibacterial activity (MIC 1µg/ ml).  
Compound Name aMIC (µg/mL)        
1.23 Teixobactin 0.25 
5.13 Leu10-teixobactin 0.25 
6.1 Arg3-Leu10-texiobactin 0.125 
6.2 D-Arg4-Leu10-texiobactin 0.125 
6.3 Arg9-Leu10-texiobactin  0.125 
6.4 Arg3-D-Arg4-Leu10-teixobactin  0.25 
6.5 Arg3-Arg9-Leu10-teixobactin  1 
6.6 D -Arg4-Arg9-Leu10-teixobactin  1 
6.7 Arg3-D-Arg4-Arg9-Leu10-teixobactin 1 
6.8 Arg3-Ile10-texiobactin 0.25 
6.9 D -Arg4-Ile10-texiobactin 0.125 
6.10 Arg9-Leu10-texiobactin 0.25 
Table 6.1: List of Teixobactin and Teixobactin analogues (1.23, 5.13, 6.1-6.10). aMIC: Minimum Inhibitory 
Concentration. MRSA ATCC 33591 was used. 
Teixobactin analogues 6.1-6.10 were further assessed against an extended panel of antibiotic-
resistant and antibiotic susceptible Gram-positive pathogens and compared to the antibiotic 
daptomycin (Figure 6.3). The MIC results indicate that the synthetic analogues are potent against the 
various strains tested, but their MIC distribution differs significantly. Interestingly, we observed a 
wider distribution of MIC values as the overall net charge of the peptide was increased (Table 6.1 
and Table 6.2). 




Notably, the MIC values for Staphylococcus were not altered, whereas significant increases in the 
Enterococcus MIC values were observed for the analogue with four cationic charges (6.7, MIC 2-
8µg/ ml). Similar trends have been reported for teixobactin analogues whereby increases in positive 
charges, confer increases in MICs against Staphylococcus aureus ATCC 2921311. Herein, for 
example, Lys3-D-Lys4-Lys10-teixobactin, which has four cationic charges (Figure 6.1E), has reported 
MIC 8µg/ ml against Staphylococcus aureus ATCC 2921311, were as we observed an MIC of 1µg/ 
ml (an 8 times improvement ) for Arg3-D-Arg4-Arg9-Leu10-teixobactin (7, four cationic charges, 
Figure 6.2) against the same bacterial strain. 
The inclusion of 3 arginines in the above case likely perturbs the amphiphilic character of teixobactin, 
resulting in a decrease in activity. The six analogues with two cationic charges, 6.1-6.3 and 6.8-6.10 
showed comparable antibacterial potencies to that of Leu10-teixobactin. Importantly, the 
hydrophobic-hydrophilic balances of these analogues were like that of natural teixobactin (two 
cationic charges). The analogues with three cationic charges, 6.4-6.6 also showed comparable 
antibacterial potencies to that of Leu10-teixobactin 5.13. All synthesized analogues showed good 
potency against a broad panel of bacteria including clinical isolates. Nine analogues, 6.1-6.6, and 
6.8-6.10 showed drug-like profiles, such as high antibacterial potencies and optimal balances of 
hydrophobicity and hydrophilicity. We have further determined the minimum bactericidal 
concentrations (MBC) of teixobactin analogues against S. aureus/MRSA strains (Table S6.4). 
Compound 6.2 displayed highly potent bactericidal properties, as its MBC values did not increase 
above 4 times its MICs against the tested strains. Compound 6.2 was found to be inactive against 
Pseudomonas aeruginosa, a Gram-negative bacterium (Table S6.3). In view of narrow MIC-
distribution values and bactericidal properties, we focused our attention on compound 6.2 and further 
investigated its biological properties.   





Table 6.2: MIC values of compounds 5.13, 6.1-6.10 against a broad panel of bacteriaa. aEnterococcus faecalis, 
VRE 1001-1002, 1004, 1008 are clinical isolates. MRSA 42412, MRSA 21455 and MRSA 1003 are clinical 
isolates. 
 
Figure 6.3: MIC distribution of various analogues of teixobactin (6.1-6.10) against 19 different Gram-positive 
pathogens (Table S6.3). Daptomycin 1.13 was included for comparison. Note the increase in MIC distribution 
as the overall net charge on the teixobactin analogues was increased. The number in parenthesis indicates the 

























saprophyticus  ATCC 
BAA 750
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 -
Staphylococcus 
saprophyticus  ATCC 
15305
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.25 <0.0625 <0.0625 <0.0625 -
Staphylococcus 
saprophyticus  ATCC 
49453
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 -
Staphylococcus 
saprophyticus  ATCC 
49907
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 -
VRE 1001 0.25 0.5 0.5 1 0.5 1 2 1 0.5 1 -
VRE 1002 0.5 1 1 1 1 1 8 1 1 1 -
VRE 1004 <0.0625 0.25 0.25 0.5 0.5 1 4 1 0.5 1 -
VRE 1008 0.125 0.5 0.25 0.5 0.5 1 8 1 0.5 1 -
VRE ATCC 700802 0.5 0.5 0.5 2 1 1 4 1 0.25 1 0.25
VRE ATCC 29212 0.5 0.5 1 1 1 1 4 1 0.25 1 0.25
MRSA ATCC 700699 0.5 0.25 0.5 0.5 1 1 2 1 0.25 1 0.25
MRSA 42412 <0.0625 0.0313 <0.0625 0.25 0.25 1 2 0.125 <0.0625 0.125 <0.0625
MRSA 21455 0.03125 0.0313 0.25 0.5 1 1 2 0.25 0.03125 0.5 <0.0625
MRSA 1003 <0.0625 0.5 0.25 1 2 0.5 2 0.125 <0.0625 0.5 -
S. aureus  29213 0.25 <0.0625 0.5 0.25 1 1 1 0.5 0.0625 1 -
S. aureus  4299 0.125 - 0.25 0.25 0.5 0.5 1 0.125 <0.0625 1 -
S. epidermidis 12228 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 -
Bacillus Cereus  ATCC 
11788
<0.0625 0.5 0.25 1 1 1 1 0.125 <0.0625 0.5 -
Bacillus Subtilis  ATCC 
6633
<0.0625 0.125 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.125 -




6.4.3 Resistance studies and time depenadat killing of bacteria using teixobactin analogue 
6.2 
D-Arg4-Leu10-teixobactin (6.2) was evaluated for single step resistance in S. aureus ATCC 29213 and 
MRSA ATCC 33591. We were unable to obtain mutants of S. aureus ATCC 29213 or MRSA ATCC 
33591 resistant to teixobactin analogue 6.2 (5, 10, and 20x MIC). The calculated frequency of 
resistance to teixobactin analogue 6.2 was found to be <10-10 (SI section V), which is comparable to 
that of teixobactin 1.23.4 A lack of resistance in preliminary studies against 6.2 is promising in the 
development of drug like molecules against resistant bacteria. 
Time-kill kinetics studies of D-Arg4-Leu10-teixobactin, 6.2, against S. aureus ATCC 29213 were 
investigated to ascertain if the chemical modifications retained the bactericidal properties. The 
exposure of bacterial inoculum to 0.5 µg/ml or 1 µg/ml of compound 6.2 resulted in ≥ 2 log10 
decrease in bacterial viability at 8 h (Figure S6.23), which is comparable to those in previous reports 
of teixobactin analogues and teixobactin.1, 4   
6.4.4 In vitro cytotoxicity studies 
It was important to evaluate the cytotoxicity of compound 6.2 on mammalian cells prior to in vivo 
studies. We determined the cytotoxicity of 6.2 in human-lung-epithelial-cell line A549 and primary 
dermal fibroblasts (hDFs). Both of these cell culture models are already established for the evaluation 
of cytotoxicity of antimicrobial peptides.12,13 An MTS assay indicated that both mammalian cell-
types exposed to various concentrations of the peptide retained significant metabolic activity (≥ 80% 
viability, Figure 6.4 a,b), even at a concentration that was ~900 times (250 µg/ml) higher than the 
average MIC (0.27 µg/ml) values, indicating excellent cell selectivity of the teixobactin analogues. 
High-content images indicated the absence of any cytoskeletal and nuclear disruptions upon exposure 
of both epithelial and fibroblasts cells to compound 6.2 (Figure 6.4 c,d), establishing its non-
cytotoxic properties. The morphology of mammalian cells exposed to 6.2 appeared similar to that of 
the untreated cells. However, exposure of cells to an antineoplastic agent (nocodazole, used as a 
control) resulted in substantial loss of adhered cells, confirming its cytotoxicity. 
 





Figure 6.4: Cytotoxicity evaluation of 6.2 in A549 lung epithelial cell line and human primary dermal 
fibroblasts (hDFs). Both A549 cells (a) and hDFs () were b treated with increasing concentrations of 6.2 
(ranging from 15.62 μg/ml to 250 μg/ml) for 24 h. The stock solution of 6.2 (500 μg/ml) was prepared fresh 
by directly dissolving 6.2 in cell culture medium just before use. Cells were treated with dimethyl sulfoxide 
(DMSO, 0.1% v/v) or nocodazole (5 μg/ml dissolved in DMSO) as controls. At the end of the treatment period, 
metabolic activities of cells were quantified by MTS-based cell viability assay. Data represents mean ± the 
standard errors of the means (SEM) of three independent triplicate experiments, (*p>0.05). After 24 h treatment 
with 6.2, A549 cells (c) and hDFs (d) were fixed; fluorescently stained with rhodamine-phalloidin (red), alexa 
fluor 488 conjugated anti-α-tubulin (green) and Hoechst 33342 (blue); and imaged using IN Cell Analyzer 
2200 automated microscope. Representative images of cells treated with 6.2 (62.5 μg/ml for 24 h) or 
nocodazole (10 μg/ml, toxicity control) are shown. 
6.4.5 In vivo Toxicity Studies 
We examined the in vivo toxicity of 6.2 in a rabbit corneal-damage model. A 0.3% (w/v) solution 
(50µL) was applied topically (4 times/day) to the circularly debrided cornea, and re-epithelialization 
was monitored by fluorescein staining. The vehicle alone served as a control. Figure 6.5 shows the 
decrease in fluorescein staining with time for both control wounds and wounds treated with 6.2. 




There was no significant difference in wound closure between PBS-treated wounds or wounds treated 
with 29 (Figure S6.24). The lack of any delay in the re-epithelialization and wound closure for the 
injured corneas treated with 6.2 suggests good biocompatibility of the peptide. 
 
Figure 6.5: Representative slit lamp fluorescence images showing the time-dependent changes in wound 
closure of corneas after the application of PBS (2 eyes) or 0.3% peptide 6.2 (4 eyes). The wounded corneas 
were stained with fluorescein to observe epithelial defects and imaged by slit-lamp biomicroscopy. 
6.4.6 In vivo antibacterial efficacy of D-Arg4-Leu10-teixobactin 6.2 in bacterial keratitis model 
We examined the in vivo efficacy of peptide 6.2 in a mouse-eye model of S.aureus keratitis. S. aureus 
is one of the major etiological agents for bacterial keratitis, and the toxic secretions produced by this 
microorganism have been implicated in corneal melt, leading to significant morbidity and vision 
loss14, 15. Scarified cornea of the mice was infected with S. aureus ATCC 29213 inocula (15 µL of 
6×106 CFU/ml). At 6 h post infections (p.i.), the infected cornea were treated with vehicle (PBS), 
peptide 6.2 (0.3% w/v in PBS) or moxifloxacin (0.3%). A total of 8 doses was applied and the 
progression of the infection was monitored by slit lamp examination, anterior segment optical 
coherent tomography (AS-OCT), and microbiological enumeration of the bacterial bioburden. 
Mouse corneas treated with PBS had severe clinical presentations indicated by chemosis, the 
significant presence of hypopyonlike materials and corneal infiltrates (Figure 6.6). 





Figure 6.6: Slit lamp examination of mice infected with S. aureus ATCC 29213 strains. After scratching the 
corneal epithelium with scalpel blade, the scarified cornea was infected with a bacterial inoculum of 6 x 106 
CFU/ml (15 µL/cornea). At 6 h post infections, the infected corneas were treated with 15 µL of PBS, peptide 
6.2 (0.3% w/v in PBS) or moxifloxacin (0.3% w/v in PBS). Note the significant presence of corneal haze and 
mucopurulent discharge in PBS-treated cornea whereas peptide 6.2 and moxifloxacin treated cornea remained 
clear and no signs of corneal defects. 
Notably, infected cornea treated with peptide 6.2 or a fluoroquinalone antibiotic, had similar clinical-
appearance presentations, as indicated by lack of any conjunctival chemosis and corneal infiltrates. 
These results indicate that peptide 6.2 halted the progression of S. aureus infections and the activity 
was comparable to that of moxifloxacin. To determine the effect of treatments on tissue severity, we 
determined the corneal thickness for various groups (Figure 6.7a, Figure S6.25). The baseline corneal 
thickness of mice (93.8±2.9 µm) decreased moderately (79.0±3.4 µm) after de-epithelialization 
followed by the S. aureus infection (6h p.i.). Treatment of the infected cornea with vehicle alone 
(PBS) resulted in substantial increases in corneal thicknesses after 24 h (151.7±12.7 µm) and 48 h 
(186.2±17.5 µm), indicating corneal edemas after infection. Infected corneas treated with peptide 6.2 
had a mean corneal thickness of 92.3±12.5 and 121.7 ± 3.2 µm 24 h and 48 h post treatment (p.t.), 
respectively. For the moxifloxacin-treated corneas the mean corneal thickness was 124.2±9.4 µm 
after 24 h p.t. and 140.3±10.3 µm after 48 h p.t. These results suggested that peptide 6.2 treatment 
resulted in significant decrease in corneal edemas after S. aureus infections as compared with those 
PBS-treated or moxifloxacin-treated groups.  





Figure 6.7: (a) Changes in corneal thickness (CT) of mice before and after infections and treatment with 
various groups. Note that the CT values for peptide 6.2 treated cornea approached the baseline values 48 h p.t., 
which did not happen in the cases of PBS- and Moxifloxacin-treated corneas. Note that a significant decrease 
in corneal edemas was observed for infected cornea treated with peptide 6.2 compared with those in the 
untreated corneas (p, 0.01 two-way ANOVA) as early as after 3 doses, and the edemas decreased further after 
8 doses (p, 0.001). The results indicated a marked decrease in the severity of the infections after treatment with 
6.2 when compared to standard antibiotic treatment. (b) Bacterial bioburden in the infected corneas 48 h after 
treatment in the various groups. The values represent colony counts from individual cornea, and bars represent 
mean CFU/tissue ± standard errors of the mean.  
Bacterial enumeration of the corneal tissues harvested after 8 dosages confirmed the in vivo efficacy 
of peptide 6.2 (Figure 6.7b). All the infected cornea that received PBS treatment contained significant 
amounts of bacteria, varying from 4.7×105 – 1.3×107 CFU/tissue. The mean log10 CFU/tissue ± 
standard error of the mean for PBS treated cornea was 6.51±0.27. Five out of six cornea treated with 
peptide 6.2 had detectable bacterial colonies. The mean log10 CFU/tissue for the peptide 6.2 treated 
cornea was 3.97±0.19. Four infected corneas treated with moxifloxacin contained detectable 
bacterial colonies with a mean log10 CFU/tissue of 3.7±0.24. These results confirmed that peptide 
6.2 had a similar antibacterial effect to that of an established antibiotic in decreasing the bacterial 
bioburden, thus demonstrating its potential as a safe therapeutic for topical applications. 





In conclusion, we have designed and synthesised 10 novel analogues of teixobactin through the 
selective replacement of Ser3, D-Gln4 and Ala9 residues by D and L arginines in Leu10-teixobactin and 
Ile10-teixobacin. We have successfully achieved a fine balance of hyrophobicity-hydrophilicity while 
maintaining a high antibacterial potency both in vitro and in vivo. Importantly, most of these 
teixobactin analogues showed highly potent antibacterial activity against S. aureus, MRSA and VRE, 
comparable to that of Leu10-teixobactin 5.13 and Ile10-teixobactin 5.12. The MIC values on a broad 
panel of Gram-positive bacteria indicate a direct correlation between overall net charge and a narrow 
distribution of MIC values; for example, as the overall net charge of the peptide increases, a wider 
distribution of MIC values results. 
The teixobactin-based peptide analogue 6.2 was found to be noncytotoxic in vitro and in vivo. In a 
mouse model of infectious keratitis, the topical instillation of 6.2 resulted in >99.0% reduction in 
bacterial bioburden, and the efficacy was comparable to that of moxifloxacin. Notably, S. aureus is 
one of the major etiological agents for bacterial keratitis and has been implicated in corneal melt, 
leading to significant morbidity and vision loss14,15. Furthermore, in our keratitis mouse models, 
synthetic teixobactin analogue 6.2 decreased the severities of corneal edemas substantially when 
compared with those in untreated corneas or moxifloxacin-treated corneas. To the best of our 
knowledge, this is the first in vivo demonstration of the excellent therapeutic potential of a teixobactin 
analogue in attenuating bacterial infections and the associated severities. We believe this work 
represents a significant advancement in the development of in vivo ready  simplified teixobactin 
analogues. Thus, the design of safe and highly potent synthetic peptide analogues of teixobactin 
presented here will enable the development of drug like analogues against antibiotic-resistant 
bacterial strains. The findings presented in this work have broad implications and are expected to 
facilitate the development of peptide-based therapies to combat the serious global challenges posed 
by AMR.  
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7 OVERVIEW OF TEIXOBACTINS, SUMMARY, 
CONCLUSIONS AND PERSPECTIVES 
7.1 Overview of teixobactin analogues 
During the last 4 years, since the first 
publication of teixobactin 1.23, it has merited 
more than 700 citations. It would be almost 
impossible to review every single work that has 
been published on teixobactin, however this 
section aims to provide a generous review of 
work that is very relevant to this thesis. Total 
synthesis of teixobactin and the unusual rare 
amino acid L-allo-End 1.21 has been discussed 
broadly in Chapter 1 and therefore more 
details about analogues, synthetic strategies, 
and the structure-activity relationship will be addressed herein.   
7.1.1 Synthesis of teixobactin analogues 
L-allo-End 1.21 is not commercially available and very laborious to synthesise1, due to this, many 
efforts utilized commercially available amino acids, especially arginine, which is a linear guanidine 
moiety compared to 1.21.       
Our group efficiently synthesised Arg10-teixobactin 2.1 that is covered in chapter 2 with an overall 
22% yield2. Other groups such as Albericio3, 4, Nowick5 and Su6, have also contributed significantly 
to the synthetic strategies of teixobactin analogues7. Among these routes, Su, Fang group (Scheme 
7.1, Route 4) uniquely utilised an aryl hydrazine solid support. An advantageous feature of this resin 
is the stability under acidic and basic conditions that is cleaved by a mild oxidative reaction. Other 
noteworthy features in this scheme were, the release of the final cyclic peptide in situ upon cleavage, 
and the suppressed racemisation on the final macrocyclisation step6. The other routes in the schemes 
all utilised the 2-CTC resin. Albericio group provided two different synthetic routes (Scheme 7.1, 
Routes 1&2), one with Arg10-teixobactin 2.1 and the other with Lys10-teixobactin 4.1 respectively3, 
4. Route 2 employed an efficient (>95% yield) on-resin cyclisation and then an elongation of the 
peptide, before finally releasing the peptide from the solid support. In route 1, the orthogonal allyl 
protection is utilised twice, and the final cyclisation is formed between residues Ala9 and Arg10, same 
ring closure to our route (chapter 2) and route 4. Nowick group5 (Scheme 7.1, Route 3) had a very 
similar scheme to route 4. However they initially elongated the first 10 amino acids with the 




conventional Fmoc SPPS, followed by the incorporation of Ile11 through esterification with the final 
ring closure between Arg10 and Ile11.  It should be noted that the synthesis schemes covered in chapter 
1 for the total synthesis of 1.23 have also been used to synthesise analogues of 1.23.  
Scheme 7.1: Synthetic routes for the teixobactin analogues. Routes 1 and 2 were employed by 
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7.1.2 Structure-activity relationship (SAR) 
As observed above, quite a number of groups, including ours have provided the synthetic routes to 
several analogues, such as Arg10-Teixobactin 2.1 which further opened avenues for the synthesis of 
unique analogues and SAR to be determined.  
2.1 showed a 10-fold decreased activity compared to the native product 1.23. The results were 
consistent with our observations previously. Our group has shown that any modification to the D-
amino acids to their L-versions leads to a significant decrease in activity and NMR studies confirmed 
that a disordered structure is essential for antibacterial activity (covered in chapters 2 and 3)8, 9. 
Nowick group reported the minimum pharmacophore of teixobactin5. In this study, analogue 2.1 
experienced an enantiomeric change (a mirror image), where all the D-amino acids were interchanged 
with L, and vice versa and similar activity was observed. This study indicated that the relative 
configurations of amino acids are essential, and not the absolute configuration, also revealing that 
teixobactin must bind to an achiral membrane. 
Interestingly, replacement of arginine with lysine showed increased activity in some strains5, 6, 10, 
providing an insight that the guanidine group is not essential in maintaining activity. In the same 
study, residues 1- 5 of teixobactin was shortened by just the addition of Arg, which resulted in a total 
loss of activity. The analysis was further tested in which residues 1-5 were replaced with a 
dodecanoyl group. The compound given the name lipobactin 7.2 (Figure 7.1) showed minimal 
decrease in activity in comparison to 2.1. These findings established that the hydrophobic tail of 
teixobactin was notable for its activity and is most likely involved in membrane anchoring. A mutated 
teixobactin 7.1, where the lactone is replaced by a lactam ring, by substituting D-Thr to D-Dap 
exhibited similar activity, again indicating that the cyclic portion together with its configuration plays 
prime importance to maintain activity. Jamieson group also reported analogues, where residues 1-7 
were replaced with a farnesyl isoprenoid 7.3 (Figure 7.1) and descent antibacterial activity was 
observed11.  
The replacement of N-Me-D-Phe to N-Me-L-Phe shows decreased activity9, perhaps due to proteolysis 
degradation, however removal of methyl group showed no change in activity6, but interestingly, a 
slight decrease in activity was observed when a second methyl was introduced12. A diminished 
activity was observed when N-Me-D-Phe was replaced with N-Me-D-Lys4.    
A lysine scan by Albericio group13, alanine scans by our group14 and Nowick group13, 15 were 
performed to decode the role of each amino acid. A lysine scan revealed that the hydrophobic 
residues especially the four Ile’s present in teixobactin are critical for activity. The replacement of 
these with lysine lead to the total loss of antibacterial activity. Furthermore, no significant change 
was observed when Ser3 and Gln4 were replaced with Lys, suggesting these positions were tolerated 
for substitution13. All analogues that were previously synthesised were less active than the natural 
product 1.23. To determine suitable positions for modifications an alanine scan was performed to 




discover more potent analogues with identical activity. Alanine scans by ours and the Nowick group 
revealed enduracididine to be non-essential for activity. Our group further went to establish that 
substituting the complicated L-allo-End10 1.21 by simple hydrophobic amino acids such as Ala, Leu 
and Ile does not hamper activity and in fact, some data showed superior potency than natural 
teixobactin 1.23, further confirming that a cationic residue at position 10 is not essential for activity. 
These findings were later on confirmed by  Xuenchen Li et al., who also reported the same analogues 
with their bactericidal activity16.  
 
Figure 7.1: Relevant or unique teixobactin analogues showing structure comparison. Alteration of positions 
shown in blue. D-aminoacids of native teixobactin shown in red.   
  




 Staphylococcus aureus 
Bacillus 
Subtilis MRSA 
Teixobactin 0.25 0.02-0.06 0.25 
Arg10-teixobactn 1.6 0.4 2 
Lys10-teixobactin 2 0.5 1 
Lipobactin - 4 - 
Lys10 -Farnesylbactin 8 - - 
D-Dap8, Arg10 -teixobactin - 1 4 
Ala10-teixobactn 1 - 1 
Leu10-teixobactn 0.0625 - 0.25 
Ile10-teixobactn 0.0625 - 0.25 
D-Arg4, Leu10-teixobactn 0.0625 0.125 - 
*Table 7.1: Minimum Inhibitory concentration (MIC) in µgmL-1 of various analogues for the determination of 
SAR of teixobactin.  
Quite a few studies on the Lipid II binding/mechanism studies have been performed with teixobactin 
and its analogues14, 17–19. Through NMR studies on various analogues such as Ala10-teixobactin, we 
revealed that the N-termini of the teixobactin to be highly structured in contrast to the unstructured 
C-termini. In the same study, we found that Ser7 had the tightest binding affinity with a lipid II mimic 
(geranyl pyrophosphate)14. Consistently Ser7 was also found to be involved in lipid binding in a study 
by Tajkhorshid et al18. By the use of molecular modelling and microsecond-scale molecular dynamic 
simulations, the authors were able to capture teixobactin-lipid II complexes18. In this study it was 
proposed that teixobactin most likely stops cell wall synthesis by inhibition of the transglycosylation 
step while not affecting the transpeptidation step. Recently, by the use of  solid state NMR, a full 
complex of native teixobactin with lipid II was also reported by Lewandowski et al19. Upon binding 
to lipid II, a conformational change (coil to β-conformation) in residues 2-6 was observed. β-
conformations are highly prone to aggregations, and it is envisaged this is a plausible mechanism for 
action. A more recent study by Nowick group confirmed a β-sheet formation behaviour and proposed 
this being the mode of action17.  
Our group has also reported highly potent analogues against various strains both in vitro and in vivo20. 
One analogue D-Arg4-Leu10-teixobactin showed a good balance between hydrophobicity and 
hydrophilicity while maintaining high potency. The analogue is found to be not only noncytotoxic, 
but in vivo studies showed >99% reduction in the bacterial bioburden of an infected S. aureus 
keratitis mouse model. Moreover, corneal edemas were reduced substantially in comparison to 
untreated mouse models and very similar data to the currently used antibiotic moxifloxacin.    
So far, there is relevant progress been made in understanding SAR of teixobactins, but several 
challenges need to be answered to make teixobactin as a viable drug. The resistance mechanism and 
the binding of teixobactin with lipid II in the native membrane setting is not still well understood. 
There is also lack of a thorough study of teixobacins in vivo. Gaining an understanding of these 
                                                     
* These data have been taken from various publications and therefore it is most likely the bacterial strains may be different. 
Data above is only meant for a general comparison of activity.  




ambiguities could unlock the door to the production of many valuable, next generation highly potent 
analogues.  
7.2 Summary of work 
This section provides the summary of work done towards my PhD at the University of Lincoln. When 
I arrived in Lincoln May 2015, I had previously gained some experience in peptide synthesis. 
Coincidently the same year, the first publication of teixobactin21 had gained much interest by Ishwar 
Singh group. My project was based on the synthesis and development of teixobactin analogues to 
discover its structure-activity relationships (SAR).  
 
Figure 7.2: Structure of native teixobactin 
Initially, the first part of the project was to design a synthetic route for the total synthesis of 
teixobactin and its analogues. To obtain total synthesis, the compulsory building block L-allo-End 
1.21 is quite time consuming and expensive. Therefore, efforts to design the analogue was probably 
the better choice. 
Chapters 1 is based on literature review. All the work from Chapter 2 to 6 has been published, which 
includes a highly efficient synthetic route to provide potent analogues and its SAR studies. A short 
description of work carried out in each publication is provided below.  
1. Parmar, A. et al. Efficient total syntheses and biological activities of two teixobactin 
analogues. Chem. Commun. 52, 6060–6063 (2016). 
An efficient synthetic route was established that can be used broadly to deliver a variety of analogues. 
Two Arg10-teixobactin analogues were synthesised, and the role of the D-amino acids was determined 
(chapter 2). 
2. Parmar, A. et al. Defining the molecular structure of teixobactin analogues and 
understanding their role in antibacterial activities. Chemical communications 53, 2016–2019 
(2017) 




For the first time, 3D molecular structures of teixobactin analogues were povided and the role of 
each D-amino acid was determined. Through NMR studies the essential of D-Gln4 and importance of 
D-Ile5 for the maintenance of an unstructured teixobactin was identified (chapter 3). 
3. Parmar, A. et al. Syntheses of potent teixobactin analogues against methicillin-resistant 
Staphylococcus aureus (MRSA) through the replacement of L-allo-enduracididine with its 
isosteres. Chemical Communications 53, 7788–7791 (2017) 
In this study the L-allo-End 1.21 was replaced with its isosteres. A rapid one-step conversion of a 
deprotected amino side to a guanidine moiety was used to expand the number of teixobactins. It was 
further reasoned that the closest isosteres to L-allo-End are key to improved activity (chapter 4).  
4. Parmar, A. et al. Teixobactin analogues reveal enduracididine to be non-essential for highly 
potent antibacterial activity and lipid II binding. Chemical Science 8, 8183–8192 (2017) 
In this work, a rapid synthetic route for potent analogues was established utilising µwave assisted 
couplings. Contrary to previous reports, that a cationic residue at position 10, including the 
synthetically challenging and expensive amino acid L-allo-End 1.21 was confirmed to be non-
essential for activity and target binding. With the new and novel design, A substituted L-allo-End10 
with simple commercially available uncharged and nonpolar residues such as Leu10 and Ile10 showed 
identical or superior activity to natural teixobatin against MRSA. Individual binding affinities were 
also confirmed and measured in the presence of geranyl pyrophosphate (lipid II mimic) by NMR to 
understand the binding modes (chapter 5).  
5. Parmar, A. et al. Design and Syntheses of Highly Potent Teixobactin Analogues against 
Staphylococcus aureus, Methicillin-Resistant Staphylococcus aureus (MRSA), and 
Vancomycin-Resistant Enterococci (VRE) in Vitro and in Vivo. Journal of Medicinal 
Chemistry 61, 2009–2017 (2018). 
In this study, novel analogues were synthesised having a good balance between hydrophobicity and 
hydrophilicity. For the first time, the therapeutic potential of simple teixobactin analogues was 
demonstrated by treating bacterial eye infection in mice. These analogues showed substantial 
reduction in bacterial burden and edema in a synergistic fashion (chapter 6).  
 
7.3 Conclusions 
For the past four years, my work has been involved in the designing of potent analogues of 
teixobactins, which is a natural cyclic depsipeptide that has potent activity against Gram-positive 
pathogens.  
The total synthesis of teixobactin was also attempted by us, however we later turned our interest to 
synthesise simpler analogues of teixobactin due to the laborious, time consuming and expensive L-
allo-End. 




To conclude the work in this thesis, we have established a synthetic route that has been used very 
extensively in the broad diversification of teixobactin analogues. We have later optimised the same 
synthesis further utilising µwave assisted 10min coupling and a 30min cyclisation step, obtaining 
yields in a range of 10-24%. Initially we determined that the role of D-amino acids was very important 
for its activity and further went on to test the role of each D-amino acid, through which we provided 
3D molecular structures of teixobactin analogues. We discovered that the any changes from the D-
amino acid to the L-version leads to decreased activity that correlated with the degree of unstructured 
peptide. We further identified the importance of D-Gln4 and D-Ile5 for the maintenance of an 
unstructured teixobactin. 
We further reasoned that the closest isosteres to L-allo-End are key to improved activity. Our 
procedure utilised a rapid one-step conversion of a deprotected amino side chain to a guanidine 
moiety to expand the number of teixobactins. To develop analogues with identical or superior 
potency to natural teixobactin, we established a novel design and through alanine scanning, we 
determined that Ala10-teixobactin possessed similar activity to Arg10-teixobactin. This further 
contributed to the development of more potent analogues by replacing L-allo-End with hydrophobic 
amino acids such as Leu10 and Ile10 that showed better activity in some strains in comparison to the 
natural product. Individual binding affinities were confirmed and measured in the presence of geranyl 
pyrophosphate (lipid II mimic) by NMR to understand the binding modes. Contrary to previous 
reports, we confirmed that a cationic residue at position 10 is non-essential for highly potent activity 
and target binding. 
The hydrophobic residues at position 10 proved to be highly potent against pathogens such as MRSA, 
but there was a loss of positive charge. The aim was then to find a good balance between hydrophobic 
and hydrophilic analogues. We successfully synthesised 10 new in vivo active compounds. For the 
first time we have treated mice eye infections by using simplified teixobactin analogues based on our 
novel design. D-Arg4 -Leu10 teixobactin showed >99% reduction of bacterial bioburden in a mouse 
keratitis model, similar to the current drug moxifloxacin. The analogue also showed a substantial 
decrease in corneal edema in comparison to untreated or moxifloxacin-treated mice, with good 
safety.  
 
We believe that the work that has been mentioned above will be pivotal for not only synthesising 
more analogues efficiently but will also provide a good understanding of teixobactin SAR and further 
deduce the mechanism of action.  The discoveries offered in this work have broader implications and 
are expected to facilitate the development of peptide-based therapies to combat the severe global 
challenges posed by AMR.  
 





A heavy load of work has already been conducted on teixobactin, majority of the work being a 
suitable synthesis route to achieve the native or analogue form of teixobactin with its SAR. Our group 
and others have significantly contributed to the development of many synthetic strategies and 
analogues which have showed higher yields in comparison to the synthesis of native teixobactin. 
Some analogues that we developed have even shown superior potency than the native compound.  
Although native teixobactin has showed excellent antibacterial efficacy, it is limited to a single 
molecule and may call for a more sophisticated biosynthetic approach to produce the native 
compound. The chemical synthesis of the native compound is not a viable option due the challenging 
and expensive building block L-allo-End and its incorporation in the total synthesis of teixobactin. In 
any case, relying on a single molecule is less likely to reach regulatory approval, due to a high 
attrition rate involved in the drug development process. 
Analogues of teixobactin, on the other hand, have shown encouraging results. It is therefore crucial 
to pursue the development of novel analogues based on teixobactin scaffolds, to generate a library 
of molecules, which addresses the challenges of drug development.  
A considerate amount of work has been done to understand SAR but research on teixobactin is still 
in its infancy. Several limitations need to be overcome to make teixobactins’ as a viable drug. Broader 
screenings of teixobactin analogues is needed against MDR strains such as VRE and MRSA, 
including clinical isolates, to further advance SAR studies, which will aid in finding future potent 
analogues. Advanced in vivo studies are also lacking and could potentially identify lead molecules 
for the future. Since the discovery of teixobactin, no detectable resistance has been reported. It is 
therefore obvious to state that there is apparently a high resistant barrier that the natural product 
possesses. A range of teixobactin analogues could enhance the barrier even further, since bacteria 
are not known to cope with such diversity. Lipid II interactions with teixobactin in native membrane 
and understanding resistance mechanisms will also be valuable in discovering more potent 
analogues. Pharmacokinetics (PK) properties are currently lacking and it is essential to investigate 
these properties to identify future lead molecules. 
Without doubt as mentioned, there are synthetic resources available to produce analogues, even 
simpler synthetic strategies could be useful to bulk up the production of many unique analogues to 
further the therapeutic advantage. Addressing these limitations can make a virtuous platform for 
developing many more robust new classes of antibiotics that will combat MDR bacterial infections.    
Currently our group is working towards resolving this using various non-proteogenic amino acids 
for the replacement of L-allo-End. These analogues have shown promising results both in vitro and 
in vivo.  
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EXPERIMENTAL SECTION FOR CHAPTER 2 
I. Materials 
All L amino acids, Fmoc-D-Ile-OH, Fmoc-D-Thr(Trt)-OH and oxyma pure were purchased from Merck 
Millipore. 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU), Fmoc-D-Gln(Trt)-OH, Boc-D-Nmethylphenyl-OH, H2N-D-Thr-OH, 
Phenylsilane (PhSiH3),   Tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)], 2-methyl-6-
nitrobenzoic anhydride (MNBA), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC/EDCI) 
Hydrochloride, Diisoproplycarbodiimide (DIC) and Triisopropylsilane (TIS) were purchased from 
Fluorochem, UK.  The protecting groups for the amino acids are tBu for Ser, Pbf for Arg and Trt for Gln 
and Thr unless specified otherwise. Diisopropylethylamine (DIPEA), supplied as extra dry, redistilled, 
99.5 % pure, Acetic anhydride, allyl chloroformate and CDCl3 and were purchased from Sigma Aldrich. 
Tritylchloride and 4-(Dimethylamino)pyridine were purchased from Alfa Aesar. Dimmethylformamide 
(DMF) peptide synthesis grade and Trifluoroacetic acid (TFA) was purchased from Rathburn chemicals.  
Triethylamine, Diethyl ether, Dimethylsulfoxide, Dichloromethane, Tetrahydrofuran (extra dry with 
molecular sieves), Formic acid 98-100% purity and Acetonitrile (HPLC grade) were purchased from 
Fisher Scientific. Water with the Milli-Q grade standard was obtained in-house from an ELGA Purelab 
Flex system. 2-Chlorotritylchloride resin (manufacturer’s loading: 1.20 mmol/g) was purchased from 
Fluorochem. Wang Resin (manufacturer’s loading: 0.7 mmol/g) was obtained from NovaBioChem. All 
chemicals were used without further purification. 
II. Equipment used for the analysis and purification of compounds: 
All peptides were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC equipped with a 
Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer systems: A: 
0.1% HCOOH in milliQ water. B: ACN using a flow rate of 1 ml/min. The column was flushed with 
95% A for 5 min prior to an injection and was flushed for 5 min with 95% B and 5% A after the run was 
finished. 
Peptides were analysed using the following gradient: 95% A for 2 min. 5-95% B in 25 min. 95% B for 
5 min. 5% A for 4 min. 
Peptides were purified using the same gradient as mentioned above, on a Thermo Scientific Dionex 
Ultimate 3000 RP-HPLC with a flow rate of 5 mL/min using a Phenomenex Gemini NX C18 110 Å (150 
x 10 mm) semi-prep column. 
LC-MS data were collected on an Agilent 1100 Series instrument with a Phenomenex Kinetex C18 100Å 
column (150 x 4.6 mm, 5 μm at 35 °C) connected to an ESMSD type VL mass detector with a flow rate 




of 1.5 ml/min was used with the following solvent systems: (A): 0.1% HCOOH in H2O and  (B) MeCN. 
The column was flushed with 100% A for 2 min, then a gradient from 0 to 100% B over 6 min was used, 
followed by 2 min of flushing with 100% B. Alternatively, LC-MS/HRMS were performed using a Xevo 
QTof mass spectrometer (Waters) coupled to an Acquity LC system (Waters) using an Acquity UPLC 
BEH C18 column (2.1 x 50 mm, Waters). 
NMR spectra were recorded on a Bruker 500 MHz Avance III HD spectrometer equipped with a 
broadband probe. 
III. Attempted synthesis of the teixobactin analogue 2.1 via route A: 
Figure S2.1: Scheme showing the attempted synthesis of the teixobactin analogue 2.1 via route A. 
(step a) Commercially available 2-Chlorortritylchloride resin (manufacturer’s loading = 1.2 mmol/g) 
was pre-swelled in DCM in a reactor. To it was added 4 eq. Fmoc-Ile-OH, 8 eq. DIPEA in DCM and the 
reaction was shaken for 3h. The resin was then washed 3 x DCM, 3 x DMF. Any unreacted resin was 
capped with MeOH:DIPEA:DCM = 1:2:7 by shaking for 1h. The loading determined by UV absorption 
of the piperidine-dibenzofulvene adduct was calculated to be 0.6 mmol/g. (step b) The Fmoc protecting 
group was deprotected using 20% piperdine in DMF by shaking for 3 min, followed by draining and 
shaking again with 20% piperidine in DMF for 10 min. The subsequent amino acids were successively 
coupled (except the Fmoc-D-Thr(Trt)-OH) using the following protocol: 4 eq. FmocHN-AA(P.G.)-OH 
(AA = Amino Acid, PG = Protecting Group), 4 eq. DIC/Oxyma in DMF using a microwave peptide 
synthesizer by irradiating for 10 min. Fmoc deprotection was performed using the procedure described 
in step a above. Washing steps were performed using DMF as follows: 4 x 45s after every deprotection 
step and 6 x 45s after every coupling step. Fmoc-D-Thr(Trt)-OH was coupled using 3 eq. Amino acid, 3 
eq. HATU and 6 eq. DIPEA in DMF and shaking for 1h at r.t. The N terminus was capped using 10% 
DIPEA/Ac2O in DMF and shaking for 30 min. (step c) The peptide was cleaved off the resin keeping the 
side chain protecting groups on using: TFA:TIS:DCM = 2:5:93 and shaking for 2h. (step d) The solvent 
was evaporated and the following conditions were used for esterification: 






Reagents Solvent Duration Temperature 
1. 1.2 eq. DCC/5 eq. DMAP DMF 24h r.t. 
2. 2 eq. DCC + 1 eq. after 4h /5 eq. DMAP DMF 24h r.t. 
3. 3 eq. DCC/20 mol% DMAP DMF 2h r.t 
4. 1.2 eq. MNBA/2.4 eq. DMAP DMF 12h r.t. 
5. 2.5 eq. EDCI/0.5 eq. DMAP DMF 24h r.t. 
6. 18 eq. DCC/28 eq. DMAP DMF 30 min, 6h 0-4 deg., r.t 
7. 1.2 DCC/6 eq. DMAP DMF 24h 60, heating 
8. 1.2 eq. DIC/6 eq. DMAP DMF 24h 60, heating 
Table S2.1: List of conditions used for cyclisation via esterification 
IV. Synthesis of teixobactin core ring structure (2.2): 
 
Figure S2.2: Synthesis scheme for the teixobactin core ring (2.2) 
(step a) Wang resin (manufacturer’s loading = 0.7 mmol/g) was weighed out in a clean dry reactor. To 
the resin, pre-swelled in DMF, was added 10 eq. Fmoc-Ala-OH, 10 eq. DIC and 1 eq. DMAP and the 
reactor was shaken for 3h. The unreacted alcohol was then capped using 10% Ac2O/DIPEA in DMF. 
The loading determined by UV absorption of the piperidine-dibenzofulvene adduct was calculated to 
be 0.47 mmol/g. (step b) 2.5 eq. Fmoc-D-Thr(Trt)-OH, 2.5 eq. HATU and 5 eq. DIPEA in DMF were 
added on the resin and the reactor was shaken for 3h at room temperature. The coupling of Fmoc-D-
Thr(Trt)-OH was verified using the Ninhydrin color test. The Fmoc protecting group was then removed 
using the protocol described in section III step (b) earlier. (step c) The free amine was protected by 
adding 4 eq. Allyl Chloroformate/8 eq. DIPEA in DCM to the resin pre-swelled in DCM and shaking 
for 1h. (step d) The trityl protecting group was removed using TFA:TIS:DCM = 1:5:94 by performing 
3 x 15 min cycles and washing with DCM. (step e) Esterification was performed using 10 eq. Fmoc-
Ile-OH, 10 eq. DIC, 10 mol% DMAP in DCM and shaking for 2h followed by capping with 10% 




Ac2O/DIPEA in DMF. (step f) Fmoc-Arg(Pbf)-OH was coupled using 4 eq. of AA, 4 eq. HATU and 8 
eq. DIPEA in DMF and shaking for 1h followed by Fmoc deprotection using 20% piperidine in DMF 
using the protocol described in section III step (b) earlier. (step g) The fragment was cleaved off the 
resin using TFA:TIS:H2O = 95:2.5.2.5 and shaking for 1h. (step h) Cyclization was performed using 
1 eq. HATU/10 eq. DIPEA in DMF by stirring for 1h. HPLC trace of crude 2.2 (Figure S2.9). ESI-
HRMS mass calcd. for compound 2.2: C23H39N7O7 = 525.2911, found M+H
+ 
= 526.3010 (Figure 
S2.10). 
 
V. Synthesis and characterisation of AllocHN-D-Thr-OH (2.4) 
 
Figure S2.3: Structure of AllocHN-D-Thr-OH (2.4) 
2 g, 16.8 mmol, H2N-D-Thr-OH was dissolved in water containing 2 eq. NaHCO3: THF = 2:1, 40 mL 
and the reaction was cooled to 0°C. Water was then added dropwise till all the H2N-D-Thr-OH dissolved. 
Ally chloroformate, 1.2 eq., 2.1 mL, was then added slowly to the reaction and was left stirring for 3 
days at r.t. The reaction was monitored by TLC after 24h intervals. The reaction was then acidified to 
pH = 2 using 6N HCl. The product was extracted using Et2O (3x). The organic layer was then dried using 
Na2SO4 and the solvent was evaporated under reduced pressure. The reaction mixture was purified using 
silica gel column chromatography DCM/MeOH = 9:1 to obtain a colourless oil. 82% yield. 1H NMR 
(500 MHz, DMSO-d6) δ 1.10 (d, J = 6.41 Hz, 3 H), 3.94 (dd, J = 9.00, 3.51 Hz, 1 H), 4.02 - 
4.13 (m, 1 H), 4.50 (d, J = 5.19 Hz, 2 H), 5.19 (dd, J = 10.68, 1.22 Hz, 1 H), 5.32 (dd, J = 17.40, 
1.53 Hz, 1 H), 5.84 - 5.98 (m, 1 H), 6.85 (d, J = 8.85 Hz, 1 H), (Figure S2.4);  13C NMR (125 
MHz, DMSO-d6) δ ppm 20.8, 60.3, 65.0, 66.9, 117.4, 134.0, 156.7, 172.7, (Figure S2.5); ESI-
HRMS calcd. for C8H14NO5 = 203.0794 found: M+ H+ = 204.0864, M+Na+ = 226.0704. Cald. for [M – 
CO2 + H+] = [203.0794 – 43.9898 + 1.0072] = 160.0968, found 160.0968, (Figure S2.6)  
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Figure S2.5: 13C NMR Spectrum for compound 2.4 
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Figure S2.6: HRMS spectrum of AllocHN-D-Thr-OH (2.4).  HRMS calcd. for C8H14NO5 = 203.0794 found: M+ 














































VI. Synthesis of the Teixobactin analogue 2.1 via route B: 
 
Figure S2.7: Synthesis scheme for the Teixobactin analogue 2.1 
(step a) Commercially available 2-Chlorotrityl chloride resin (manufacturer’s loading = 1.2 mmol/g, 170 
mg resin) was swelled in DCM in a reactor. To this resin was added 4 eq. Fmoc-Ala-OH/8 eq. DIPEA 
in DCM and the reactor was shaken for 3h. The loading determined by UV absorption of the piperidine-
dibenzofulvene adduct was calculated to be 0.6 mmol/g, (170mg resin, 0.102mmol). Any unreacted resin 
was capped with MeOH:DIPEA:DCM = 1:2:7 by shaking for 1h. (step b) The fmoc protecting group 
was removed using 20% piperidine in DMF following the protocol described earlier in section III. (step 
b) The previously synthesized AllocHN-D-Thr-OH (2.4) was then coupled to the resin by adding 3 eq. 
of the AA, 3 eq. HATU and 6 eq. DIPEA in DMF and shaking for 3h at room temperature. (step c) 
















































































































































shaking the reaction for 2h. This was followed by capping the unreacted alcohol using 10% Ac2O/DIPEA 
in DMF shaking for 30 min and Fmoc was removed using protocol described earlier in section III. (step 
d) Fmoc-Arg(Pbf)-OH was coupled using 4 eq. of AA, 4 eq. HATU and 8 eq. DIPEA in DMF and 
shaking for 1h followed by Fmoc deprotection using 20% piperidine in DMF as described earlier. (step 
e) The N terminus of Arg was protected using 10 eq. Trt-Cl and 15% Et3N in DCM and shaking for 1h. 
The protection was verified by the Ninhydrin colour test. (step f) The Alloc protecting group of D-Thr 
was removed using 0.2 eq. [Pd(PPh3)]0 and 24 eq. PhSiH3 in dry DCM under argon for 1 h. This 
procedure was repeated twice and the resin was washed thoroughly with DCM and DMF to remove any 
Pd stuck to the resin. (step g) All amino acids were coupled using 4 eq. AA, 4 eq. HATU and 8 eq. 
DIPEA. Deprotection cycles were performed as described earlier. Each coupling and deprotection cycle 
were checked by the Ninhydrin colour test. (step h) The peptide was cleaved off from the resin without 
cleaving off the protecting groups for the amino acid side chains using TFA:TIS:DCM = 2:5:93 and 
shaking for 2h. (step i) The solvent was evaporated and the peptide was redissolved in DMF to which 1 
eq. HATU and 10 eq. DIPEA were added and the reaction was stirred for 1h to perform the cyclization. 
The reaction was monitored on HPLC till all starting material had been consumed (Fig. S13). (step j) 
The side-chain protecting groups were then cleaved off using TFA:TIS:H2O = 95:2.5:2.5 by stirring for 
1h. The peptide was precipitated using cold Et2O (-20°C) and centrifuging at 7000 rpm to obtain a white 
solid. This solid was further purified using RPHPLC using protocols as described in the section II. 
Fractions were collected, concentrated and lyophilised to obtain a white solid (28 mg, 22% yield). HRMS 
mass calcd for 2.1: C58H98N15O15 = 1243.7289, found M+ H+ = 1244.7336 HRMS. HPLC trace of crude 
and purified 2.1 (Figure S2.12Figure S2.13), HRMS of 2.1 (Figure S2.14).  
VII. Synthesis of the Teixobactin analogue 2.3 via route B: 
 
Figure S2.8: Complete structure of teixobactin analogue 2.3 
The synthesis of analogue 2.3 (Figure S2.8) was achieved (200 mg resin, 0.12 mmol scale) using the 
same procedure as analogue 2.1 except for the final acetylation. Fmoc removal of the L-phenyl alanine 




was performed using the protocol described previously (in section III) and acetylation of the amine was 
achieved by using 10% Ac2O/DIPEA in DMF and shaking for 30 min. TFA cleavage was performed as 
described in IV. step j above. The solvent was evaporated and the peptide was redissolved in DMF to 
which 1 eq. HATU and 10 eq. DIPEA were added and the reaction was stirred for 1h to perform the 
cyclization. The reaction was monitored on HPLC till all starting material had been consumed (Figure 
S2.15). The side-chain protecting groups were then cleaved off using TFA:TIS:H2O = 95:2.5:2.5 by 
stirring for 1h. The peptide was precipitated using cold Et2O (-20°C) and centrifuging at 7000 rpm to 
obtain a white solid. This solid was further purified using RPHPLC using protocols as described in the 
section II. Fractions were collected, concentrated and lyophilised to obtain a white solid (24 mg, 17% 
yield). ESI-HRMS mass calcd for 2.3 C59H98N15O16: 1272.7316, found 1272.7379. HPLC trace of crude 
and purified 2.3 (Figure S2.16 and Figure S2.17), ESI- HRMS of 2.3 (Figure S2.18). 
VIII. Antimicrobial Activity. 
The “Dilution Susceptibility” test1 was used to determine the Minimum inhibitory concentration (MIC) 
in 96 well plate format.  The test used cation adjusted Mueller-Hinton broth (OXOID) medium and was 
performed in triplicate. Plates were incubated at 37oC for 24hrs. The MIC was defined as the lowest 
concentration of antibiotic which resulted in no visible growth. 
IX. HPLC/LC-MS analysis 
 
Figure S2.9: HPLC trace of the crude compound 2.2 (gradient: 0-100% ACN in 6 min using A: 0.1% HCOOH in 
water, B: ACN) 
 
 





Figure S2.10: HRMS of compound 2.2. Mass calcd for C23H39N7O7: 525.2911, found M+H+ = 526.3010. 





Figure S2.11: HPLC trace showing the progress of cyclisation reaction (i): conversion of the uncyclized protected 
teixobactin analogue 2.1a tR= 17.257 min (shown in blue) to the cyclized protected teixobactin analogue 2.1b tR = 
21.973 min (shown in black) (Gradient: 5-95% in 25 min) 
 
Figure S2.12: HPLC trace of crude teixobactin analogue 2.1 tR = 9.263 min (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN)  





Figure S2.13: HPLC trace of HPLC purified teixobactin analogue 2.1 tR = 9.287 min (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S2.14: HRMS of teixobactin analogue 2.1. Mass calcd for C58H98N15O15: 1243.7289, found M+H+ = 
1244.7336, M/2 + H+ = 622.8715  
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Figure S2.15: HPLC trace showing the progress of reaction of teixobactin analogue 2.3: conversion of the 
uncyclized protected teixobactin analogue 2.3a tR= 15.560 min (shown in black) to the cyclized protected 
teixobactin analogue 2.3b tR = 20.310 min (shown in blue) (Gradient: 5-95% in 25 min)  





Figure S2.16: HPLC trace of crude teixobactin analogue 2.3 tR = 10.773 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S2.17: HPLC trace of purified teixobactin analogue 2.3 tR = 10.713 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN)  





Figure S2.18: ESI-HRMS of purified teixobactin analogue 2.3. ESI-HRMS mass calcd for C59H98N15O16: 
1271.7238, found M+H+ = 1272.7379, M/2 +H+ = 636.8646, (M+ Na+ + H+)/2 = 647.8555 
 
X. Detailed NMR Analysis of Compounds 2.1 and 2.3 
NMR was performed at 303.15°K on 1mM solutions of 2.1 and 2.3 dissolved in DMSO-d6 on a Bruker 
500 MHz Avance III HD spectrometer equipped with a broadband probe. Proton spectra were recorded 
with 128 transients and 64k points. Two dimensional spectra (H-H NOESY, H-H TOCSY, H-C HSQC, 
H-C HMBC) were recorded with 16 transients and 4k and 196 complex points in the direct and indirect 












































Figure S2.20: Structure of teixobactin analogue 2.3 with numbering. NMR assignments are shown in Table S2.3 
  





Figure S2.21: NMR spectra obtained from product 2.1 (red) and product 2.3 (blue). A. Overlaid proton spectra. B. 
Overlaid 1H-13C HSQC spectra, showing complete assignment. Inset shows aromatic correlations. Samples were 
1mM teixobactin analogue in DMSO-d6, and spectra were recorded on 500 MHz Bruker Avance III HD at 303.15 
K.  










Figure S2.22: Through-space and through-bond proton-proton correlation spectra of product 2.1 and product 2.3 
showing complete spectral assignment. A. Fingerprint region of product 2.1 showing 1H-1H NOESY (red contours) 
and 1H-1H TOCSY (green contours). The presence of only intra-residue and sequential NOEs is characteristic of 
an unstructured peptide. B. Fingerprint region of product 3 showing 1H-1H NOESY (blue contours) and 
1H-1H TOCSY (magenta contours). The presence of mid-range NOEs in addition to short-range NOEs suggests 
that this peptide has adopted a certain degree of structure. Samples were 1mM teixobactin analogue in DMSO-d6, 
and spectra were recorded on 500 MHz Bruker Avance III HD at 303.15 K. The extremely broad resonance at ~7.1 
ppm is the guanidinium group of Arg10. 
  





Product 2.1 from ref. 2 Product 2.1 
 
Position Carbon Proton Carbon Proton Notes 
1 31.9 2.48 34.79 2.169 Δδ1 1.01 ppm. Confirmed by NOE to 2-NH 
2 61.8 4.17 65.45 3.275 
(t, 7.0 Hz) 




   
3 36.5 3.00 39.50 2.696 
(dd, 13.5, 
6.5 Hz) 











Δδ 1.30 ppm. Confirmed by HMBC to 6, 3 
5, 5' 129.7 7.24 129.61 7.192 
(d, 7.0 Hz)  
 
6, 6' 129.0 7.33 128.50 7.244 
(t, 7.5 Hz) 
 
7 127.6 7.27 126.41 7.170 






Δδ 2.23 ppm. Confirmed by HMBC to 3 
9 57.8 4.16 56.92 4.202 








10 36.6 1.55 36.73 1.681 
 
                                                   
1 Difference from chemical shift published in ref. 2 of greater than 1 ppm. Calculated using the equation 
Δδ, =  	
Δδ +  
Δδ3  




11 15.5 0.62 15.80 0.746 
 






















16 62.4 3.55 62.35 3.570 
(q, 5.7 Hz) 
 
16' 
   
3.599 
(q, 6.3 Hz) 
 
16-OH 






















20 31.9 2.10 31.87 2.074 
 
20' 






































24 37.5 1.82 
  
Overlapped 
25 14.7 0.82 15.94 0.823 
 








27 10.5 0.82 10.88 0.822 
 
28 171.6 
    








30 36.6 1.82 37.24 1.731 
 
31 15.5 0.88 15.82 0.812 
 








33 11.3 0.82 11.44 0.806 
 
34 171.6 
   
Broad signal 
35 52.6 4.35 57.17 4.387 Δδ 1.52 ppm. Confirmed by NOE to 38-
NH. 





9.087 Δδ 1.06 ppm. Confirmed by NOEs to 29 
and 38-NH. 
Minor form3 at 8.189 ppm 
36 62.4 3.62 62.49 3.724 
(q, 4.0 Hz) 






(q, 5.7 Hz) 
Minor form3 at 3.642 ppm 








38 56.4 4.50 56.10 4.649 
(d, 8.5 Hz) 





8.800 Minor form3 at 8.548 ppm 
39 71.0 5.38 70.76 5.634 
(q, 7.2 Hz) 
 
40 15.8 1.11 16.10 1.105 
(d, 6.1 Hz) 
Minor form3 at 1.166 ppm 
41 158.4 
   
Broad signal 
42 52.1 3.93 51.98 3.939 
(quint, 7.1) 





8.197 Minor form3 at 8.548 ppm 
43 17.3 1.31 17.36 1.295 
(d, 7.5 Hz) 





45 52.1 3.60 57.23 4.290 Δδ 1.84 ppm. Confirmed by HSQC 
45-NH 
   
8.185 
 
46 25.7 1.44 29.57 1.661 Δδ 1.31 ppm. Confirmed by NOE intensity 
46' 
   
1.765 
 
47 29.4 1.26 25.48 1.429 Δδ 1.32 ppm. Confirmed by NOE intensity 
47' 
   
1.475 
 
48, 48' 43.9 3.17 40.51 3.119 
(q, 6.6 Hz) 
Δδ 1.13 ppm. Confirmed by TOCSY to 45, 
46, 47, 48, 45-NH and 48-NH 
48-NH 
   
7.719 
 





   
Broad Signal 
49-NH2 








   
Broad Signal 
51 57.5 4.05 57.56 4.039 
(t, 9.9 Hz) 





8.411 Minor form3 at 7.995 ppm 
52 37.0 1.82 36.90 1.693 Minor form3 at 1.767 ppm 
53 16.0 0.82 15.82 0.808 Minor form3 at 0.833 ppm 













Table S2.2: Complete NMR assignment for product 2.1  




Position Carbon Proton Position Carbon Proton 






2 54.12 4.5761 30 37.05 1.736 
2-NH 
 
8.075 31 15.81 0.825 








33 11.35 0.822 
5, 5' 129.59 7.252 34 
  
6, 6' 128.37 7.253 35 57.01 4.376 





36 62.56 3.672 








10 37.05 1.740 37 171.86 
 
11 15.81 0.827 38 55.84 4.645 





1.430 39 70.87 5.361 
                                                   
2 Chemical shift difference from 2.1 due to presence of N-terminal acetyl group 
3 The small number of differences observed to previously published chemical shifts were attributable to the cyclic 
portion of 2.1 existing in equilibrium between two unevenly distributed populations. The chemical shifts match 
those described in ref. 2. However, there exists an additional minor form of the cyclic portion of 2.1 whose chemical 





















16 62.09 3.568 43 17.29 1.290 
16' 
 























































24 36.89 1.726 52 36.64 1.681 
25 15.72 0.805 53 15.81 0.814 
26 24.77 1.064 54 24.77 1.098 














Table S2.3: Complete NMR assignment for product 2.3 
XI. References: 
1.  J. H. Jorgensen, M. J. Ferraro, Antimicrobial susceptibility testing: a review of general principles 
and contemporary practices. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America. 49, 1749–55 (2009). 
2.  Y. E. Jad, G. A. Acosta, T. Naicker, M. Ramtahal, A. El-Faham, T. Govender, H. G. Kruger, B. 
G. De La Torre, F. Albericio, Synthesis and Biological Evaluation of a Teixobactin Analogue. 
Organic Letters. 17, 6182–6185 (2015). 
 




EXPERIMENTAL SECTION FOR CHAPTER 3 
I. Materials 
All L amino acids, Fmoc-D-Ala-OH Fmoc-D-Gln(Trt)-OH, Boc-N-methyl-D-phenylalanine, 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxidhexafluorophosphate 
(HATU), Phenylsilane (PhSiH3), Tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)], 
Diisoproplycarbodiimide (DIC) and Triisopropylsilane (TIS) were purchased from Fluorochem, UK.  
Fmoc-D-allo-Ile-OH and oxyma pure were purchased from Merck Millipore. The side chain 
protecting groups for the amino acids are tBu for Ser, Pbf for Arg and Trt for Gln and Thr unless 
specified otherwise. Diisopropylethylamine (DIPEA), supplied as extra dry, redistilled, 99.5 % pure, 
Acetic anhydride, allyl chloroformate and CDCl3 and were purchased from Sigma Aldrich. 
Tritylchloride and 4-(Dimethylamino)pyridine were purchased from Alfa Aesar. 
Dimmethylformamide (DMF) peptide synthesis grade was purchased from Rathburn chemicals.  
Triethylamine, Diethyl ether (Et2O), Dimethylsulfoxide (DMSO), Dichloromethane (DCM), 
Tetrahydrofuran (extra dry with molecular sieves), Formic acid 98-100% purity and Acetonitrile 
(HPLC grade) were purchased from Fisher Scientific. Water with the Milli-Q grade standard was 
obtained in-house from an ELGA Purelab Flex system. 2-Chlorotritylchloride resin (manufacturer’s 
loading: 1.20 mmol/g) was purchased from Fluorochem. All chemicals were used without further 
purification. 
II. Equipment used for the analysis and purification of compounds 
All peptides were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC equipped with 
a Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer systems: 
A: 0.1% HCOOH in milliQ water. B: ACN using a flow rate of 1 ml/min. The column was flushed 
with 95% A for 5 min prior to an injection and was flushed for 5 min with 95% B and 5% A after 
the run was finished. 
Peptides were analysed using the following gradient: 95% A for 2 min. 5-95% B in 25 min. 95% B 
for 5 min. 5% A for 4 min. 
Peptides were purified using the same gradient as mentioned above, on a Thermo Scientific Dionex 
Ultimate 3000 RP-HPLC with a flow rate of 5 mL/min using a Phenomenex Gemini NX C18 110 Å 
(150 x 10 mm) semi-prep column. 
LC-MS data were collected on an Agilent 1100 Series instrument with a Phenomenex Kinetex C18 
100Å column (150 x 4.6 mm, 5 μm at 35 °C) connected to an ESMSD type VL mass detector with a 
flow rate of 1.5 ml/min was used with the following solvent systems: (A): 0.1% HCOOH in H2O and  
(B) MeCN. The column was flushed with 100% A for 2 min, then a gradient from 0 to 100% B over 
6 min was used, followed by 2 min of flushing with 100% B. 




NMR spectra were recorded on a Bruker AV 500 NMR. 








[M + H+] 
Overall 
yield 
      
1 2.12 LLLL 1243.73 1244.4 16% 
2 2.13 DDLD 1243.73 1244.4 17% 
3 2.14 DLDD 1243.73 1244.4 9% 
4 2.15 LDDD 1243.73 1244.4 13% 
5 2.16 LLDD 1243.73 1244.4 14% 
Table S3.1: Mass analysis and overall yields for compounds 2.12-2.16. Analysis and overall yields for 
compounds 2.11 & 2.17 have been published previously (See Chapter 2).1 
 
Figure S3.1: HPLC trace showing the progress of cyclisation reaction for 2.12 (LLLL) (i): conversion of the 
uncyclized protected teixobactin analogue tR= 16.067 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 21.403 min (shown in blue) (Gradient: 5-95% in 25 min) 





Figure S3.2: HPLC trace of crude teixobactin analogue 2.12 (LLLL) tR = 8.257 min (gradient: 5-95% ACN in 
25 min using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S3.3: HPLC trace of HPLC purified teixobactin analogue 2.12 (LLLL) (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 






Figure S3.4: HPLC trace showing the progress of cyclisation reaction for 2.13 (DDLD) (i): conversion of the 
uncyclized protected teixobactin analogue tR= 17.457 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 21.520 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S3.5: HPLC trace of crude teixobactin analogue 2.13 (DDLD) tR = 8.983 min (gradient: 5-95% ACN 
in 25 min using A: 0.1% HCOOH in water, B: ACN) 





Figure S3.6: HPLC trace of HPLC purified teixobactin analogue 2.13 (DDLD) (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S3.7: HPLC trace showing the progress of cyclisation reaction for 2.14 (DLDD) (i): conversion of the 
uncyclized protected teixobactin analogue tR= 17.493 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 22.097 min (shown in blue) (Gradient: 5-95% in 25 min) 





Figure S3.8: HPLC trace of crude teixobactin analogue 2.14 (DLDD) tR = 9.017 min (gradient: 5-95% ACN 
in 25 min using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S3.9: HPLC trace of HPLC purified teixobactin analogue 2.14 (DLDD) (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 





Figure S3.10: HPLC trace showing the progress of cyclisation reaction for 2.15 (LDDD) (i): conversion of the 
uncyclized protected teixobactin analogue tR= 16.863 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 21.603 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S3.11: HPLC trace of crude teixobactin analogue 2.15 (LDDD) tR = 8.697 min (gradient: 5-95% ACN 
in 25 min using A: 0.1% HCOOH in water, B: ACN) 





Figure S3.12: HPLC trace of HPLC purified teixobactin analogue 2.15 (LDDD) (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S3.13: HPLC trace showing the progress of cyclisation reaction of 2.16 (LLDD) (i): conversion of the 
uncyclized protected teixobactin analogue tR= 17.263 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 21.790 min (shown in blue) (Gradient: 5-95% in 25 min) 





Figure S3.14: HPLC trace of crude teixobactin analogue 2.16 LLDD tR = 8.480 min (gradient: 5-95% ACN in 
25 min using A: 0.1% HCOOH in water, B: ACN) 
 
Figure S3.15: HPLC trace of HPLC purified teixobactin analogue 2.16 LLDD (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
 
 




IV. NMR Analysis 
Spectra were recorded using 1 mM teixobactin analogues dissolved in DMSO-d6 at 298.2 K on a 
Bruker Avance III 500 MHz spectrometer. Assignments were made using 1H-1H TOCSY, 1H-13C 
HSQC and 1H-13C HMBC. Through-space dipolar correlations were measured using 1H-1H NOESY 
with 200 ms mixing time. Spectra were acquired with 2048 complex points, and either 196 (TOCSY, 
NOESY, HSQC) or 512 (HMBC) complex points in the direct and indirect dimensions, respectively. 
Spectra were processed using Bruker TopSpin and analysed using CcpNmr Analysis.2 Structures of 
the homologues were obtained via the process of iterative NOE assignment, with the structural 
calculations carried out using Cyana 2.1.3 A final round of energy minimisation in explicit solvent 
was carried out using Gromacs 5.1.24 and the RSFF2 forcefield,5 which has been shown to perform 
favourably with cyclic peptides.6 Structures were visualised and analysed using PyMOL. 




Figure S3.16: 1H-1H NOESY spectra obtained from teixobactin homologues 2.15 (LDDD, red contours) and 
LLDD (blue contours), which only differ from each other in the stereochemistry of position 4. There are many 
more crosspeaks visible in the spectrum of 2.16 (LLDD) when compared to 2.15 (LDDD), some of which are 
due to medium- to long-range interactions. These differences are borne out by the RMSDs of the structural 




ensembles generated using these crosspeaks: 2.15 (LDDD) with few crosspeaks resulted in an unstructured 
peptide with an RMSD of ~3 Å (Table 3.1; Figure 3.3A,D), whereas 2.16 (LLDD) with many crosspeaks of 
different classes resulted in a structured peptide of ~1 Å (Table 3.1; Figure 3.3A,E). Samples were prepared 
identically and spectra were acquired under identical conditions. Contours for each spectrum were set to 
identical levels, which was set at one level above noise. 
 2.13 (DDLD) 2.14 (DLDD) 2.15 (LDDD) 2.16 (LLDD) 2.12 (LLLL) 
1Phe H*      












1Phe Hδ* 7.193 7.195 7.180 7.198 7.197
1Phe Hε* 7.193 7.234 7.248 7.214 7.246
1Phe Hζ 7.191 7.173 7.190 7.239 7.193
2Ile H 7.926 7.928 7.930 7.914 7.910
2Ile Hα 4.210 4.167 4.294 4.279 4.281












2Ile Hγ2* 0.734 0.726 0.804 0.800 0.802
2Ile Hδ1* 0.734 0.726 0.804 0.800 0.802
3Ser H 7.980 7.955 8.031 8.065 8.084












3Ser Hγ 5.009 5.073 4.998 5.041 5.007
4Gln H 7.909 8.059 7.946 8.023 7.976


































5Ile H 7.851 7.819 7.804 7.799 7.888
5Ile Hα 4.254 4.326 4.281 4.444 4.195












5Ile Hγ2* 0.788 0.807 0.798 0.773 0.796
5Ile Hδ1* 0.788 0.807 0.798 0.773 0.799
6Ile H 7.851 8.010 7.958 7.963 7.887
6Ile Hα 4.229 4.265 4.282 4.284 4.239
6Ile Hβ 1.731 1.761 1.728 1.775 1.723
6Ile Hγ1 1.065 1.113 1.106 1.106 1.073




1.438 1.407 1.377 1.413 1.402
6Ile Hγ2* 0.809 0.815 0.822 0.815 0.805
6Ile Hδ1* 0.809 0.815 0.822 0.815 0.806
7Ser H 8.965 9.124 9.124 9.202 8.079












7Ser Hγ 5.655 5.592 5.616 5.643 4.918
8Thr H 8.953 8.763 8.798 8.820 7.759
8Thr Hα 4.644 4.638 4.642 4.645 4.796
8Thr Hβ 5.361 5.359 5.361 5.361 4.482
8Thr Hγ2* 1.091 1.091 1.095 1.092 1.075
9Ala H 8.211 8.185 8.202 8.197 9.454
9Ala Hα 3.932 3.930 3.928 3.929 4.466
9Ala Hβ* 1.290 1.288 1.287 1.279 1.339
10Arg H 8.211 8.159 8.190 8.205 9.168























































11Ile H 8.471 8.415 8.434 8.481 7.972
11Ile Hα 4.035 4.028 4.032 4.031 4.412












11Ile Hγ2* 0.811 0.813 0.801 0.801 0.848
11Ile Hδ1* 0.811 0.808 0.801 0.801 0.849
 
Table S3.2: Chemical shift assignments of the teixobactin homologues. Underlined values are more than 2 
standard deviations away from the average values. Chemical shifts for analogues 2.11 (DDDD) and 2.17 








V. Structural Statistics for teixobactin analogues 
 
  2.11 (DDDD) 2.13 (DDLD) 2.14 (DLDD) 2.15 (LDDD) 2.16 (LLDD) 2.17 (LLLD) 2.12 (LLLL) 
NMR distance restraints        
    Intra-residue 38 56 55 43 57 50 44 
    Sequential (|i – j| = 1) 11 18 18 14 21 19 18 
    Med range (|i – j| < 5) 5 7 1 6 6 6 1 
    Long range (|i – j| > 4) 0 0 2 0 8 2 1 
    TOTAL 54 81 76 63 92 77 64 
Statistics of overall structural quality       
    Ensemble pairwise RMSD       
        Heavy atom (Å) 3.16 ± 1.44 1.83 ± 0.55 0.76 ± 0.20 2.96 ± 1.26 1.06 ± 0.45 0.93 ± 0.44 1.08 ± 0.32 
        Backbone (Å) 1.83 ± 1.10 0.93 ± 0.37 0.37 ± 0.15 1.92 ± 0.93 0.59 ± 0.30 0.53 ± 0.28 0.50 ± 0.20 
    Restr violations > 0.1 Å 0 0 0 0 0 0 0 
    RMSD from idealised covalent geometry7      
        Bond lengths (Å) 0.013 0.013 0.013 0.013 0.013 0.011 0.013 
        Bond angles (°) 2.1 1.9 1.9 2.0 2.1 1.8 1.9 
    Ramachandran analysis8       
        Allowed (%) 58.8 ± 6.3 95.6 ± 5.6 77.7 ± 0.0 88.9 ± 0.0 88.8 ± 0.0 98.3 ± 4.1 98.9 ± 3.4 
        Gen allowed (%) 20.5 ± 6.7 4.4 ± 5.6 22.2 ± 0.0 2.2 ± 4.5 0.0 ± 0.0 1.7 ± 4.0 1.1 ± 3.4 
        Disallowed (%) 20.5 ± 6.5 0.0 ± 0.0 0.0 ± 0.0 8.9 ± 4.5 11.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
    ProCheck G-factor -0.58 ± 0.1 -0.37 ± 0.1 -0.31 ± 0.1 -0.25 ± 0.1 -0.32 ± 0.1 -0.12 ± 0.1 -0.27 ± 0.1 
    MolProbity clash score9 0.27 ± 1.20 1.06 ± 2.18 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.06 ± 2.18 5.85 ± 1.64 
 
Table S3.3: Structural statistics for teixobactin analogues. 
  





VI. Molecular Dynamic simulations 
Molecular dynamics simulations were carried out using Gromacs 5.1.2 and RSFF2. The lowest 
energy structure from each ensemble was solvated in TIP3P water and neutralised with chloride ions. 
This system was subjected to 100 ps of NVT and NPT equilibration. 100 ns of simulation was carried 
out with periodic boundary conditions at 298.2 K, and the trajectory analysed with VMD.10 
 
Figure S3.17: Molecular dynamics simulations of teixobactin stereochemical analogues. A. The sidechain of 
Arg10 consistently presents ~15% less surface area to the solvent in non-native teixobactin 2.17 (LLLD, teal 
line) when compared to the native 2.11 (DDDD, red line) over the course of the simulation. B. Hydrophobic 
packing between the sidechains of Ile6 and Ile11 is consistent over the course of the simulation in the analogue 
(teal line), whereas this packing is only infrequently visited in the native form (red line). Simulations were 
performed using Gromacs 5.1.2 and the RSFF2 forcefield. Surface area, hydrogen bonds and interatomic 
distances were calculated using the Gromacs modules sasa, hbond and distance, respectively. Data were 
recorded every 10 ps and were plotted as a rolling average over 50 data points. 
  




VII. MIC testing 
For MIC testing all peptides were dissolved in DMSO. Bacteria were grown on Mueller Hinton broth 
(oxoid). All incubations were at 37°C. Dilutions were carried out using Mueller Hinton. 100 µl of 
autoclaved Mueller Hinton broth was added to wells 2-12 on a 96-well plate. 200 µl of the peptide 
was added to well one at a concentration of 512 µg/ml. 100µl of peptide in well one was taken up 
and pipetted into well two. The mixture was then mixed via pipetting before 100µl was taken up and 
pipetted into well three. This process was repeated up to well 11. Once peptide was added to well 11 
100 µl was taken up and then discarded ensuring the well 12 had no peptide present. Each well was 
then inoculated with 100µl of bacteria that had been diluted to an OD600nm of 0.1. This was repeated 
three times. The 96-well plates were then incubated for 24 hours. The MIC was determined to be the 
lowest concentration at which there was no growth visible. 
VIII. Complex formation of teixobactin with lipid II and geranyl pyrophosphate 
Complex formation of teixobactin analogues 21 (DDDD) and 22 (LLLL) with lipid II and geranyl 
pyrophosphate was performed using TLC as described previously11. Binding of teixobactin to lipid 
II and geranyl pyrophosphate was analysed by incubating 30 µL of 2 nmol of each precursor with 2 
or 4 nmoles of teixobactin in 50 mM Tris/HCl, pH 7.5, for 30 min at room temperature. Complex 
formation was analysed by extracting unbound precursors from the reaction mixture with 30 µL n- 
butanol/6M pyridine acetate (pH 4.2) (2:1; vol/vol) followed by TLC analysis of the organic layer 
using chloroform/methanol/water/ammonia (88:48:10:1, v/v/v/v) as the solvent and detection of 
lipid/phosphate containing precursors by phosphomolybdic acid staining12. The TLC figures 
represent the results obtained through three independent experiments. 
 
Figure S3.18: Binding of teixobactin analogues 21 (DDDD) and 22 (LLLL) with lipid II using the protocols 
described in literature11. Partial binding is observed when the ratio of lipid II to the analogue is 1:1 (indicated 
by lighter spots on the TLC) and complete binding is observed when the ratio of lipid II to the analogue is 1:2 
(indicated by no spots on TLC). 





Figure S3.19: Binding of teixobactin analogues 21 (DDDD) and 22 (LLLL) with geranyl pyrophosphate using 
the protocols described in literature11. No binding is observed when the ratio of the phosphate to the analogue 
is 1:2 (indicated by no spots on the TLC). 
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EXPERIMENTAL SECTION FOR CHAPTER 4 
I. Materials 
All L amino acids including Fmoc-Orn(Boc)-OH, Fmoc-Dab(Boc)-OH and Fmoc-Dap(Boc)-OH and 
D amino acids Fmoc-D-Ala-OH Fmoc-D-Gln(Trt)-OH, Boc-N-methyl-D-phenylalanine and 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxidhexafluorophosphate 
(HATU), Phenylsilane (PhSiH3), Tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)], 
Diisoproplycarbodiimide (DIC), Triisopropylsilane (TIS) and and 1H-Pyrazole-carboxamidine 
hydrochloride were purchased from Fluorochem, UK.  Fmoc-D-allo-Ile-OH and oxyma pure were 
purchased from Merck Millipore. The side chain protecting groups for the amino acids are tBu for 
Ser, Pbf for Arg and Trt for Gln and Thr unless specified otherwise. Diisopropylethylamine (DIPEA), 
supplied as extra dry, redistilled, 99.5 % pure, Acetic anhydride, allyl chloroformate, CDCl3 and 
polysorbate 80 and were purchased from Sigma Aldrich. Tritylchloride and 4-
(Dimethylamino)pyridine were purchased from Alfa Aesar. Dimmethylformamide (DMF) peptide 
synthesis grade was purchased from Rathburn chemicals.  Triethylamine, Diethyl ether (Et2O), 
Dimethylsulfoxide (DMSO), Dichloromethane (DCM), Tetrahydrofuran (extra dry with molecular 
sieves), Formic acid 98-100% purity and Acetonitrile (HPLC grade) were purchased from Fisher 
Scientific. Water with the Milli-Q grade standard was obtained in-house from an ELGA Purelab Flex 
system. 2-Chlorotritylchloride resin (manufacturer’s loading: 1.20 mmol/g) was purchased from 
Fluorochem, UK. All chemicals were used without further purification. 
II. Equipment used for the analysis and purification of compounds 
All peptides were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC equipped with 
a Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer systems: 
A: 0.1% HCOOH in milliQ water. B: ACN using a flow rate of 1 ml/min. The column was flushed 
with 95% A for 5 min prior to an injection and was flushed for 5 min with 95% B and 5% A after 
the run was finished. 
Peptides were analysed using the following gradient: 95% A for 2 min. 5-95% B in 25 min. 95% B 
for 5 min. 5% A for 4 min. 
Peptides were purified using the same gradient as mentioned above, on a Thermo Scientific Dionex 
Ultimate 3000 RP-HPLC with a flow rate of 5 mL/min using a Phenomenex Gemini NX C18 110 Å 
(150 x 10 mm) semi-prep column. 
HRMS spectra were recorded on a Thermo Scientific Q Exactive Plus Orbitrap Mass Spectrometer 
in the positive ion mode. 
 
 






III. Syntheses of teixobactin analogues 
Teixobactin analogues 2.1, 4.1, 4.3, 4.4 & 4.6 were synthesized according to our previously described 
protocol.1 
Procedure for Guanidation: 5 mg of the amino precursor for the corresponding guanidine 
teixobactin was dissolved in 200 µL of MeOH. 15 eq. of Et3N was then added to it and the solution 
was stirred till all the teixobactin analogue dissolved. 1.5 eq. of 1H-Pyrazole-carboxamidine 
hydrochloride was then added and stirred vigorously. MeOH was added dropwise (if necessary) till 
all the reagent dissolved and the reaction mixture was stirred for 8h at r.t. The reaction mixture was 
then analysed on RP-HPLC followed by RP-HPLC purification and freeze dried to yield the 
corresponding guanidine teixobactin. 
 








[M + H+] 
Overall 
yield [%] 
      
4.1 Lys10-teixobactin C58H97N13O15 1215.7227 1216.7314 19 a 
4.2 HoArg10-teixobactin C59H99N15O15 1257.7445 1258.7533 64 b 
4.3 Orn10-teixobactin C57H95N13O15 1201.7071 1202.7153 16 a 
4.4 Dab10-teixobactin C56H93N13O15 1187.6914 1188.7009 20 a 
4.5 NorArg10-teixobactin C57H95N15O15 1229.7132 1230.7216 50 b 
4.6 Dap10-teixobactin C55H91N13O15 1173.6758 1174.6852 13 a 
4.7 GAPA10-teixobactin C56H93N15O15 1215.6976 1216.7057 48 b 
Table S4.1: Compound number, name, chemical formula, exact mass, mass found and overall yield for 
compounds 4.1, 4.3, 4.6 & 4.2, 4.5, 4.7. 
a isolated yield. 
b isolated yields for guanidation step. 
 
  





Figure S4.1: HPLC trace showing the progress of the cyclisation reaction for analogue 4.1: conversion of the 
uncyclized protected teixobactin analogue tR= 15.977 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 20.897 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S4.2: HPLC trace of crude teixobactin analogue 4.1 tR = 9.393 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 





Figure S4.3: HPLC trace of HPLC purified teixobactin analogue 4.1 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
Figure S4.4: HRMS spectra from of HPLC purified teixobactin analogue 4.1. Exact Mass calcd. for 
C58H97N13O15 = 1215.7227, found M+H+ = 1216.7314 and M/2 + H+ = 608.8687 
anish_17_5_17_AP172 #59-108 RT: 0.55-1.01 AV: 50 NL: 3.63E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]













































Figure S4.5: HPLC trace of HPLC purified teixobactin analogue 4.2 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S4.6: HRMS spectra of HPLC purified teixobactin analogue 4.2. Exact Mass calcd. for C59H99N15O15 
= 1257.7445, found M+H+ = 1258.7533 and M/2 + H+ = 630.3787 
 
anish_16_5_17_170516151934 #1 RT: 0.00 AV: 1 NL: 7.71E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]












































Figure S4.7: HPLC trace showing the progress of the cyclisation reaction for analogue 4.3: conversion of the 
uncyclized protected teixobactin analogue tR= 16.000 min (shown in black) to the cyclised protected 
teixobactin analogue tR = 20.720 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S4.8: HPLC trace of crude teixobactin analogue 4.3 tR = 9.057 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 





Figure S4.9: Ornithine HPLC trace of HPLC purified teixobactin analogue 4.3 (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
 
 
Figure S4.10: ESI-MS spectra from LC-MS of HPLC purified teixobactin analogue 4.3. Exact Mass calcd. for 
C57H95N13O15 = 1201.71, found M+H+ = 1202.7153 and M/2 + H+ = 601.8609 
  
anish_24_5_17_ap184 #73-79 RT: 0.68-0.73 AV: 7 NL: 5.25E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]












































Figure S4.11: HPLC trace showing the progress of cyclisation reaction for analogue 4.4: conversion of the 
uncyclized protected teixobactin analogue tR= 15.527 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 20.787 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
 
Figure S4.12: HPLC trace of crude teixobactin analogue 4.4 tR = 9.243 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 





Figure S4.13: HPLC trace of HPLC purified teixobactin analogue 4.4 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S4.14: HRMS spectra from LC-MS of HPLC purified teixobactin analogue 4.4. Exact Mass calcd. for 
C56H93N13O15 = 1187.6914, found M+H+ = 1188.7009 and M/2 + H+ = 594.8532 
 
anish_17_5_17_AP124A_170517143600 #1 RT: 0.00 AV: 1 NL: 7.79E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]












































Figure S4.15: HPLC trace of HPLC purified teixobactin analogue 4.5 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
Figure S4.16: ESI-MS spectra from LC-MS of HPLC purified teixobactin analogue 4.5. Exact Mass calcd. for 
C57H95N15O15 = 1229.7132, found M+H+ = 1230.7216 and M/2 + H+ = 615.8638 
 
 
anish_17_5_17_AP188 #1 RT: 0.00 AV: 1 NL: 1.97E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]












































Figure S4.17: HPLC trace showing the progress of cyclisation reaction of analogue 4.6: conversion of the 
uncyclized protected teixobactin analogue tR= 16.010 min (shown in black) to the cyclized protected 
teixobactin analogue tR = 20.693 min (shown in blue) (Gradient: 5-95% in 25 min) 
Figure S4.18: HPLC trace of crude teixobactin analogue 4.6 tR = 9.230 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 





Figure S4.19: HPLC trace of HPLC purified teixobactin analogue 4.6 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S4.20: ESI-MS spectra from LC-MS of HPLC purified teixobactin analogue 4.6. Exact Mass calcd. for 
C55H91N13O15 = 1173.6758, found M+H+ = 1174.6852 and M/2 + H+ = 587.8454 
anish_17_5_17_AP185 #1 RT: 0.00 AV: 1 NL: 6.02E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]













































Figure S4.21: HPLC trace of HPLC purified teixobactin analogue 4.7 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
Figure S4.22: ESI-MS spectra from LC-MS of HPLC purified teixobactin analogue 4.7. Exact Mass calcd. for 
C56H93N15O15 = 1215.6976, found M+H+ = 1216.7057 
  
anish_18_5_17_DAB #72-76 RT: 0.67-0.71 AV: 5 NL: 6.56E8
T: FTMS + p ESI Full lock ms [300.0000-1500.0000]











































V. MIC testing 
For MIC assays all peptides were dissolved in DMSO containing 0.002% polysorbate 802. All 
bacteria were grown in Mueller Hinton broth (Oxoid). All incubations were at 37°C. Dilutions were 
carried out in triplicate. 100 µl of autoclaved Mueller Hinton broth was added to wells 2-12 on a 96-
well plate. 200 µl of the peptide was added to well one at a concentration of 512 µg/mL. 100µl of 
peptide in well one was taken up and pipetted into well two. The mixture was then mixed via pipetting 
before 100µl was taken up and pipetted into well three. This process was repeated up to well 11. 
Once peptide was added to well 11 100 µl was taken up and then discarded ensuring the well 12 had 
no peptide present. Thus, the concentrations (in µg/mL) were: 512, 256, 128, 64, 32, 16, 8, 4, 2, 1, 
0.5 and no peptide present. Each well was then inoculated with 100µl of bacteria that had been diluted 
to an OD600nm of 0.1. This was repeated three times. The 96-well plates were then incubated for 24 
hours. The MIC was determined to be the lowest concentration at which there was no growth visible. 
For all the compounds in which the MIC lower than 1 µg/ml for the initial test, the above procedure 
was repeated at an altered initial concentration of 64 µg/ml. Therefore, the new concentrations for 
MIC were: 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 and no peptide present. Vancomycin was 
used as a control.  
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EXPERIMENTAL SECTION FOR CHAPTER 5 
I. Materials 
All L-amino acids, Fmoc-D-Ala-OH Fmoc-D-Gln(Trt)-OH, Boc-N-methyl-D-phenylalanine, 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxidhexafluorophosphate 
(HATU), Phenylsilane (PhSiH3), Tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)], 
Diisoproplycarbodiimide (DIC) and Triisopropylsilane (TIS) were purchased from Fluorochem, UK.  
Fmoc-D-allo-Ile-OH and oxyma pure were purchased from Merck Millipore. The side chain 
protecting groups for the amino acids are tBu for Ser, Pbf for Arg and Trt for Gln and Thr unless 
specified otherwise. Diisopropylethylamine (DIPEA), supplied as extra dry, redistilled, 99.5 % pure, 
Acetic anhydride, allyl chloroformate, CDCl3 and polysorbate 80 and were purchased from Sigma 
Aldrich. Tritylchloride and 4-(Dimethylamino)pyridine were purchased from Alfa Aesar. 
Dimmethylformamide (DMF) peptide synthesis grade was purchased from Rathburn chemicals.  
Triethylamine, Diethyl ether (Et2O), Dimethylsulfoxide (DMSO), Dichloromethane (DCM), 
Tetrahydrofuran (extra dry with molecular sieves), Formic acid 98-100% purity and Acetonitrile 
(HPLC grade) were purchased from Fisher Scientific. Water with the Milli-Q grade standard was 
obtained in-house from an ELGA Purelab Flex system. 2-Chlorotritylchloride resin (manufacturer’s 
loading: 1.20 mmol/g) was purchased from Fluorochem. All chemicals were used without further 
purification. Geranyl pyrophosphate ammonium salt, 1 mg/mL in MeOH was purchased from Sigma 
Aldrich. 
II. Equipment used for the analysis and purification of compounds 
All peptides were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC equipped with 
a Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer systems: 
A: 0.1% HCOOH in milliQ water. B: ACN using a flow rate of 1 ml/min. The column was flushed 
with 95% A for 5 min prior to an injection and was flushed for 5 min with 95% B and 5% A after 
the run was finished. 
Peptides were dissolved in (1:1) 0.1% HCOOH buffer in water and acetonitrile (ACN) and analysed 
using the following gradient: 95% A for 2 min. 5-95% B in 25 min. 95% B for 5 min. 5% A for 4 
min. 
Peptides were dissolved in 0.1% HCOOH buffer in water and in ACN (10-30% ACN) and purified 
using the same gradient as mentioned above, on a Thermo Scientific Dionex Ultimate 3000 RP-
HPLC with a flow rate of 5 mL/min using a Phenomenex Gemini NX C18 110 Å (150 x 10 mm) 
semi-prep column. 
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LC-MS data were collected on an Agilent 1100 Series instrument with a Phenomenex Kinetex C18 
100Å column (150 x 4.6 mm, 5 μm at 35 °C) connected to an ESMSD type VL mass detector with a 
flow rate of 1.5 ml/min was used with the following solvent systems: (A): 0.1% HCOOH in H2O and 
(B) MeCN. The column was flushed with 100% A for 2 min, then a gradient from 0 to 100% B over 
6 min was used, followed by 2 min of flushing with 100% B. 
NMR spectra were recorded on a Bruker AV 500 NMR. HRMS spectra were recorded on a Thermo 
Scientific Q Exactive Plus Orbitrap Mass Spectrometer in the positive ion mode. 
III. Syntheses of teixobactin analogues 
  
Figure S5.1: Synthesis of Leu10-teixobactin 5.13 
(step a) Commercially available 2-Chlorotrityl chloride resin (manufacturer’s loading = 1.2 mmol/g, 
170 mg resin) was swelled in DCM in a reactor. To this resin was added 4 eq. Fmoc-Ala-OH/8 eq. 
DIPEA in DCM and the reactor was shaken for 3h. The loading determined by UV absorption of the 




piperidine-dibenzofulvene adduct was calculated to be 0.6 mmol/g, (170mg resin, 0.102 mmol). Any 
unreacted resin was capped with MeOH:DIPEA:DCM = 1:2:7 by shaking for 1h. (step b) The Fmoc 
protecting group was deprotected using 20% piperdine in DMF by shaking for 3 min, followed by 
draining and shaking again with 20% piperidine in DMF for 10 min. AllocHN-D-Thr-OH was then 
coupled to the resin by adding 3 eq. of the AA, 3 eq. HATU and 6 eq. DIPEA in DMF and shaking 
for 1.5h at room temperature. (step c) Esterification was performed using 10 eq. of Fmoc-Ile-OH, 10 
eq. DIC and 5 mol% DMAP in DCM and shaking the reaction for 2h. This was followed by capping 
the unreacted alcohol using 10% Ac2O/DIPEA in DMF shaking for 30 min and Fmoc was removed 
using protocol described earlier in step (b). (step d) Fmoc-Leu-OH was coupled using 4 eq. of AA, 
4 eq. HATU and 8 eq. DIPEA in DMF and shaking for 1h followed by Fmoc deprotection using 20% 
piperidine in DMF as described earlier. (step e) The N terminus of Leu was protected using 10 eq. 
Trt-Cl and 15% Et3N in DCM and shaking for 1h. The protection was verified by the Ninhydrin 
colour test. (step f) The Alloc protecting group of D-Thr was removed using 0.2 eq. [Pd(PPh3)]0 and 
24 eq. PhSiH3 in dry DCM under argon for 20 min. This procedure was repeated again increasing 
the time to 45 min and the resin was washed thoroughly with DCM and DMF to remove any Pd stuck 
to the resin. (step g) All amino acids were coupled using 4 eq. Amino Acid, 4 eq. DIC/Oxyma using 
a microwave peptide synthesizer. Coupling time was 10 min. Deprotection cycles were performed 
as described earlier. (step h) The peptide was cleaved from the resin without cleaving off the 
protecting groups of the amino acid side chains using TFA:TIS:DCM = 2:5:93 and shaking for 1h. 
(step i) The solvent was evaporated and the peptide was redissolved in DMF to which 1 eq. HATU 
and 10 eq. DIPEA were added and the reaction was stirred for 30 min to perform the cyclization. 
(step j) The side-chain protecting groups were then cleaved off using TFA:TIS:H2O = 95:2.5:2.5 by 
stirring for 1h. The peptide was precipitated using cold Et2O (-20°C) and centrifuging at 7000 rpm 
to obtain a white solid. This solid was further purified using RP-HPLC using the protocols described 
previously1.  
All other teixobactin analogues were synthesised according to the above procedure. 
  



















C53H93N15O16 1195.69 1196.4 12 
2 5.2 Ala2-Arg10-
teixobactin 
C55H91N15O15 1201.68 1202.4 10 
3 5.3 Ala3-Arg10-
teixobactin 
C58H97N15O14 1227.73 1228.5 11 
4 5.4 D-Ala4-Arg10-
teixobactin 
C56H94N14O14 1186.71 1187.4 12 
5 5.5 D-Ala5-Arg10-
teixobactin 
C55H91N15O15 1201.68 1202.4 11 
6 5.6 Ala6-Arg10-
teixobactin 
C55H91N15O15 1201.68 1202.4 12 
7 5.7 Ala7-Arg10-
teixobactin 
C58H97N15O14 1227.73 1228.5 12 
8 5.8 Ala10-
teixobactin 
C55H90N12O15 1158.66 1159.5 13 
9 5.9 D-Ala10-
teixobactin 
C55H90N12O15 1158.66 1159.5 10 
10 5.10 Gly10-
teixobactin 
C54H88N12O15 1144.65 1145.6 18* 
11 5.11 Val10-
teixobactin 
C57H94N12O15 1186.70 1187.6 24 
12 5.12 Ile10-
teixobactin 
C58H96N12O15 1200.71 1201.5 10 
13 5.13 Leu10-
teixobactin 
C58H96N12O15 1200.71 1201.5 20 
14 5.14 Ser10-
teixobactin 






Table S5.1: Compound number, code, exact mass, chemical formula, mass found and overall yields for 
compounds 5.1-5.15. 
*  Gly10-teixobactin afforded a yield of 2% when synthesised for the first time possibly due to deletion 
sequences. Since the yield was unusually low, therefore, the synthesis was repeated a second time 
thereby affording a yield of 18%.  




IV. HPLC/LC-MS analysis 
 
Figure S5.2: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.1 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 14.677 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 19.240 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.3: HPLC trace of crude teixobactin analogue 5.1 tR = 9.633 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.4: HPLC trace of HPLC purified teixobactin analogue 5.1 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.5: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.1. Exact mass calcd. for 
C53H93N15O16 = 1195.69, found M + H+ = 1196.4, M/2 + H+ = 598.8. 





Figure S5.6: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.2 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 15.843 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.623 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.7: HPLC trace of crude teixobactin analogue 5.2 tR = 8.603 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.8: HPLC trace of HPLC purified teixobactin analogue 5.2 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.9: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.2. Exact mass calcd. for 
C55H91N15O15 = 1201.68, found M + H+ = 1202.4, M/2 + H+ = 601.8, M/3 + H+ = 401.7. 
 





Figure S5.10: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.3 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 16.390 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.650 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.11: HPLC trace of crude teixobactin analogue 5.3 tR = 9.293 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.12: HPLC trace of HPLC purified teixobactin analogue 5.3 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.13: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.3. Exact mass calcd. for 
C58H97N15O14 = 1227.73, found M + H+ = 1228.5, M/2 + H+ = 614.8, M/3 + H+ = 410.2. 





Figure S5.14: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.4 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 14.917 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 19.540 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.15: HPLC trace of crude teixobactin analogue 5.4 tR = 9.223 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.16: HPLC trace of HPLC purified teixobactin analogue 5.4 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.17: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.4. Exact mass calcd. for 
C56H94N14O14 = 1186.71, found M + H+ = 1187.4, M/2 + H+ = 594.3. 
 





Figure S5.18: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.5 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 16.323 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.863 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.19: HPLC trace of crude teixobactin analogue 5.5 tR = 8.657 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.20: HPLC trace of HPLC purified teixobactin analogue 5.5 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.21: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.5. Exact mass calcd. for 
C55H91N15O15 = 1201.68, found M + H+ = 1202.4, M/2 + H+ = 601.8, M/3 + H+ = 401.7. 
 





Figure S5.22: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.6 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 16.467 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.933 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.23: HPLC trace of crude teixobactin analogue 5.6 tR = 8.657 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.24: HPLC trace of HPLC purified teixobactin analogue 5.6 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.25: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.6. Exact mass calcd. for 
C55H91N15O15 = 1201.68, found M + H+ = 1202.4, M/2 + H+ = 601.8, M/3 + H+ = 401.7. 





Figure S5.26: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.7 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 16.100 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.763 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.27: HPLC trace of crude teixobactin analogue 5.7 tR = 9.173 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.28: HPLC trace of HPLC purified teixobactin analogue 5.7 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.29: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.7. Exact mass calcd. for 
C58H97N15O14 = 1227.73, found M + H+ = 1228.5, M/2 + H+ = 614.8, M/3 + H+ = 410.2. 





Figure S5.30: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.8 (i): 
conversion of the uncyclised protected teixobactin analogue tR= 15.640 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.763 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.31: HPLC trace of crude teixobactin analogue 5.8 tR = 10.347 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 
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Figure S5.32: HPLC trace of HPLC purified teixobactin analogue 5.8 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.33: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.8. Exact mass calcd. for 











Figure S5.34: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.9 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 16.940 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.577 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.35: HPLC trace of crude teixobactin analogue 5.9 tR = 10.570 min (gradient: 5-95% ACN in 25 min 
using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.36: HPLC trace of HPLC purified teixobactin analogue 5.9 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.37: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.9. Exact mass calcd. for 
C55H90N12O15 = 1158.66, found M + H+ = 1159.5, M/2 + H+ = 580.3. 





Figure S5.38: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.10 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 16.423 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.257 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.39: HPLC trace of crude teixobactin analogue 5.10 tR = 10.373 min (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.40: HPLC trace of HPLC purified teixobactin analogue 5.10 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.41: HRMS of HPLC purified teixobactin analogue 5.10. Exact mass calcd. for C54H88N12O15 = 
1144.6492, found M + H+ = 1145.6322, M/2 + H+ = 573.3190. 












































Figure S5.42: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.11 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 15.130 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.407 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.43: HPLC trace of crude teixobactin analogue 5.11 tR = 10.630 min (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.44: HPLC trace of HPLC purified teixobactin analogue 5.11 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.45: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.11. Exact mass calcd. for 
C57H94N12O15 = 1186.7, found M + H+ = 1187.6, M/2 + H+ = 594.3. 





Figure S5.46: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.12 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 15.353 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.640 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.47: HPLC trace of crude teixobactin analogue 5.12 tR = 10.793 min (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.48: HPLC trace of HPLC purified teixobactin analogue 5.12 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.49: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.12. Exact mass calcd. for 
C58H96N12O15 = 1200.71, found M + H+ = 1201.5, M/2 + H+ = 601.3. 





Figure S5.50: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.13 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 15.303 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.677 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.51: HPLC trace of crude teixobactin analogue 5.13 tR = 10.837 min (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.52: HPLC trace of HPLC purified teixobactin analogue 5.13 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.53: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.13. Exact mass calcd. for 
C58H96N12O15 = 1200.71, found M + H+ = 1201.5, M/2 + H+ = 601.3. 





Figure S5.54: HPLC trace showing the progress of cyclisation reaction for the synthesis of analogue 5.14 (i): 
conversion of the uncyclized protected teixobactin analogue tR= 15.673 min (shown in black) to the cyclized 
protected teixobactin analogue tR = 20.760 min (shown in blue) (Gradient: 5-95% in 25 min) 
 
Figure S5.55: HPLC trace of crude teixobactin analogue 5.14 tR = 10.630 min (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 




Figure S5.56: HPLC trace of HPLC purified teixobactin analogue 5.14 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S5.57: ESI-MS from LC-MS of HPLC purified teixobactin analogue 5.14. Exact mass calcd. for 
C55H90N12O16 = 1174.66, found M + H+ = 1175.6, M/2 + H+ = 588.3. 
  





Figure S5.58: HPLC trace of HPLC purified teixobactin analogue 5.15 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
 
Figure S5.59: HRMS of HPLC purified teixobactin analogue 5.15. Exact mass calcd. for C61H94N12O15 = 
1235.6962, found M = 1235.7040, M/2 + H+ = 618.3558.  
20170911_R10F #105 RT: 0.97 AV: 1 NL: 7.78E8
T: FTMS + p ESI Full lock ms [500.0000-1500.0000]
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V. NMR Analysis 
All NMR was carried out in DMSO-d6 at 27°C on a Bruker Avance III HD 500 MHz spectrometer 
equipped with a room-temperature broadband probe. The following spectra were utilised in the 
assignment of 1 mM solutions of the teixobactin mutants: 1H (128k points, 16 scans); 13C{1H} (64k 
points, 1024 scans); 1H- 13C HSQC (2k and 256 points in the direct and indirect dimensions, 4 scans); 1H- 
13C HMBC (2k and 512 points, 8 scans); 1H- 1H TOCSY (2k and 192 points; 32 scans); and 1H- 1H 
NOESY (2k and 192 points, 48 scans). Spectral analysis was carried out using CCPNMR Analysis.2 NOE-
derived distance restraints obtained from the NOESY spectra were used in structural calculations using 
Cyana 2.13 prior to energy minimisation using Gromacs 5.14 and RSFF2 forcefield.5 Geranyl 
pyrophosphate titrations were carried out using 0.5 mM teixobactin mutants and the following molar 
equivalents of geranyl pyrophosphate: 0.0, 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.25 and 1.5. Geranyl pyrophosphate 
was freeze-dried and dissolved in MeOH:D2O (7:3, 1 mM concentration) for the titration experiments. 
1H- 1H TOCSY spectra were acquired and assigned at each titration point to yield accurate chemical shift 
perturbations (CSPs). Residue-specific binding isotherms obtained from Hα CSPs were fit using the Hill 
equation with a Hill coefficient of 1.0 or > 1.0 in the case of sigmoidal curves. (Hα resonances were 
chosen for CSP analysis because they are common to each residue and because they were resolved for the 
majority of residues.) Full spectrum analysis of the titration was carried out using TREND6, which uses 
principal component analysis (PCA) to give an overall binding isotherm free from the influence of 
intermediate exchange. 
   5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 
1 D-NmPhe HNm        2.165 
1 D -NmPhe H 8.103        
1 D -NmPhe Hα 4.339 3.184 3.244 3.259 3.258 3.262 3.264 3.278 















1 D -NmPhe Hδ*   7.190 7.180    7.184 
1 D -NmPhe Hε*        7.240 
1 D -NmPhe Hζ        7.175 
2 Ile H 8.045 8.046 7.898 7.943 7.933 7.946 7.944 7.950 
2 Ile Hα 4.215 4.313 4.146 4.215 4.185 4.199 4.197 4.198 
2 Ile Hβ 1.798 1.123 1.648 1.686 1.675 1.679 1.679 1.664 















2 Ile Hγ2* 0.832  0.735 0.745 0.739 0.734 0.736 0.733 
2 Ile Hδ1* 0.832  0.735 0.745 0.739 0.734 0.736 0.733 
3 Ser H 7.968 7.964 8.017 7.971 7.974 7.946 7.949 7.918 




3 Ser Hα 4.286 4.276 4.309 4.284 4.293 4.305 4.299 4.316 
















3 Ser Hγ 5.003 5.022  4.987 5.020 4.999 5.039 4.958 
4 D -Gln H 7.820 8.025 7.989 7.884 7.938 7.922 7.966 7.958 
4 D -Gln Hα 4.287 4.290 4.313 4.332 4.270 4.292 4.299 4.306 














































5 D -Ile H 7.710 7.680 7.749 7.766 8.015 7.801 7.824 7.712 
5 D-Ile Hα 4.379 4.400 4.380 4.265 4.326 4.193 4.244 4.367 
5 D-Ile Hβ 1.779 1.788 1.783 1.728 1.209 1.690 1.721 1.772 















5 D-Ile Hγ2* 0.774 0.765 0.775 0.806  0.787 0.804 0.782 
5 D-Ile Hδ1* 0.774 0.765 0.775 0.806  0.787 0.804 0.784 
6 Ile H 7.957 7.929 7.918 7.889 7.807 8.074 7.992 7.970 
6 Ile Hα 4.269 4.286 4.292 4.280 4.314 4.405 4.191 4.160 
6 Ile Hβ 1.780 1.776 1.776 1.759 1.747 1.232 1.778 1.757 















6 Ile Hγ2* 0.821 0.816 0.824 0.815 0.810  0.814 0.822 
6 Ile Hδ1* 0.821 0.816 0.819 0.815 0.810  0.814 0.822 
7 Ser H 9.087 9.207 9.188 9.149 9.282 9.565 8.521 8.607 
7 Ser Hα 4.385 4.404 4.402 4.394 4.413 4.279 4.336 4.233 
















7 Ser Hγ 5.652 5.671 5.674 5.665 5.646 5.718   
8 D-Thr H 8.717 8.856 8.865 8.897 8.847 8.679 8.905 7.987 
8 D-Thr Hα 4.639 4.655 4.650 4.642 4.649 4.647 4.554 4.568 
8 D-Thr Hβ 5.363 5.366 5.362 5.360 5.363 5.351 5.330 5.355 
8 D-Thr Hγ2* 1.105 1.097 1.097 1.094 1.097 1.059 1.112 1.136 
9 Ala H 8.217 8.203 8.210 8.210 8.193 8.103 8.204 8.101 
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9 Ala Ha 3.932 3.931 3.933 3.933 3.931 3.908 3.992 3.950 
9 Ala Hβ* 1.294 1.280 1.283 1.282 1.286 1.248 1.351 1.340 
10 Arg H 8.156 8.219 8.235 8.233 8.206 8.349 8.274 7.687 
10 Arg Hα 4.275 4.274 4.280 4.273 4.285 4.271 4.265 4.395 
















































10 Arg Hε 7.693 7.733 7.735 7.750 7.745 7.634 7.911  
10 Arg Hη1 




    
10 Arg Hη2 




    
11 Ile H 8.390 8.499 8.502 8.495 8.48 8.495 8.104 7.562 
11 Ile Hα 4.033 4.030 4.033 4.033 4.033 4.036 4.054 4.027 
11 Ile Hβ 1.686 1.681 1.675 1.668 1.682 1.609 1.712 1.680 

















11 Ile Hγ2* 0.811 0.798 0.806 0.814 0.800 0.763 0.814 0.829 
11 Ile Hδ1* 0.811 0.798 0.806 0.814 0.800 0.763 0.814 0.830 
Table S5.2: Proton chemical shifts obtained from the mutants used in this study. The residue replaced by 
alanine is shown with a grey background, with the introduced methyl group shown in bold. 
E
xperim






Figure S5.60: 1H NMR spectra obtained from compound 5.1 
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Figure S5.61: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.1. For clarity, 












Figure S5.62: 1H NMR spectra obtained from compound 5.2 
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Figure S5.63: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.2. For clarity, 











Figure S5.64: 1H NMR spectra obtained from compound 5.3 
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Figure S5.65: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.3. For clarity, 











Figure S5.66: 1H NMR spectra obtained from compound 5.4 
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Figure S5.67: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.4. For clarity, 













Figure S5.68: 1H NMR spectra obtained from compound 5.5 
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Figure S5.69: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.5. For clarity, 













 Figure S5.70: 1H NMR spectra obtained from compound 5.6 
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Figure S5.71: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.6. For clarity, 











Figure S5. 72: 1H NMR spectra obtained from compound 5.7 
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Figure S5.73: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.7. For clarity, 











Figure S5. 74: 1H NMR spectra obtained from compound 5.8 
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Figure S5.75: 1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra obtained from compound 5.8. For clarity, 
grey boxes obscure solvent signals. 
 
1H NMR spectra were from 1mM compounds 1-8 dissolved in DMSO-d6. 128K complex points 
acquired at 300°C with 16 scans. 
1H-1H TOCSY (blue) and 1H-1H NOESY (red) spectra were acquired from 1 mM compounds 5.1-
5.8 dissolved in DMSO-d6 at 300°C on a Bruker Avance III HD 500 MHz equipped with a room-
temperature broadband probe. Spectra were 2048 and 192 complex points in the direct and indirect 
dimensions, respectively. For clarity, grey boxes obscure solvent signals. 
  




VI. MIC testing (screening) 
For MIC assays all peptides were dissolved in DMSO containing 0.002% polysorbate 807. All 
bacteria were grown in Mueller Hinton broth (Oxoid) in triplicate. All incubations were at 37°C. 
Dilutions were carried out in triplicate. 100 µl of autoclaved Mueller Hinton broth was added to wells 
2-12 in a 96-well plate. 200 µl of the peptide was added to well one at a concentration of 256 
µg/mL. 100µl of peptide in well one was taken up and pipetted into well two. The mixture was then 
mixed via pipetting before 100µl was taken up and pipetted into well three. This process was repeated 
up to well 11. Once peptide was added to well 11 100 µl was taken up and then discarded ensuring 
the well 12 had no peptide present. Thus, the concentrations (in µg/mL) were: 256, 128, 64, 32, 16, 
8, 4, 2, 1, 0.5, 0.25 and no peptide present. Each well was then inoculated with 100µl of bacteria that 
had been diluted to an OD600nm of 0.1. This was repeated three times. The 96-well plates were then 
incubated at 37°C for 24 hours. The MIC was determined to be the lowest concentration at which 
there was no growth visible. 
For all the compounds in which the MIC lower than 1 µg/ml for the initial test, the above procedure 
was repeated at an altered initial concentration of 64 µg/ml. Therefore, the new concentrations for 
MIC were: 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 and no peptide present. Vancomycin was 
used as a control. 
To determine the MIC of M. smegmatis ATCC 607 an inoculum was shaken at 140rpm, 37°C in 5ml 
Middlebrook 7H9 broth (SIGMA) supplemented to 5% Middlebrook ADC (SIGMA) growth 
supplement for 3-4 days and harvested mid-late exponential phase (OD ~0.6). The harvested cells 
were washed once in fresh media and diluted 10-fold from the original volume. Then plated out in a 
96-well plate as previously described, incubated at 37°C 140RPM with MIC readings taken after 72 
hours. 
To determine the effect of serum on antibacterial activity, the MIC of compounds 5.12 and 5.13 were 
measured in presence of 10% human serum using the above protocols. Both the compounds were 
pre-treated with 10% human serum (Sigma, H4522) for 30 mins and 2 hours. These pre-treated 
samples were used for MIC determination using Mueller Hinton Broth supplemented with 10% 
human serum.  
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VII. Antagonization assay 
An antagonization assay was performed using Leu10-teixobactin (5.13) and Lipid II as reported in 
literature.7 MIC was tested using the protocols described in section VI. 
Precursor Molar ratio of precursor to Leu10-teixobactin 
 0x 0.5x 1x 2x 5x 
Lipid II - + + + + 
Table S5.3: Leu10-teixobactin at 8x MIC exposed to increasing concentrations of lipid II. MIC was tested 
against the strain reported in ref 7. S. aureus ATCC 29213. Experiments were performed in triplicate. 
VIII. MIC testing (extended panel) 
Bacterial cultures were grown overnight in Mueller-Hinton Agar (MHA) plates and adjusted to a 
final concentration of 105 – 106 CFU/ml. 100 µl of inoculum in Meuller-Hinton broth (MHB) was 
mixed with equal volume of peptides (dissolved in MHB) at 2x their concentration in a 96 well plate. 
In parallel experiments, MIC values were determined in the media containing polysorbate 80 
(0.002%, v/v) to prevent non-specific adsorption of the peptides to plastic surfaces. The final peptides 
concentrations ranged from 0.0625 – 32 µg/ml. Positive and negative controls contained 200 µl of 
inoculum without any peptide dissolved in broth, respectively. The 96 well plates were then 
incubated at 37 °C for 24 h. All the experiments were performed in two independent duplicates and 
the MIC was determined as the lowest concentration in which no visible growth was observed. 
Minimum bactericidal concentration (MBC) was determined by plating out the dilution representing 
the MIC and concentrations up to 16x MIC on MHA plates kept at 37 °C for 24 h. The lowest 
concentration in which no visible colonies could be detected was taken as the MBC.   





Table S5.4: MIC and MBC (in µg/mL) of the lead teixobactin analogues 5.8, 5.11-5.13, 2.1 and Daptomycin 
control against an extended panel of Gram positive bacteria in the presence and absence of polysorbate 80. 
Strain information: MRSA 1: MRSA ATCC 700699, MRSA 2: MRSA DR 42412 (sputum), MRSA 3: MRSA 
DM21455 (eye). MRSA 2 and MRSA 3 are clinical isolates. Staphylococcus aureus ATCC 29213, 
Enterococcus faecalis, (VRE 1:  VRE ATCC 700802, VRE 2: VRE ATCC 29212). 
Compound 




1.13 Strain  




4 1 0.25 0.25 1 1 0.5 
MIC (without 
polysorbate 80) 
8 4 2 2 4 2 - 




1 0.5 ≤ 0.0625 ≤ 0.0625 0.125 1 0.5 
MIC (without 
polysorbate 80) 
4 2 2 2 2 2 - 
MBC 4 4 ≤ 0.0625 ≤ 0.0625 0.5 - - 
MRSA 3  
MIC (with 
polysorbate 80) 
1 0.25 ≤ 0.0625 ≤ 0.0625 0.5 1 0.5 
MIC (without 
polysorbate 80) 
4 4 2 2 4 2 - 




1 0.25 ≤ 0.0625 ≤ 0.0625 0.25 2 0.25 
MIC (without 
polysorbate 80) 
4 2 1 1 2 4 - 




4 0.5 ≤ 0.0625 0.25 2 >4 0.5 
MIC (without 
polysorbate 80) 




4 0.5 ≤ 0.0625 0.25 2 >4 0.5 
MIC (without 
polysorbate 80) 
8 4 1 2 4 >4 - 
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IX. Time-dependent killing of bacteria by teixobactin analogues 5.12 and 5.13 
Time-kill kinetics against MRSA DM21455 strains (clinical isolates from patients) was 
carried out in MHB. Cultures were grown overnight in MHA plates and adjusted to a final 
inoculum of 105 – 106 CFU/ml in MHB (containing 0.002% v/v, polysorbate 80) with 
teixobactin analogues 5.12 and 5.13 maintained at a final concentration of 0.5 µg/ml. For 
vancomycin, the concentration was varied from 0.5 – 16 µg/ml without polysorbate 80. The 
tubes were then incubated at 37 °C. 100 µl of cell suspension was withdrawn at various time 
points (0, 2, 4, 8, 24 h), serially diluted (101-105 fold dilutions) and plated onto a MHA plates 
and incubated for 24 h at 37 °C. Colonies were then enumerated using a haemocytometer. 
Colony counting too numerous to count (>300 colonies) was taken as 1010 CFU. Average 
values from two independent experiments are reported.    
 
X. Complex formation of teixobactin with lipid II and geranyl pyrophosphate 
Complex formation of teixobactin analogues 5.8 (Ala10-teixobactin) and 2.1 (Arg10-
teixobactin) with lipid II and geranyl pyrophosphate was performed using TLC as described 
previously.7 Binding of teixobactin to lipid II and geranyl pyrophosphate was analysed by 
incubating 30 µL of 2 nmol of each precursor with 2 or 4 nmoles of teixobactin in 50 mM Tris/HCl, 
pH 7.5, for 30 min at room temperature. Complex formation was analysed by extracting unbound 
precursors from the reaction mixture with 30 µL n- butanol/6M pyridine acetate (pH 4.2) (2:1; 
vol/vol) followed by TLC analysis of the organic layer using chloroform/methanol/water/ammonia 
(88:48:10:1, v/v/v/v) as the solvent and detection of lipid/phosphate containing precursors by 
phosphomolybdic acid staining. The TLC figures represent the results obtained through three 
independent experiments. 
 
Figure S5.76: Binding of teixobactin analogues 5.8 (Ala10-teixobactin) and 2.1 (Arg10-teixobactin) with lipid 
II using the protocols described in literature.7 Partial binding is observed when the ratio of lipid II to the 
analogue is 1:1 (indicated by lighter spots on the TLC) and complete binding is observed when the ratio of 
lipid II to the analogue is 1:2 in case of analogue 5.8 and 1:4 in case of analogue 2.1 (indicated by no spots on 
TLC). 





Figure S5.77: Binding of teixobactin analogues 5.8 (Ala10-teixobactin) and 2.1 (Arg10-teixobactin) with 
geranyl pyrophosphate using the protocols described in literature.7 complete binding is observed when the ratio 
of the phosphate to the analogue is 1:2 (indicated by no spots on the TLC). 
 
 
Figure S5.78: Binding of teixobactin analogue 5.13 (Leu10-teixobactin) with lipid II using the protocols 
described in literature.7 Partial binding is observed when the ratio of lipid II to the analogue is 1:1 (indicated 
by lighter spots on the TLC) and complete binding is observed when the ratio of lipid II to the analogue is 1:2 
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XI. Cytotoxicity assay  
a) Cytotoxicity assay by Formazan bioreduction 
HeLa cells were seeded in a 96-well plate at 104 cells/cm2 density in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% serum. The cells were repeatedly rinsed with Hank’s 
Balanced Salt Solution (HBSS) prior to be exposed to different peptides in the range of 0.5 – 100 
µM in HBSS 24 hrs post-seeding. Following 6 hrs of exposure to the teixobactin analogue, CellTiter 
96 AQueous Nonradioactive Cell Proliferation Assay (Promega) was used according to the 
manufacturer’s instructions.8 Not ingested teixobactin analogue was removed by repeated washings 
with fresh medium. 20 μL of the combined MTS/PMS solution was added to 100 μL fresh medium 
in each well and plates were incubated for 3 hrs at 37°C. Absorbance was measured at 490 nm on 
Tecan Infinite M200 PRO plate reader with i-control 1.10 software (Molecular Devices). 
 
Figure S5.79: Toxicity results showing relative survival vs. Concentration (in µM) in HeLa cells for 
teixobactin analogues 5.8 (Ala10-teixobactin), 5.11 (Val10-teixobactin) and 5.13 (Leu10-teixobactin). 
b) Haemolytic Assay Protocol 
This assay was done at Singapore Eye Research Institute, Singapore. Hemolytic assay was performed 
on rabbit red blood cells (RBCs) immediately after collecting the blood samples from adult rabbits. 
All procedures for isolating blood from rabbits were approved by IACUC Singhealth and performed 
according to the standards of the Association for the Research in Vision and Ophthalmology. 
Haemolytic activity of peptides was determined for rabbit red blood cells (rRBC), as reported before.9 
Rabbit erythrocytes were isolated from freshly collected blood samples and washed twice with sterile 




PBS. Two-fold serial dilutions of peptides (0.195 – 250 µg/ml) was mixed with rRBC (final 
concentration 4% v/v), incubated at 37oC for 1h and centrifuged at 3000 rpm for 5 minutes. The 
release of hemoglobin in the supernatant was monitored by measuring the hemoglobin absorbance 
at 576nm. The readings from negative control (PBS and rRBC without any additives) and positive 
control (2% Triton-X100 and rRBC) were used as 0% and 100% haemolysis, respectively. Prolific 
pore forming and haemolytic melittin was used as comparator peptide. The data represents average 
value from triplicates experiments.  
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EXPERIMENTAL SECTION FOR CHAPTER 6 
I. Materials 
All L amino acids, Fmoc-D-Arg(pbf)-OH, Fmoc-D-Gln(Trt)-OH, Boc-N-methyl-D-phenylalanine, 1 
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxidhexafluorophosphate 
(HATU), Phenylsilane (PhSiH3), Tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)], 
Diisoproplycarbodiimide (DIC) and Triisopropylsilane (TIS) were purchased from Fluorochem, UK. 
Fmoc-D-allo-Ile-OH and oxyma pure were purchased from Merck Millipore. The side chain 
protecting 
groups for the amino acids are tBu for Ser, Pbf for Arg and Trt for Gln and Thr unless specified 
otherwise. Diisopropylethylamine (DIPEA), supplied as extra dry, redistilled, 99.5 % pure, Acetic 
anhydride, allyl chloroformate, CDCl3 and polysorbate 80 and were purchased from Sigma Aldrich. 
Tritylchloride and 4-(Dimethylamino)pyridine were purchased from Alfa Aesar. 
Dimmethylformamide (DMF) peptide synthesis grade was purchased from Rathburn chemicals. 
Triethylamine, Diethyl ether (Et2O), Dimethylsulfoxide (DMSO), Dichloromethane (DCM), 
Tetrahydrofuran (extra dry with molecular sieves), Formic acid 98-100% purity and Acetonitrile 
(HPLC grade) were purchased from Fisher Scientific. Water with the Milli-Q grade standard was 
obtained in-house from an ELGA Purelab Flex system. 2-Chlorotritylchloride resin (manufacturer’s 
loading: 1.20 mmol/g) was purchased from Fluorochem. All chemicals were used without further 
purification.  
II. Equipment used for the analysis and purification of compounds 
All peptides were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC equipped with 
a Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer systems: 
A: 0.1% HCOOH in milliQ water. B: ACN using a flow rate of 1 ml/min. The column was flushed 
with 95% A for 5 min prior to an injection and was flushed for 5 min with 95% B and 5% A after 
the run was finished. Peptides were dissolved in (1:1) 0.1% HCOOH buffer in water and acetonitrile 
(ACN) and analysed using the following gradient: 95% A for 2 min. 5-95% B in 25 min. 95% B for 
5 min. 5% A for 4 min. Peptides were dissolved in 0.1% HCOOH buffer in water and in ACN (10-
30% ACN) and purified using the same gradient as mentioned above, on a Thermo Scientific Dionex 
Ultimate 3000 RP-HPLC with a flow rate of 5 mL/min using a Phenomenex Gemini NX C18 110 Å 
(150 x 10 mm) semi-prep column.  
HRMS spectra were recorded on a Thermo 
Scientific Q Exactive Plus Orbitrap Mass Spectrometer in the positive ion mode. 
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III. Syntheses of teixobactin analogues 
 
  
Scheme S6.1: Synthesis of D-Arg4-Leu10-teixobactin (6.2) 
(step a) Commercially available 2-Chlorotrityl chloride resin (manufacturer’s loading = 1.2 mmol/g, 
170 mg resin) was swelled in DCM in a reactor. To this resin was added 4 eq. Fmoc-Ala-OH/8 eq. 
DIPEA in DCM and the reactor was shaken for 3h. The loading determined by UV absorption of the 
piperidine-dibenzofulvene adduct was calculated to be 0.6 mmol/g, (170mg resin, 0.102 mmol). Any 
unreacted resin was capped with MeOH:DIPEA:DCM = 1:2:7 by shaking for 1h. (step b) The Fmoc 
protecting group was deprotected using 20% piperdine in DMF by shaking for 3 min, followed by 
draining and shaking again with 20% piperidine in DMF for 10 min. AllocHN-D-Thr-OH was then 
coupled to the resin by adding 3 eq. of the AA, 3 eq. HATU and 6 eq. DIPEA in DMF and shaking 
for 1.5h at room temperature. (step c) Esterification was performed using 10 eq. of Fmoc-Ile-OH, 10 
eq. DIC and 5 mol% DMAP in DCM and shaking the reaction for 2h. This was followed by capping 
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using protocol described earlier in step (b). (step d) Fmoc-Leu-OH was coupled using 4 eq. of AA, 
4 eq. HATU and 8 eq. DIPEA in DMF and shaking for 1h followed by Fmoc deprotection using 20% 
piperidine in DMF as described earlier. (step e) The N terminus of Leu was protected using 10 eq. 
Trt-Cl and 15% Et3N in DCM and shaking for 1h. The protection was verified by the Ninhydrin 
colour test. (step f) The Alloc protecting group of D-Thr was removed using 0.2 eq. [Pd(PPh3)]0 and 
24 eq. PhSiH3 in dry DCM under argon for 20 min. This procedure was repeated increasing the time 
to 45 min and the resin was washed thoroughly with DCM and DMF to remove any Pd stuck to the 
resin. (step g) All amino acids were coupled using 4 eq. Amino Acid, 4 eq. DIC/Oxyma using a 
microwave peptide synthesizer. Coupling time was 10 min. Deprotection cycles were performed as 
described earlier. (step h) The peptide was cleaved from the resin without cleaving off the protecting 
groups of the amino acid side chains using TFA:TIS:DCM = 2:5:93 and shaking for 1h. (step i) The 
solvent was evaporated and the peptide was redissolved in DMF to which 1 eq. HATU and 10 eq. 
DIPEA were added and the reaction was stirred for 30 min to perform the cyclization. (step j) The 
side-chain protecting groups were then cleaved off using TFA:TIS:H2O = 95:2.5:2.5 by stirring for 
1h. The peptide was precipitated using cold Et2O (-20°C) and centrifuging at 7000 rpm to obtain a 
white solid. This solid was further purified using RP-HPLC using the protocols described previously.  











6.1 Arg3-Leu10-teixobactin C61H104N15O14 1270.7887 1270.7913 
6.2 D-Arg4-Leu10-teixobactin C59H101N14O14 1229.7622 1229.7650 
6.3 Arg9-Leu10-teixobactin C61H104N15O15 1286.7836 1286.7843 
6.4 Arg3-D-Arg4-Leu10-teixobactin C62H108N17O13 1298.8313 1298.8325 
6.5 Arg3-Arg9-Leu10-teixobactin C64H111N18O14 1355.8527 1355.8606 
6.6 D-Arg4-Arg9-Leu10-teixobactin C62H108N17O14 1314.8262 1314.8263 
6.7 Arg3-D-Arg4-Arg9-Leu10-teixobactin C65H115N20O13 1383.8952 1383.8943 
6.8 Arg3-Ile10-teixobactin C61H104N15O14 1270.7887 1270.7896 
6.9 D-Arg4-Ile10-teixobactin C59H101N14O14 1229.7622 1229.7607 
6.10 Arg9-Ile10-teixobactin C61H104N15O15 1286.7836 1286.7780 
Table S6.1: Compound number, name, chemical formula, mass calculated and mass observed for 
compounds 6.1-6.10. The overall yields were typically in the range of 13-22%.  
                                                     
§ Parmar, A. et al. Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity 
and lipid II binding. Chemical Science 8, 8183–8192 (2017) 
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IV. HPLC/MS analysis 
 
 
Figure S6.1: HPLC trace of HPLC purified teixobactin analogue 6.1 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.2: HRMS of HPLC purified teixobactin analogue 6.1. Mass calcd. for 
C61H104N15O14 = 1270.7887, found M + H+ = 1270.7913, M/2 + H+ = 635.8981.  
20170717_R10LS3R #1 RT: 0.00 AV: 1 NL: 1.89E9
T: FTMS + p ESI Full lock ms [500.0000-1600.0000]









































































































Figure S6.3: HPLC trace of HPLC purified teixobactin analogue 6.2 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.4: HRMS of HPLC purified teixobactin analogue 6.2. Mass calcd. for 
C59H101N14O14 = 1229.7622, found M + H+ = 1229.7650, M/2 + H+ = 615.8850. 
20170717_R10LQ4R #51 RT: 0.47 AV: 1 NL: 2.11E9
T: FTMS + p ESI Full ms [500.0000-1600.0000]
























































































Figure S6.5: HPLC trace of HPLC purified teixobactin analogue 6.3 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.6: HRMS of HPLC purified teixobactin analogue 6.3. Mass calcd. for 
C61H104N15O15 = 1286.7836, found M + H+ = 1286.7843, M/2 + H+ = 643.8951. 
20170717_R10LA9R #75 RT: 0.70 AV: 1 NL: 3.56E8
T: FTMS + p ESI Full lock ms [500.0000-1600.0000]































































































Figure S6.7: HPLC trace of HPLC purified teixobactin analogue 6.4 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.8: HRMS of HPLC purified teixobactin analogue 6.4. Mass calcd. for 
C62H108N17O13 = 1298.8313, found M + H+ = 1298.8325, M/2 + H+ = 649.9198. 
 
20170717_R10LS3Q4R #40-57 RT: 0.37-0.52 AV: 18 NL: 1.05E9
T: FTMS + p ESI Full lock ms [500.0000-1600.0000]
















































































Figure S6.9: HPLC trace of HPLC purified teixobactin analogue 6.5 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.10: HRMS of HPLC purified teixobactin analogue 6.5. Mass calcd. for 
C64H111N18O14 = 1355.8527, found M + H+ = 1355.8606, M/2 + H+  = 678.4319. 
 
20170717_R10LS3A9R #82-95 RT: 0.76-0.89 AV: 14 NL: 1.84E7
T: FTMS + p ESI Full lock ms [500.0000-1600.0000]
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Figure S6.11: HPLC trace of HPLC purified teixobactin analogue 6.6 (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
Figure S6.12: HRMS of HPLC purified teixobactin analogue 6.6. Mass calcd. for 
C62H108N17O14 = 1314.8262, found M + H+ = 1314.8263, M/2 + H+ = 657.9165. 
 
20170717_R10LA9Q4R #25 RT: 0.23 AV: 1 NL: 4.42E8
T: FTMS + p ESI Full lock ms [500.0000-1600.0000]
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Figure S6.13: HPLC trace of HPLC purified teixobactin analogue 6.7 (gradient: 5-95% ACN in 25 
min using A: 0.1% HCOOH in water, B: ACN) 
Figure S6.14: HRMS of HPLC purified teixobactin analogue 6.7. Mass calcd. For C65H115N20O13 = 
1383.8952, found M + H+ = 1383.8943, M/2 + H+ = 692.4503. 
20170717_R10LS3Q4A9R #37 RT: 0.34 AV: 1 NL: 6.10E8
T: FTMS + p ESI Full ms [500.0000-1600.0000]
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Figure S6.15: HPLC trace of HPLC purified teixobactin analogue 6.8 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.16: HRMS of HPLC purified teixobactin analogue 6.8. Mass calcd. For C61H104N15O14 = 1270.7887, 
found M + H+ = 1270.7896, M/2 + H+ = 635.8973. 
20170717_R10IS3R #1 RT: 0.00 AV: 1 NL: 1.92E9
T: FTMS + p ESI Full lock ms [500.0000-1600.0000]















































































Figure S6.17: HPLC trace of HPLC purified teixobactin analogue 6.9 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.18: HRMS of HPLC purified teixobactin analogue 6.9. Mass calcd. for 
C59H101N14O14 = 1229.7622, found M + H+ = 1229.7607, M/2 + H+ = 615.3836. 
20170717_R10IQ4R #1 RT: 0.00 AV: 1 NL: 1.27E9
T: FTMS + p ESI Full ms [500.0000-1600.0000]
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Figure S6.19: HPLC trace of HPLC purified teixobactin analogue 6.10 (gradient: 5-95% ACN in 25 min using 
A: 0.1% HCOOH in water, B: ACN) 
 
Figure S6.20: HRMS of HPLC purified teixobactin analogue 6.10. Mass calcd. For C61H104N15O15 = 1286.7836, 
found M + H+ = 1286.7780, M/2 + H+ = 643.8924.  
20170717_R10IA9R #1 RT: 0.00 AV: 1 NL: 2.94E9
T: FTMS + p ESI Full ms [500.0000-1600.0000]
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V. NMR analysis  
All NMR was carried out in DMSO-d6 at 27°C on a Bruker Avance III HD 500 MHz spectrometer 
equipped with a room-temperature broadband probe. The following spectra were utilised in the 
assignment of 1 mM solution of the teixobactin analogue 6.2: 1H (128k points, 16 scans); 13C{1H} 




Table S6.2: NMR Assignments of teixobactin analogue 6.2.  
D-Arg4-Leu10-Teixobactin 6.2 




Figure S6.21: 1H NMR Spectrum of teixobactin analogue 6.2. 
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VI. MIC & MBC testing  
For MRSA ATCC 33591: For MIC assays all peptides were dissolved in DMSO containing 0.002% 
polysorbate 80. MRSA ATCC 33591 was grown in Mueller Hinton broth (Oxoid) in triplicate. All 
incubations were at 37°C. Dilutions were carried out in triplicate. 100 µl of autoclaved Mueller 
Hinton broth was added to wells 2-12 in a 96-well plate. 200 µl of the peptide was added to well one 
at a concentration of 256 µg/mL. 100µl of peptide in well one was taken up and pipetted into well 
two. The mixture was then mixed via pipetting before 100µl was taken up and pipetted into well 
three. This process was repeated up to well 11. Once peptide was added to well 11 100 µl was taken 
up and then discarded ensuring the well 12 had no peptide present. Thus, the concentrations (in 
µg/mL) were: 256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25 and no peptide present. Each well was then 
inoculated with 100µl of bacteria that had been diluted to an OD600nm of 0.1. This was repeated 
three times. The 96-well plates were then incubated at 37°C for 24 hours. The MIC was determined 
to be the lowest concentration at which there was no growth visible. 
For all the compounds in which the MIC lower than 1 µg/ml for the initial test, the above procedure 
was repeated at an altered initial concentration of 64 µg/ml. Therefore, the new concentrations for 
MIC were: 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625 and no peptide present.  
(Extended panel) 
Bacterial cultures were grown overnight in Mueller-Hinton Agar (MHA) plates and adjusted to a 
final 
concentration of 105 – 106 CFU/ml. 100 µl of inoculum in Meuller-Hinton broth (MHB) was mixed 
with equal volume of peptides (dissolved in MHB) at 2x their concentration in a 96 well plate. In 
parallel experiments, MIC values were determined in the media containing polysorbate 80 (0.002%, 
v/v) to prevent non-specific adsorption of the peptides to plastic surfaces. The final peptides 
concentrations ranged from 0.0625 – 32 µg/ml (for lower range 0.031 – 16 µg/ml was used). Positive 
and negative controls contained 200 µl of inoculum without any peptide dissolved in broth, 
respectively. The 96 well plates were then incubated at 37 °C for 24 h. All the experiments were 
performed in two independent duplicates and the MIC was determined as the lowest concentration 
in which no visible growth was observed. Minimum bactericidal concentration (MBC) was 
determined by plating out the dilution representing the MIC and concentrations up to 16x MIC on 
MHA plates kept at 37 °C for 24 h. The lowest concentration in which no visible colonies could be 
detected was taken as the MBC. 
 
Resistance studies: For single step resistance, 100µl S. aureus ATCC 29213 or MRSA ATCC 33591 
at 1010 c.f.u./ml were plated onto MHB containing 20 x MIC of teixobactin analogues 6.2. Agarose 
was used as a solidifying agent. After 24 h of incubation at 37⁰ C, no resistant colonies were detected, 
giving the calculated frequency of resistance to teixobactin analogues 6.2 of <10-10.  




Table S6.3: MIC (in µg/mL) of the teixobactin analogues 6.1-6.10 and Daptomycin control against an extended 
panel of Gram-positive bacteria in the presence of polysorbate 80. 
Peptides Minimum Bactericidal Concentration (in µg/ml) against 
S. aureus 29213 S. aureus 4299 MRSA 700699 MRSA 21455 
6.1 >2 (8×) 1 (>8×) 2 (4×) 0.0625 (2×) 
6.2 0.125 (1×) ≤0.0625 (1×) 2 (4×) ≤0.0625 (1×) 
6.3 >4 (8×) 2 (8) >4 (>8×) >2 (>8×) 
6.4 >2 (>8×) >2 (>8×) >4 (>8×) 1 (2×) 
6.5 2 (2×) 4 (8×) 2 (2×) 1 (2×) 
6.6 4 (4×) 2 (4×) 8 (8×) 2 (2×) 
6.7 2 (2×) 1 (1×) >8 (>4×) 2 (1×) 
6.8 4 (8×) 1 (8×) 2 (2×) 0.5 (2×) 
6.9 >0.5 (>8×) >0.5 (>8×) 0.5 (2×) 0.25 (8×) 
6.10 8 (8×) 8 (8×) 1 (1×) 2 (4×) 
Table S6.4: Minimum bactericidal concentrations of teixobactin peptides against S. aureus and MRSA strains 

























saprophyticus  ATCC 
BAA 750
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.125
Staphylococcus 
saprophyticus  ATCC 
15305
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.25 <0.0625 <0.0625 <0.0625 0.125
Staphylococcus 
saprophyticus  ATCC 
49453
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.125
Staphylococcus 
saprophyticus  ATCC 
49907
<0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.125
VRE 1001 0.25 0.5 0.5 1 0.5 1 2 1 0.5 1 2
VRE 1002 0.5 1 1 1 1 1 8 1 1 1 4
VRE 1004 <0.0625 0.25 0.25 0.5 0.5 1 4 1 0.5 1 1
VRE 1008 0.125 0.5 0.25 0.5 0.5 1 8 1 0.5 1 4
VRE ATCC 700802 0.5 0.5 0.5 2 1 1 4 1 0.25 1 0.25
VRE ATCC 29212 0.5 0.5 1 1 1 1 4 1 0.25 1 0.25
MRSA ATCC 700699 0.5 0.25 0.5 0.5 1 1 2 1 0.25 1 1
MRSA 42412 <0.0625 0.0313 <0.0625 0.25 0.25 1 2 0.125 <0.0625 0.125 0.5
MRSA 21455 0.03125 0.0313 0.25 0.5 1 1 2 0.25 0.03125 0.5 0.5
MRSA 1003 <0.0625 0.5 0.25 1 2 0.5 2 0.125 <0.0625 0.5 0.5
S. aureus  29213 0.25 <0.0625 0.5 0.25 1 1 1 0.5 0.0625 1 0.5
S. aureus  4299 0.125 - 0.25 0.25 0.5 0.5 1 0.125 <0.0625 1 0.5
S. epidermidis 12228 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.125
Bacillus Cereus  ATCC 
11788
<0.0625 0.5 0.25 1 1 1 1 0.125 <0.0625 0.5 0.25
Bacillus Subtilis  ATCC 
6633
<0.0625 0.125 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 0.125 0.125
P.aeruginosa ATCC 
27853
- >64 - - - - - - - - -
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VII. Time-dependent killing of bacteria by teixobactin analogue 6.2 
Time-kill kinetics against S. aureus ATCC 29213 was carried out in MHB. Cultures were grown 
overnight in MHA plates and adjusted to a final inoculum of 105 – 106 CFU/ml in MHB (containing 
0.002% v/v, polysorbate 80) with teixobactin analogue 2 maintained at a final concentration of 0.5 
and 1 µg/ml. The tubes were then incubated at 37 °C. 100 µl of cell suspension was withdrawn at 
various time points (0, 2, 4, 8h), serially diluted (101-105 fold dilutions) and plated onto a MHA plates 
and incubated for 24 h at 37 °C. Colonies were then enumerated using a haemocytometer. Colony 
counting too numerous to count (>300 colonies) was taken as 1010 CFU. Average values from two 
independent experiments are reported. 
 
Figure S6.23: Time-kill kinetics of teixobactin analogue 6.2 against S. aureus ATCC 29213. The concentration 
of teixobactin analogue 6.2 was maintained at 0.5 and 1 µg/ml. 
VIII. Cytocompatibility of 6.2 for mammalian cells 
Cytocompatibility assessment of 6.2 for A549 lung adenocarcinoma cell line and primary human 
dermal fibroblasts (hDF) were determined by MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) assay and high content analysis 
(HCA). Both A549 or hDF cells (2 X 103 cells/well)  seeded on 96-well plates were treated with 
various concentrations of peptide (15.625 – 250 mg/ml) and incubated for 24 h at 37 °C and 5% CO2. 
The stock solution of 2 (500µg/ml) was prepared fresh by directly dissolving 2 in cell culture medium 
(Dulbecco’s Modified Eagle Medium, Gibco®) and used. The metabolic activity was determined 
using CellTier 96® Aqueous One solution cell proliferation assay kit according to the manufacturer’s 
instruction (Promega Corporation, Madison, WI). The relative cell viability was determined from 
UV readings of untreated control cells. The antineoplastic agent, nocodazole (5 µg/ml dissolved in 
DMSO) served as the negative control. Data represents mean ± standard error of the mean of three 
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independent triplicate experiments.  For HCA, cells treated with peptide 6.2 were washed with PBS 
and fixed in 3% paraformaldehyde. A549/hDF cells were fluorescently stained with Alex Fluor 488 
anti-α-tubulin (green), Hoechst 33342 (blue) and Rhodamine-Phalloidin (red) to visualize cellular 
morphologies and imaged by IN Cell Analyzer 2200 automated microscope.  
 
Figure S6.24: Quantitative determination of corneal wound healing after topical instillation of PBS or peptide 
6.2 after corneal injury in rabbits. The re-establishment of corneal epithelium after injury confirm that peptide 
6.2 does not interfere with regular wound healing process, thus establishing its safety for topical applications.  
 
Figure S6.25: Representative AS-OCT images showing the changes in corneal thickness before and after 
infections or Treatment with various groups. Note the significant presence of corneal edema and hyper 
reflective materials throughout the cornea in the case of PBS treated groups but were minimized in peptide 6.2 
or moxifloxacin treated groups.   
IX. The in vivo toxicity in a rabbit model of corneal epithelium-injured 
All the animals used in this study were treated in accordance to the tenets of the Association for 
Research in Vision and Ophthalmology (ARVO) statement, and the protocol was approved by 
SingHealth Institutional Animal Care and Use Committee (IACUC) (AALAC accredited; protocol 
number 2012/SHS/775 for wound healing). Six New Zealand White rabbits, aged 8 months old and 
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body weight 3-3.5 kg were used for the study. Prior to the creation of corneal wound, all the rabbit 
eyes were examined by slit-lamp photography to ensure absence of any ocular defects.  The rabbits 
were anesthetized and a 7.5-mm-diameter region of the corneal surface was de-epithelialized with a 
sterile mini blade (BD Beaver, MA, USA) and divided into two groups.  Rabbits received a 50 µl 
topical instillation of peptide 6.2 (0.3% w/v in PBS) (4 eyes) or PBS (2 eyes) 4 times/day for ten 
days. The corneal epithelial wound healing was visualized using 2% w/v fluorescein sodium (Bausch 
& Lomb) staining. The progression of wound healing was examined by illumination with cobalt blue 
light with a digital camera. The area of corneal abrassion was quantified using Image J software. 
X. In vivo efficacy of peptide in a mice model of infectious keratitis 
We have used eighteen pathogen free 6-8 weeks old Female mice (wild type C57BL/6). As per the 
Sing- Health Institutional Animal Care and Use Committee (IACUC) guidelines, all the animals were 
handled, and for the animal experimentation, the guidelines of Association for Research in Vision 
and Ophthalmology (ARVO) were followed. The designated groups, with six mice each were 
categorized as group I treated with PBS, group II treated with 0.3% of moxifloxacin Hydrochloride, 
group III treated with 0.3% of peptide 6.2. Staphylococcus aureus ATCC 29213  strains were grown 
overnight in Tryptic Soy Agar (TSA) plates at 35°C. Isolated single bacterial colonies were identified 
and suspended in sterile PBS at a final inoculum concentration of 3 x 106 CFU/mL. Slit-lamp 
biomicroscopy (FS-3V Zoom Photo Slit Lamp, Nikon, Tokyo, Japan) and AS-OCT (RTvue, 
Optovue, Fremont, CA) were carried out on the days before bacterial inoculation (Baseline), and 6 h 
post infection (p.i.), 24 h and 48 post treatment (p.t.).  
Prior to infection all the mice eyes were examined by slit-lamp photography and AS-OCT to make 
sure that there was no corneal aberration, such as vascularization or any other ocular defects.  Mice 
were anesthetized by an intraperitoneal injection of xylazine (10 mg/kg, Troy Laboratories, 
Smithfield, Australia) and ketamine (80 mg/kg, Ketamine, Parnell Laboratories, Australia) under the 
dissecting microscope (Zeiss, Stemi-2000C). The mice corneal epithelium were then scratched and 
removed using a sterile Beaver 6400 Mini-Blade to create a superficial wound without damaging the 
stroma and one drop of 1-5% lignocaine hydrochloride were used as topical anesthesia instilled 
before corneal wounding and then the cornea was irrigated with sterile saline to wash away any debris 
and residual topical anesthetic agent. Immediately following this procedure, 15µL of bacterial 
suspension containing 3 x 106 CFU/mL of Staphylococcus aureus ATCC 29213 was applied topically 
on the corneal surface. After 6 h post infection, mice were treated with peptide 6.2, Moxifloxacin 
and PBS topically (15µL). 
The dosage regimen are two times on Day 1 (2:30PM; 5:30PM), four times (8AM; 11AM; 2PM; 
5PM) on day 2 and two times on day 3. The eyes were examined daily by slit lamp and OCT, 
sacrificed at 48 hr post-treatment (day 3) for evaluation of bacteria quantification analysis. 
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After treatment with various groups, the mice corneas were dissected and homogenized in sterile 
PBS by using Pellet pestles cordless motor (Z359971, Sigma) with sterile plastic pestles followed by 
fine homogenization with bead beating using sterile glass beads (2 mm). The homogenates were 
vortexed and 10-fold serial dilutions were prepared using sterile PBS to give 102 to 104 dilutions. A 
0.1 mL of each suspension was inoculated onto Tryptic Soy Agar (TSA) plates in duplicate and 
incubated at 35°C for 48 h. The numbers of colonies were enumerated, and the results were expressed 
as the log10 number of CFU/cornea. 
